

Adjuvant Chemotherapy Guided by a 21-Gene Expression

New England Journal of Medicine

379, 111-121

DOI: [10.1056/nejmoa1804710](https://doi.org/10.1056/nejmoa1804710)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Development of an e-health app to support women prescribed adjuvant endocrine therapy after treatment for breast cancer. Patient Preference and Adherence, 2018, Volume 12, 2639-2647.	0.8	19
2	BCL-2 expression aids in the immunohistochemical prediction of the Oncotype DX breast cancer recurrence score. BMC Clinical Pathology, 2018, 18, 14.	1.8	3
3	In the literature: August 2018. ESMO Open, 2018, 3, e000427.	2.0	0
5	Development of a Precise, Clinically Relevant, Digital Classification Schema for Cancer. JCO Clinical Cancer Informatics, 2018, 2, 1-10.	1.0	5
6	Constructive Deep Neural Network for Breast Cancer Diagnosis. IFAC-PapersOnLine, 2018, 51, 98-103.	0.5	23
10	21-Gene assay as predictor of chemotherapy benefit in HER2-negative breast cancer. Npj Breast Cancer, 2018, 4, 37.	2.3	65
11	Case 35-2018: A 68-Year-Old Woman with Back Pain and a Remote History of Breast Cancer. New England Journal of Medicine, 2018, 379, 1946-1953.	13.9	4
12	Use and Impact of the 21-Gene Recurrence Score in Relation to the Clinical Risk of Developing Metastases in Early Breast Cancer Patients in the Netherlands. Public Health Genomics, 2018, 21, 85-92.	0.6	4
13	The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes. Frontiers in Genetics, 2018, 9, 638.	1.1	23
15	Management of young women with early breast cancer. ESMO Open, 2018, 3, e000458.	2.0	15
16	Moving Breast Cancer Therapy up a Notch. Frontiers in Oncology, 2018, 8, 518.	1.3	63
17	Update Breast Cancer 2018 (Part 3) " Genomics, Individualized Medicine and Immune Therapies " in the Middle of a New Era: Prevention and Treatment Strategies for Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2018, 78, 1110-1118.	0.8	8
18	Can Less Be More for Individuals With Low-Risk Breast Cancer?. Journal of the National Cancer Institute, 2018, 110, 1287-1289.	3.0	0
19	Cronomique du cancer du sein appliquée aux traitements. Revue Francophone Des Laboratoires, 2018, 2018, 52-60.	0.0	0
20	ASO Author Reflections: Predicting High-Risk Oncotype DX Recurrence Scores as a Strategy for Assessing Neoadjuvant Chemotherapy Eligibility. Annals of Surgical Oncology, 2018, 25, 683-684.	0.7	0
21	Gene Expression"Guided Adjuvant Chemotherapy in Breast Cancer. New England Journal of Medicine, 2018, 379, 1680-1682.	13.9	1
22	An Update on Breast Cancer Multigene Prognostic Tests"Emergent Clinical Biomarkers. Frontiers in Medicine, 2018, 5, 248.	1.2	139
23	Personalized Treatment in Inflammatory Bowel Disease: For Another Time. Gastroenterology, 2018, 155, 963-964.	0.6	3

#	ARTICLE	IF	CITATIONS
24	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer—From Cell Line Models to Liquid Biopsies. <i>Diagnostics</i> , 2018, 8, 60.	1.3	15
25	Balancing the Economics and Ethics of Personalised Oncology. <i>Trends in Cancer</i> , 2018, 4, 608-615.	3.8	4
27	Lymph Node Status in Breast Cancer Does Not Predict Tumor Biology. <i>Annals of Surgical Oncology</i> , 2018, 25, 2884-2889.	0.7	23
28	Molecular subtypes of screen-detected breast cancer. <i>Breast Cancer Research and Treatment</i> , 2018, 172, 191-199.	1.1	20
29	Perspectives on Geriatric Oncology Research presented at the 2018 American Society of Clinical Oncology Annual Meeting. <i>Journal of Geriatric Oncology</i> , 2018, 9, 419-422.	0.5	1
30	Omission of chemotherapy for low-grade, luminal A N1 breast cancer: Patterns of care and clinical outcomes. <i>Breast</i> , 2018, 41, 67-73.	0.9	10
31	TAILORing Adjuvant Systemic Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2018, 379, 191-192.	13.9	4
32	Impact of Screening Mammography on Treatment in Women Diagnosed with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2018, 25, 2979-2986.	0.7	26
34	The Price of Precision: Genetic Testing and Drug Costs in America. <i>Genetic Testing and Molecular Biomarkers</i> , 2018, 22, 403-404.	0.3	1
35	Treatment Intensity for Mammographically Detected Tumors: An Alternative Viewpoint. <i>Annals of Surgical Oncology</i> , 2018, 25, 2502-2505.	0.7	4
37	Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years. <i>European Journal of Cancer</i> , 2018, 102, 82-94.	1.3	22
38	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714.	0.8	3
39	Clinical relevance of the 21-gene Recurrence Score [®] assay in treatment decisions for patients with node-positive breast cancer in the genomic era. <i>Npj Breast Cancer</i> , 2018, 4, 27.	2.3	28
40	Distribution and Clinical Utility of the 21-gene Recurrence Score in Pure Mucinous Breast Cancer Patients: a case-control study. <i>Journal of Cancer</i> , 2018, 9, 3216-3224.	1.2	9
41	Seven in 10 women with early breast cancer do not need chemotherapy, study finds. <i>BMJ: British Medical Journal</i> , 2018, , k2473.	2.4	2
42	Pathologist's health-care value in the triage of Oncotype [®] testing: a value-based pathology study of tumour biology with outcomes. <i>Histopathology</i> , 2018, 73, 692-700.	1.6	3
43	Avoiding overuse of adjuvant therapies. <i>Nature Reviews Clinical Oncology</i> , 2018, 15, 469-469.	12.5	0
44	21-gene recurrence score testing in the older population with estrogen receptor-positive breast cancer. <i>Journal of Geriatric Oncology</i> , 2019, 10, 322-329.	0.5	27

#	ARTICLE	IF	CITATIONS
45	Optimizing adjuvant endocrine therapy for early ER+ breast cancer: An update for surgeons. American Journal of Surgery, 2019, 217, 152-155.	0.9	4
46	Impact of Genomic Assay Testing and Clinical Factors on Chemotherapy Use After Implementation of Standardized Testing Criteria. Oncologist, 2019, 24, 595-602.	1.9	8
47	Identification of Axillary Lymph Node Metastasis in Patients With Breast Cancer Using Dual-Phase FDG PET/CT. American Journal of Roentgenology, 2019, 213, 1129-1135.	1.0	17
48	Artificial intelligence-directed prognostication of breast cancer. EBioMedicine, 2019, 46, 6-7.	2.7	2
49	Personalized circulating tumor DNA analysis to detect residual disease after neoadjuvant therapy in breast cancer. Science Translational Medicine, 2019, 11, .	5.8	197
50	Noninferiority trials with nonadherence to the assigned randomized treatment. Clinical Trials, 2019, 16, 673-681.	0.7	1
51	Artificial intelligence in digital pathology " new tools for diagnosis and precision oncology. Nature Reviews Clinical Oncology, 2019, 16, 703-715.	12.5	807
53	Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Annals of Oncology, 2019, 30, 1541-1557.	0.6	464
54	Prospective Validation of an Ex Vivo, Patient-Derived 3D Spheroid Model for Response Predictions in Newly Diagnosed Ovarian Cancer. Scientific Reports, 2019, 9, 11153.	1.6	44
55	The effect of Oncotype DX [®] on adjuvant chemotherapy treatment decisions in early breast cancer. Annals of the Royal College of Surgeons of England, 2019, 101, 596-601.	0.3	3
56	Progesterone receptor status and tumor grade predict the 21-gene recurrence score of invasive lobular breast cancer. Biomarkers in Medicine, 2019, 13, 1005-1012.	0.6	8
57	Practice Changing Potential of TAILORx: A Retrospective Review of the National Cancer Data Base from 2010 to 2015. Annals of Surgical Oncology, 2019, 26, 3397-3408.	0.7	7
58	Adjuvant chemotherapy for node negative, high Recurrence Score™ breast cancer: in defense of de-escalation. Npj Breast Cancer, 2019, 5, 24.	2.3	1
59	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Update Summary. Journal of Oncology Practice, 2019, 15, 495-497.	2.5	9
60	Value of Molecular Classification for Prognostic Assessment of Adrenocortical Carcinoma. JAMA Oncology, 2019, 5, 1440.	3.4	57
61	A preliminary report of head-to-head comparison of 18-gene-based clinical-genomic model and oncotype DX 21-gene assay for predicting recurrence of early-stage breast cancer. Japanese Journal of Clinical Oncology, 2019, 49, 1029-1036.	0.6	9
62	Utility of a ready-to-use PCR system for neuroendocrine tumor diagnosis. PLoS ONE, 2019, 14, e0218592.	1.1	17
63	Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer. Frontiers in Oncology, 2019, 9, 667.	1.3	12

#	ARTICLE	IF	CITATIONS
64	Overall survival is improved when DCIS accompanies invasive breast cancer. <i>Scientific Reports</i> , 2019, 9, 9934.	1.6	20
65	The ESMO clinical practise guidelines for early breast cancer: diagnosis, treatment and follow-up: on the winding road to personalized medicine. <i>Annals of Oncology</i> , 2019, 30, 1183-1184.	0.6	18
66	Reply to J.A. Sparano et al. <i>Journal of Clinical Oncology</i> , 2019, 37, 1842-1842.	0.8	0
67	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 2338-2348.	0.8	56
68	Are we Overtreating Hormone Receptor Positive Breast Cancer with Neoadjuvant Chemotherapy? Role of OncotypeDx [®] for Hormone Receptor Positive Patients Undergoing Neoadjuvant Chemotherapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3232-3239.	0.7	15
69	Oncotype DX: Where Does It Stand in India?. <i>Journal of Global Oncology</i> , 2019, 5, 1-2.	0.5	9
70	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage Breast Cancer: Update Summary of ASCO Cancer Care Ontario Guideline Endorsement. <i>Journal of Oncology Practice</i> , 2019, 15, 599-602.	2.5	0
71	Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy. <i>Annals of Surgical Oncology</i> , 2019, 26, 3159-3165.	0.7	8
72	Is Routine Recurrence Score Testing in Patients Older than 70 Years of Age Warranted? An Evaluation of the National Cancer Database After TAILORx. <i>Annals of Surgical Oncology</i> , 2019, 26, 3152-3158.	0.7	2
73	Black Phosphorus-Based Multimodal Nanoagent: Showing Targeted Combinatory Therapeutics against Cancer Metastasis. <i>Nano Letters</i> , 2019, 19, 5587-5594.	4.5	73
74	Clinical Features and Outcomes of Invasive Breast Cancer: Age-Specific Analysis of a Modern Hospital-Based Registry. <i>Journal of Global Oncology</i> , 2019, 5, 1-9.	0.5	13
75	Treating HR+/HER2 ⁻ breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 549-559.	1.1	29
76	Invasive lobular breast cancer: A review of pathogenesis, diagnosis, management, and future directions of early stage disease. <i>Seminars in Oncology</i> , 2019, 46, 121-132.	0.8	90
77	Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings. <i>Breast Cancer Research</i> , 2019, 21, 114.	2.2	17
78	Implications of ARTIC: Is This the Beginning of a Climate Change?. <i>Journal of Clinical Oncology</i> , 2019, 37, 3329-3332.	0.8	0
79	Adjuvant chemotherapy and survival among patients 70 years of age and younger with node-negative breast cancer and the 21-gene recurrence score of 26-30. <i>Breast Cancer Research</i> , 2019, 21, 110.	2.2	25
80	A Value of Information Analysis of Research on the 21-Gene Assay for Breast Cancer Management. <i>Value in Health</i> , 2019, 22, 1102-1110.	0.1	12
81	Postmastectomy radiotherapy in T1-2 patients with one to three positive lymph nodes – Past, present and future. <i>Breast</i> , 2019, 48, 73-81.	0.9	20

#	ARTICLE	IF	CITATIONS
82	Reply to E. Hindi and A.K. Goel et al. Journal of Clinical Oncology, 2019, 37, 2705-2707.	0.8	0
83	Breast Cancer Screening: Beyond Mortality. Journal of Breast Imaging, 2019, 1, 161-165.	0.5	7
84	Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal of the National Comprehensive Cancer Network: JNCCN, 2019, 17, 39-46.	2.3	21
85	Emerging immune gene signatures as prognostic or predictive biomarkers in breast cancer. Archives of Pharmacal Research, 2019, 42, 947-961.	2.7	24
87	Translational Research and Onco-Omics Applications in the Era of Cancer Personal Genomics. Advances in Experimental Medicine and Biology, 2019, , .	0.8	0
88	Genomic Risk Predicts Molecular Imaging-detected Metastatic Nodal Disease in Prostate Cancer. European Urology Oncology, 2019, 2, 685-690.	2.6	21
89	Integrated pan-cancer gene expression and drug sensitivity analysis reveals SLFN11 mRNA as a solid tumor biomarker predictive of sensitivity to DNA-damaging chemotherapy. PLoS ONE, 2019, 14, e0224267.	1.1	26
90	Cost-effectiveness of BRCA1/2 mutation profiling to target olaparib use in patients with metastatic breast cancer. Personalized Medicine, 2019, 16, 439-448.	0.8	7
91	Update Breast Cancer 2019 Part 4 Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Und Frauenheilkunde, 2019, 79, 1079-1089.	0.8	18
92	Breast cancer statistics, 2019. Ca-A Cancer Journal for Clinicians, 2019, 69, 438-451.	157.7	2,068
93	Breast Cancer Index and prediction of benefit from extended endocrine therapy in breast cancer patients treated in the Adjuvant Tamoxifen To Offer More? (aTTom) trial. Annals of Oncology, 2019, 30, 1776-1783.	0.6	108
94	Docetaxel Versus Surveillance After Radical Radiotherapy for Intermediate- or High-risk Prostate Cancer Results from the Prospective, Randomised, Open-label Phase III SPCG-13 Trial. European Urology, 2019, 76, 823-830.	0.9	21
95	Cross comparison and prognostic assessment of breast cancer multigene signatures in a large population-based contemporary clinical series. Scientific Reports, 2019, 9, 12184.	1.6	39
96	Agreement between molecular subtyping and surrogate subtype classification: a contemporary population-based study of ER-positive/HER2-negative primary breast cancer. Breast Cancer Research and Treatment, 2019, 178, 459-467.	1.1	23
97	Simulation Modeling to Extend Clinical Trials of Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Early Breast Cancer. JNCI Cancer Spectrum, 2019, 3, pkz062.	1.4	2
98	St Gallen International Consensus Guidelines in early breast cancer: experts to prevent patients' overtreatment and breaking the bank?. Annals of Oncology, 2019, 30, 1533-1535.	0.6	3
99	Available and emerging molecular markers in the clinical management of breast cancer. Expert Review of Molecular Diagnostics, 2019, 19, 919-928.	1.5	9
100	De-escalation yes, but not at the expense of efficacy: in defense of better treatment. Npj Breast Cancer, 2019, 5, 25.	2.3	3

#	ARTICLE	IF	CITATIONS
101	Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification. <i>Npj Breast Cancer</i> , 2019, 5, 26.	2.3	12
103	Oncoplastic Central Partial Mastectomy and Neoareolar Reduction Mammoplasty with Immediate Nipple Reconstruction: An Initial Report of a Novel Option for Breast Conservation in Patients with Subareolar Tumors. <i>Annals of Surgical Oncology</i> , 2019, 26, 4284-4293.	0.7	6
104	Panoptic View of Prognostic Models for Personalized Breast Cancer Management. <i>Cancers</i> , 2019, 11, 1325.	1.7	7
105	The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics. <i>Expert Opinion on Drug Safety</i> , 2019, 18, 1009-1015.	1.0	11
106	21-Gene Recurrence Score and Adjuvant Chemotherapy Decision for Breast Cancer Patients with Positive Lymph Nodes. <i>Scientific Reports</i> , 2019, 9, 13123.	1.6	13
107	A Nomogram to Predict Factors Associated with Lymph Node Metastasis in Ductal Carcinoma In Situ with Microinvasion. <i>Annals of Surgical Oncology</i> , 2019, 26, 4302-4309.	0.7	12
108	Clinical implications of drug-screening assay for recurrent metastatic hormone receptor-positive, human epidermal receptor 2-negative breast cancer using conditionally reprogrammed cells. <i>Scientific Reports</i> , 2019, 9, 13405.	1.6	6
109	Decentralization of Next-Generation RNA Sequencing-Based MammaPrint® and Blueprint® Kit at University Hospitals Leuven and Curie Institute Paris. <i>Translational Oncology</i> , 2019, 12, 1557-1565.	1.7	6
110	A Radiation Oncologist's Guide to Axillary Management in Breast Cancer: a Walk Through the Trials. <i>Current Breast Cancer Reports</i> , 2019, 11, 293-302.	0.5	1
111	AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. <i>Breast Care</i> , 2019, 14, 224-245.	0.8	72
112	90-gene signature assay for tissue origin diagnosis of brain metastases. <i>Journal of Translational Medicine</i> , 2019, 17, 331.	1.8	12
113	Risk of Hematologic Malignant Neoplasms after Postoperative Treatment of Breast Cancer. <i>Cancers</i> , 2019, 11, 1463.	1.7	13
114	Clinical and Genomic Risk in Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 1289-1291.	13.9	2
115	21-gene recurrence score influences the chemotherapy decision for patients with breast cancer of different luminal subtypes. <i>Oncology Letters</i> , 2019, 18, 4346-4356.	0.8	2
116	Susan G. Komen Big Data for Breast Cancer Initiative: How Patient Advocacy Organizations Can Facilitate Using Big Data to Improve Patient Outcomes. <i>JCO Precision Oncology</i> , 2019, 3, 1-9.	1.5	8
117	Oncotype DX recurrence score implications for disparities in chemotherapy and breast cancer mortality in Georgia. <i>Npj Breast Cancer</i> , 2019, 5, 32.	2.3	17
118	Breast cancer. <i>Nature Reviews Disease Primers</i> , 2019, 5, 66.	18.1	1,620
119	Breast Cancer Treatment. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 288.	3.8	2,785

#	ARTICLE	IF	CITATIONS
120	A spectroscopic and thermal investigation into the relationship between composition, secondary structure and physical characteristics of electrospun zein nanofibers. <i>Materials Science and Engineering C</i> , 2019, 98, 409-418.	3.8	33
121	Molecular and epigenetic profiles of BRCA1-like hormone-receptor-positive breast tumors identified with development and application of a copy-number-based classifier. <i>Breast Cancer Research</i> , 2019, 21, 14.	2.2	5
122	Selecting the Right Tumors for Genomic Testing. <i>Annals of Surgical Oncology</i> , 2019, 26, 313-314.	0.7	0
123	The impact of the 21-gene recurrence score (Oncotype DX) on concordance of adjuvant therapy decision making as measured by the Liverpool Systemic Therapy Adjuvant Decision Tool. <i>Breast</i> , 2019, 44, 94-100.	0.9	1
124	Whole genome sequencing of breast cancer. <i>Apmis</i> , 2019, 127, 303-315.	0.9	23
125	Double Trouble: Contralateral Breast Cancer Risk Management in the Modern Era. <i>Journal of the National Cancer Institute</i> , 2019, 111, 641-643.	3.0	2
126	Modernizing Clinical Trials for Patients With Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 447.	3.8	15
127	Multi-gene assays: effect on chemotherapy use, toxicity and cost in estrogen receptor-positive early stage breast cancer. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 289-304.	0.6	11
128	Insights into Molecular Classifications of Triple-Negative Breast Cancer: Improving Patient Selection for Treatment. <i>Cancer Discovery</i> , 2019, 9, 176-198.	7.7	778
130	A Phase II Randomized Study of Neoadjuvant Letrozole Plus Apelcisib for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer (NEO-ORB). <i>Clinical Cancer Research</i> , 2019, 25, 2975-2987.	3.2	76
131	Evaluation of the Incidence of Hematologic Malignant Neoplasms Among Breast Cancer Survivors in France. <i>JAMA Network Open</i> , 2019, 2, e187147.	2.8	17
132	<p>A novel LARClassifier3 classification predicts outcomes in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy: a retrospective training and validation analysis</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 4153-4170.	0.9	2
133	Race and risk of subsequent aggressive breast cancer following ductal carcinoma in situ. <i>Cancer</i> , 2019, 125, 3225-3233.	2.0	18
134	Xenograft-based, platform-independent gene signatures to predict response to alkylating chemotherapy, radiation, and combination therapy for glioblastoma. <i>Neuro-Oncology</i> , 2019, 21, 1141-1149.	0.6	17
135	Breast Cancer Pathology. , 2019, , 87-127.		1
136	Role of Patient and Disease Factors in Adjuvant Systemic Therapy Decision Making for Early-Stage, Operable Breast Cancer: Update of the ASCO Endorsement of the Cancer Care Ontario Guideline. <i>Journal of Clinical Oncology</i> , 2019, 37, 1965-1977.	0.8	47
137	The Changing Role of Gene-Expression Profiling in the Era of De-escalating Adjuvant Chemotherapy in Early-Stage Breast Cancer. <i>Annals of Surgical Oncology</i> , 2019, 26, 3495-3501.	0.7	7
138	Cancer Genomics for Oncologists: Cancer Risk and Management of BRCA1 and BRCA2 Carriers. <i>Current Genetic Medicine Reports</i> , 2019, 7, 116-123.	1.9	0

#	ARTICLE	IF	CITATIONS
140	Underdiagnosis is the main challenge in breast cancer screening. <i>Lancet Oncology</i> , The, 2019, 20, 1044-1046.	5.1	7
141	Should a Multigene Signature be Used in all Luminal Early Breast Cancers. <i>Frontiers in Oncology</i> , 2019, 9, 454.	1.3	2
142	Artificial intelligence in oncology, its scope and future prospects with specific reference to radiation oncology. <i>BJR Open</i> , 2019, 1, 20180031.	0.4	17
143	6 versus 12 months of adjuvant trastuzumab for HER2-positive early breast cancer (PERSEPHONE): 4-year disease-free survival results of a randomised phase 3 non-inferiority trial. <i>Lancet</i> , The, 2019, 393, 2599-2612.	6.3	225
144	MammaPrint and BluePrint Molecular Diagnostics Using Targeted RNA Next-Generation Sequencing Technology. <i>Journal of Molecular Diagnostics</i> , 2019, 21, 808-823.	1.2	15
145	A simple immunohistochemical bio-profile incorporating Bcl2 curbs those cases of invasive breast carcinoma for which an Oncotype Dx characterization is needed. <i>PLoS ONE</i> , 2019, 14, e0217937.	1.1	4
146	The Pros and Cons of Incorporating Transcriptomics in the Age of Precision Oncology. <i>Journal of the National Cancer Institute</i> , 2019, 111, 1016-1022.	3.0	8
147	TAILORx: Questions Answered, Lessons Learned, and Remaining Knowledge Gaps. <i>Journal of Clinical Oncology</i> , 2019, 37, 1841-1842.	0.8	5
148	Molecular and histological correlations in liver cancer. <i>Journal of Hepatology</i> , 2019, 71, 616-630.	1.8	308
149	Innate and Adaptive Immunology. , 2019, , 313-321.		0
150	Update Breast Cancer 2019 Part 1 â€œ Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 256-267.	0.8	17
151	The use of contralateral prophylactic mastectomy among elderly patients in the United States. <i>Breast Cancer Research and Treatment</i> , 2019, 177, 175-183.	1.1	9
156	Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: ASCO Clinical Practice Guideline Updateâ€”Integration of Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2019, 37, 1956-1964.	0.8	189
157	The Precision of Evidence Needed to Practice â€œPrecision Medicineâ€œ. <i>New England Journal of Medicine</i> , 2019, 380, 2472-2474.	13.9	23
158	Clinical and Genomic Risk to Guide the Use of Adjuvant Therapy for Breast Cancer. <i>New England Journal of Medicine</i> , 2019, 380, 2395-2405.	13.9	349
159	Implications of Neoadjuvant Therapy in Human Epidermal Growth Factor Receptor 2â€œPositive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 2189-2192.	0.8	12
160	Tumorâ€œTargeting W₁₈O₄₉ Nanoparticles for Dualâ€œModality Imaging and Guided Heatâ€œShockâ€œResponseâ€œInhibited Photothermal Therapy in Gastric Cancer. <i>Particle and Particle Systems Characterization</i> , 2019, 36, 1900124.	1.2	19
161	Update Breast Cancer 2019 Part 3 â€œ Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 470-482.	0.8	26

#	ARTICLE	IF	CITATIONS
162	Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1194-1220.	0.6	1,241
163	Heterogeneous intracellular TRAIL-receptor distribution predicts poor outcome in breast cancer patients. <i>Journal of Molecular Medicine</i> , 2019, 97, 1155-1167.	1.7	9
164	Do we need higher-level evidence of improved quality of life outcomes before promoting uptake of oncoplastic breast conservation surgery techniques?. <i>ANZ Journal of Surgery</i> , 2019, 89, 626-627.	0.3	0
165	Risk stratification of ER-positive breast cancer patients: A multi-institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26. <i>Cancer Medicine</i> , 2019, 8, 4176-4188.	1.3	13
166	Update Breast Cancer 2019 Part 2 – Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 268-280.	0.8	21
167	Molecular Testing in Breast Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, e1-e7.	1.8	27
168	Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. <i>Breast</i> , 2019, 46, 116-125.	0.9	44
169	Economic Evaluation of Companion and Complementary Diagnostics. , 2019, , 381-398.		1
170	Oncotype DX for Comprehensive Treatment in Male Breast Cancer: A Case Report and Literature Review. <i>American Journal of Men's Health</i> , 2019, 13, 155798831984785.	0.7	2
171	Female breast cancers (T1-2, N0, M0, HR+, HER2 ⁺) with an intermediate genetic-based recurrence risk: a real-world estimate in Italy. <i>Tumori</i> , 2019, 105, 483-487.	0.6	1
172	Breast Cancer Subtype Classification Using 4-Plex Droplet Digital PCR. <i>Clinical Chemistry</i> , 2019, 65, 1051-1059.	1.5	19
173	Evolution in practice patterns of axillary management following mastectomy in patients with 1-2 positive sentinel nodes. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 435-444.	1.1	20
174	A Multigene Assay Determines Risk of Recurrence in Patients with Triple-Negative Breast Cancer. <i>Cancer Research</i> , 2019, 79, 3466-3478.	0.4	32
176	Distribution and Short-term Prognostic Value of the 21-gene recurrence score in African American compared to White American breast cancer patients. <i>Breast Journal</i> , 2019, 25, 667-671.	0.4	4
177	Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 377-386.	1.1	61
178	Highlights of the 16th St Gallen International Breast Cancer Conference, Vienna, Austria, 20-23 March 2019: personalised treatments for patients with early breast cancer. <i>Ecancermedicalscience</i> , 2019, 13, 924.	0.6	19
179	A novel hydrogen sulfide-releasing donor, HA-ADT, suppresses the growth of human breast cancer cells through inhibiting the PI3K/AKT/mTOR and Ras/Raf/MEK/ERK signaling pathways. <i>Cancer Letters</i> , 2019, 455, 60-72.	3.2	58
180	Clinical significance of 21-gene recurrence score assay for hormone receptor-positive, lymph node-negative breast cancer in early stage. <i>Experimental and Molecular Pathology</i> , 2019, 108, 150-155.	0.9	4

#	ARTICLE	IF	CITATIONS
181	A blood-based prognostic biomarker in IBD. <i>Gut</i> , 2019, 68, 1386-1395.	6.1	132
182	Communicating prognosis to women with early breast cancer – overview of prediction tools and the development and pilot testing of a decision aid. <i>BMC Health Services Research</i> , 2019, 19, 171.	0.9	11
183	Author's reply to: Comparing the performance of gene expression assays in breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1163-1164.	2.3	0
184	Comparing the performance of gene expression assays in breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 1162-1162.	2.3	2
185	Cancer Treatment in the Genomic Era. <i>Annual Review of Biochemistry</i> , 2019, 88, 247-280.	5.0	24
186	Clinical validation of an immunohistochemistry-based CanAssist-Breast test for distant recurrence prediction in hormone receptor-positive breast cancer patients. <i>Cancer Medicine</i> , 2019, 8, 1755-1764.	1.3	29
187	Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. <i>Journal of Evaluation in Clinical Practice</i> , 2019, 25, 196-204.	0.9	8
188	US Food and Drug Administration Approval of New Drugs Based on Noninferiority Trials in Oncology. <i>JAMA Oncology</i> , 2019, 5, 607.	3.4	7
189	A clinical decision support system learned from data to personalize treatment recommendations towards preventing breast cancer metastasis. <i>PLoS ONE</i> , 2019, 14, e0213292.	1.1	32
190	One-step Nucleic Acid Amplification Can Identify Sentinel Node-negative Breast Cancer Patients With Excellent Prognosis. <i>Anticancer Research</i> , 2019, 39, 1447-1454.	0.5	10
191	Genomic Assays to Assess Local Recurrence Risk and Predict Radiation Therapy Benefit in Patients With Ductal Carcinoma In Situ. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 103, 1021-1025.	0.4	3
192	Clinical validation of Ki67 by quantitative reverse transcription-polymerase chain reaction (RT-PCR) in HR+/HER2- early breast cancer. <i>Journal of Cancer</i> , 2019, 10, 1110-1116.	1.2	9
194	Prediction of Oncotype Dx recurrence score using clinical parameters: A comparison of available tools and a simple predictor based on grade and progesterone receptor. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2019, 12, 89-96.	0.6	22
195	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625.	1.1	35
196	Accurate Estrogen Receptor Quantification in Patients with Negative and Low-Positive Estrogen-Receptor-Expressing Breast Tumors: Sub-Analyses of Data from Two Clinical Studies. <i>Advances in Therapy</i> , 2019, 36, 828-841.	1.3	10
197	The 21-gene recurrence score and effects of adjuvant radiotherapy after breast conserving surgery in early-stage breast cancer. <i>Future Oncology</i> , 2019, 15, 1629-1639.	1.1	8
199	Clinical Cancer Advances 2019: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. <i>Journal of Clinical Oncology</i> , 2019, 37, 834-849.	0.8	66
200	Estimating Risk of Recurrence for Early Breast Cancer: Integrating Clinical and Genomic Risk. <i>Journal of Clinical Oncology</i> , 2019, 37, 689-692.	0.8	26

#	ARTICLE	IF	CITATIONS
201	Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 95-100.	1.1	3
202	St. Gallen/Vienna 2019: A Brief Summary of the Consensus Discussion on the Optimal Primary Breast Cancer Treatment. <i>Breast Care</i> , 2019, 14, 103-110.	0.8	131
203	<p>Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 2071-2078.	1.0	2
204	Avoiding over- and undertreatment in patients with resected node-positive breast cancer with the use of gene expression signatures: are we there yet?. <i>Annals of Oncology</i> , 2019, 30, 1044-1050.	0.6	28
205	Reconsidering â€œlowâ€•riskâ€•criteria for breast cancer recurrence in hormone positive patients. <i>Breast Journal</i> , 2019, 25, 545-547.	0.4	2
206	Identification of Prognostic Alternative Splicing Signature in Breast Carcinoma. <i>Frontiers in Genetics</i> , 2019, 10, 278.	1.1	49
207	Efficacy and safety of taxane plus anthracycline with or without cyclophosphamide in Chinese node-positive breast cancer patients: an open-label, randomized controlled trial. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 659-666.	1.1	0
208	pH-Triggered Charge-Reversal Mesoporous Silica Nanoparticles Stabilized by Chitosan Oligosaccharide/Carboxymethyl Chitosan Hybrids for Effective Intracellular Delivery of Doxorubicin. <i>ACS Applied Bio Materials</i> , 2019, 2, 1907-1919.	2.3	39
209	West German Study PlanB Trial: Adjuvant Four Cycles of Epirubicin and Cyclophosphamide Plus Docetaxel Versus Six Cycles of Docetaxel and Cyclophosphamide in HER2-Negative Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2019, 37, 799-808.	0.8	85
210	Prognostic value of tumor cell DNA content determined by flow cytometry using formalin-fixed paraffin-embedded breast cancer tissues. <i>Breast Cancer Research and Treatment</i> , 2019, 176, 75-85.	1.1	5
211	Adjuvant Systemic Treatment of Premenopausal Women With Hormone Receptorâ€•Positive Early Breast Cancer: Lights and Shadows. <i>Journal of Clinical Oncology</i> , 2019, 37, 862-866.	0.8	17
212	Breast Cancer, Version 3.2018. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2019, 17, 118-126.	2.3	158
213	Routine Use of Oncotype DX Recurrence Score Testing in Node-Positive Hormone Receptor-Positive HER2-Negative Breast Cancer: The Time Has Come. <i>Annals of Surgical Oncology</i> , 2019, 26, 1173-1175.	0.7	11
214	Dose intensification of chemotherapy for early breast cancer in the age of de-escalation. <i>Lancet, The</i> , 2019, 393, 1390-1392.	6.3	6
215	Pathological profiles and clinical management challenges of breast cancer emerging in young women in Indonesia: a hospital-based study. <i>BMC Women's Health</i> , 2019, 19, 28.	0.8	24
216	Tailored NEOadjuvant epirubicin, cyclophosphamide and Nanoparticle Albumin-Bound paclitaxel for breast cancer: The phase II NEONAB trialâ€•Clinical outcomes and molecular determinants of response. <i>PLoS ONE</i> , 2019, 14, e0210891.	1.1	13
217	Time for a change and to adopt a novel molecular genomic approach in NETs. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 269-270.	12.5	1
218	Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon. <i>Yonsei Medical Journal</i> , 2019, 60, 235.	0.9	11

#	ARTICLE	IF	CITATIONS
219	Major clinical research advances in gynecologic cancer in 2018. <i>Journal of Gynecologic Oncology</i> , 2019, 30, e18.	1.0	29
220	SHON expression predicts response and relapse risk of breast cancer patients after anthracycline-based combination chemotherapy or tamoxifen treatment. <i>British Journal of Cancer</i> , 2019, 120, 728-745.	2.9	3
221	The prognostic relevance of urokinase-type plasminogen activator (uPA) in the blood of patients with metastatic breast cancer. <i>Scientific Reports</i> , 2019, 9, 2318.	1.6	27
222	Systemic treatment and radiotherapy, breast cancer subtypes, and survival after long-term clinical follow-up. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 287-295.	1.1	18
223	Adjuvant chemotherapy in lobular carcinoma of the breast: a clinicopathological score identifies high-risk patient with survival benefit. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 379-387.	1.1	20
224	New and important changes in breast cancer TNM: incorporation of biologic factors into staging. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 309-318.	1.1	8
225	Comparison of six breast cancer classifiers using qPCR. <i>Bioinformatics</i> , 2019, 35, 3412-3420.	1.8	4
226	Cases in Precision Medicine: The Role of Tumor and Germline Genetic Testing in Breast Cancer Management. <i>Annals of Internal Medicine</i> , 2019, 171, 925.	2.0	10
229	Genomics applied to the treatment of breast cancer. <i>Oncotarget</i> , 2019, 10, 4786-4801.	0.8	20
231	Clinicopathologic analysis of 722 breast cancer patients who met the inclusion criteria of the TAILORx trial. <i>Chinese Medical Journal</i> , 2019, 132, 2914-2919.	0.9	2
232	Neoadjuvant Management of Early Breast Cancer: A Clinical and Investigational Position Statement. <i>Oncologist</i> , 2019, 24, 603-611.	1.9	43
234	Evaluation of the Incorporation of Recurrence Score into the American Joint Committee on Cancer Eighth Edition Staging System in Patients with T1â€²N0M0, Estrogen Receptorâ€²Positive, Human Epidermal Growth Receptor 2â€²Negative Invasive Breast Cancer: A Populationâ€²Based Analysis. <i>Oncologist</i> , 2019, 24, e1014-e1023.	1.9	1
235	Intercalating TOP2 Poisons Attenuate Topoisomerase Action at Higher Concentrations. <i>Molecular Pharmacology</i> , 2019, 96, 475-484.	1.0	34
237	Meta-analysis of the impact of progesterone receptor status on oncological outcomes in oestrogen receptor-positive breast cancer. <i>British Journal of Surgery</i> , 2019, 107, 33-43.	0.1	22
238	Ten-year clinical outcomes in NO ER+ breast cancer patients with Recurrence Score-guided therapy. <i>Npj Breast Cancer</i> , 2019, 5, 41.	2.3	23
240	Reconfigurable Probabilistic AI Architecture for Personalized Cancer Treatment. , 2019, , .		1
241	21-Gene Recurrence Score Adds Significant Value for Grade 3 Breast Cancers: Results From a National Cohort. <i>JCO Precision Oncology</i> , 2019, 3, 1-15.	1.5	6
242	Biomarker-Driven Oncology Clinical Trials: Key Design Elements, Types, Features, and Practical Considerations. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	36

#	ARTICLE	IF	CITATIONS
243	Oncotype DX Breast Cancer recurrence score resists inter-assay reproducibility with RT2-Profiler Multiplex RT-PCR. <i>Scientific Reports</i> , 2019, 9, 20266.	1.6	11
244	Chemotherapy effectiveness in trial-underrepresented groups with early breast cancer: A retrospective cohort study. <i>PLoS Medicine</i> , 2019, 16, e1003006.	3.9	14
245	Editorial: Optimizing treatment strategy in early breast cancer: less is more, or more is better?. <i>Current Opinion in Oncology</i> , 2019, 31, 469-471.	1.1	1
246	<p>Decision of Adjuvant Systemic Treatment in HR+ HER2- Early Invasive Breast Cancer: Which Biomarkers Could Help?</p>. <i>Cancer Management and Research</i> , 2019, Volume 11, 10353-10373.	0.9	8
247	Integrating poly(ADP-ribose) polymerase (PARP) inhibitors in the treatment of early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 247-255.	1.1	7
248	I-SPY 2: a Neoadjuvant Adaptive Clinical Trial Designed to Improve Outcomes in High-Risk Breast Cancer. <i>Current Breast Cancer Reports</i> , 2019, 11, 303-310.	0.5	49
249	Diagnosis and Treatment of Breast Cancer in Young Women. <i>Current Treatment Options in Oncology</i> , 2019, 20, 86.	1.3	70
250	First person profile: Joseph Sparano, MD. <i>Cancer</i> , 2019, 125, 4121-4123.	2.0	0
251	Chromatin regulators mediate anthracycline sensitivity in breast cancer. <i>Nature Medicine</i> , 2019, 25, 1721-1727.	15.2	27
252	Advancing Precision Oncology Through Biomarker-Driven Trials: Theory vs. Practice. <i>Chance</i> , 2019, 32, 23-31.	0.1	2
253	Tissue-based genomics. <i>Current Opinion in Urology</i> , 2019, 29, 598-604.	0.9	3
254	Harmonizing gene signatures to predict benefit from adjuvant chemotherapy in early breast cancer. <i>Current Opinion in Oncology</i> , 2019, 31, 472-479.	1.1	3
255	From the Broad Phase II Trial to Precision Oncology: A Perspective on the Origins of Basket and Umbrella Clinical Trial Designs in Cancer Drug Development. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 245-253.	1.0	4
256	Letter in reply. <i>Journal of Comparative Effectiveness Research</i> , 2019, 8, 1261-1263.	0.6	0
257	Prognostic gene expression profiling in melanoma: necessary steps to incorporate into clinical practice. <i>Melanoma Management</i> , 2019, 6, MMT32.	0.1	28
258	Can precision medicine help achieve the goal of reducing care when the risks exceed the benefits?. <i>Personalized Medicine</i> , 2019, 16, 365-367.	0.8	0
260	ASCO 2019â€™Personal highlights on adjuvant breast cancer: (neo-)adjuvant therapy of HER2-negative HR-positive BC. <i>Memo - Magazine of European Medical Oncology</i> , 2019, 12, 305-307.	0.3	1
261	Estimating the magnitude of clinical benefit from (neo)adjuvant chemotherapy in patients with ER-positive/HER2-negative breast cancer. <i>Breast</i> , 2019, 48, S81-S84.	0.9	1

#	ARTICLE	IF	CITATIONS
262	Breast cancer survivorship care beyond local and systemic therapy. <i>Breast</i> , 2019, 48, S103-S109.	0.9	10
263	Systemic treatment of patients with early breast cancer: recent updates and state of the art. <i>Breast</i> , 2019, 48, S7-S20.	0.9	21
264	Risk stratification in early breast cancer in premenopausal and postmenopausal women: integrating genomic assays with clinicopathological features. <i>Current Opinion in Oncology</i> , 2019, 31, 29-34.	1.1	14
265	The current role for adjuvant and neoadjuvant therapy in renal cell cancer. <i>Current Opinion in Urology</i> , 2019, 29, 636-642.	0.9	12
266	Practical Cancer Genetics and Genomics in Women's Health. <i>Clinical Obstetrics and Gynecology</i> , 2019, 62, 687-699.	0.6	1
267	A Robust Gene Expression Prognostic Signature for Overall Survival in High-Grade Serous Ovarian Cancer. <i>Journal of Oncology</i> , 2019, 2019, 1-12.	0.6	6
268	Identification of Distinct Prognostic Groups: Implications for Patient Selection to Targeted Therapies Among Anti-Endocrine Therapy-Resistant Early Breast Cancers. <i>JCO Precision Oncology</i> , 2019, 3, 1-13.	1.5	0
269	Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study. <i>Oncologist</i> , 2019, 24, 1424-1431.	1.9	22
270	Developing and Validating Risk Assessment Models of Clinical Outcomes in Modern Oncology. <i>JCO Precision Oncology</i> , 2019, 3, 1-12.	1.5	20
271	Mammprint, a comprehensive review. <i>Future Oncology</i> , 2019, 15, 207-224.	1.1	37
272	Progress in adjuvant systemic therapy for breast cancer. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 27-44.	12.5	175
273	Postmastectomy radiation therapy for triple negative, node-negative breast cancer. <i>Radiotherapy and Oncology</i> , 2019, 132, 48-54.	0.3	17
274	TNM classification of malignant tumors (Breast Cancer Study Group). <i>Japanese Journal of Clinical Oncology</i> , 2019, 49, 228-231.	0.6	34
275	OncotypeDX Recurrence Score Does Not Predict Nodal Burden in Clinically Node Negative Breast Cancer Patients. <i>Annals of Surgical Oncology</i> , 2019, 26, 815-820.	0.7	10
276	Caveat Emptor: Let Our Acclaim of the Apotheosis of PRRT Not Blind Us to the Error of Prometheus. <i>Journal of Nuclear Medicine</i> , 2019, 60, 7-8.	2.8	10
277	Patient-centered simulations to assess the usefulness of the 70-gene signature for adjuvant chemotherapy administration in early-stage breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 537-542.	1.1	1
278	Breast Cancer Staging. , 2019, , 99-122.		0
279	Breast Cancers With Magee Equation Score of Less Than 18, or 18-25 and Mitosis Score of 1, Do Not Require Oncotype DX Testing. <i>American Journal of Clinical Pathology</i> , 2019, 151, 316-323.	0.4	21

#	ARTICLE	IF	CITATIONS
280	Positive sentinel node in luminal A-like breast cancer patients - implications for adjuvant chemotherapy?. <i>Acta Oncologica</i> , 2019, 58, 162-167.	0.8	8
281	SEOM clinical guidelines in early stage breast cancer (2018). <i>Clinical and Translational Oncology</i> , 2019, 21, 18-30.	1.2	48
282	Recent advances in breast cancer research impacting clinical diagnostic practice. <i>Journal of Pathology</i> , 2019, 247, 552-562.	2.1	24
283	Anthracycline and taxane-based chemotherapy versus docetaxel and cyclophosphamide in the adjuvant treatment of HER2-negative breast cancer patients: a systematic review and meta-analysis of randomized controlled trials. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 27-37.	1.1	40
284	The Prognostic Significance of the Oncotype DX Recurrence Score in T1-2N1M0 Estrogen Receptor-Positive HER2-Negative Breast Cancer Based on the Prognostic Stage in the Updated AJCC 8th Edition. <i>Annals of Surgical Oncology</i> , 2019, 26, 1227-1235.	0.7	19
285	Gene expression profiling in melanoma: past results and future potential. <i>Future Oncology</i> , 2019, 15, 791-800.	1.1	5
286	21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer. <i>Biomarkers in Medicine</i> , 2019, 13, 83-93.	0.6	19
287	Summary of head-to-head comparisons of patient risk classifications by the 21-gene Recurrence Score® (RS) assay and other genomic assays for early breast cancer. <i>International Journal of Cancer</i> , 2019, 145, 882-893.	2.3	32
289	Truly personalized therapy “an end to the era of one size fits all. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 77-78.	12.5	8
290	PIWI-interacting RNA-36712 restrains breast cancer progression and chemoresistance by interaction with SEPW1 pseudogene SEPW1P RNA. <i>Molecular Cancer</i> , 2019, 18, 9.	7.9	139
291	Going to the negative: genomics for optimized medical prescription. <i>Nature Reviews Genetics</i> , 2019, 20, 1-2.	7.7	34
292	The American Joint Commission Cancer 8th Edition Prognostic Stage Including Oncotype DX® Recurrence Score: Impact on Staging of Early Breast Cancer. <i>Pathobiology</i> , 2019, 86, 77-82.	1.9	5
293	Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 375-383.	1.1	1
294	PAM50 for prediction of response to neoadjuvant chemotherapy for ER-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 533-543.	1.1	34
295	Risk of incident claims for chemotherapy-induced peripheral neuropathy among women with breast cancer in a Medicare population. <i>Cancer</i> , 2019, 125, 269-277.	2.0	18
296	Optimizing multi-modal cancer treatment under 3D spatio-temporal tumor growth. <i>Mathematical Biosciences</i> , 2019, 307, 53-69.	0.9	11
297	Community clinical practice patterns and mortality in patients with intermediate oncotype DX recurrence scores: Who benefits from chemotherapy?. <i>Cancer</i> , 2019, 125, 213-222.	2.0	28
298	Online accounts of gene expression profiling in early-stage breast cancer: Interpreting genomic testing for chemotherapy decision making. <i>Health Expectations</i> , 2019, 22, 74-82.	1.1	10

#	ARTICLE	IF	CITATIONS
299	Lymph node involvement: Positive about the role of the recurrence score in estrogen-driven breast cancer?. <i>Cancer</i> , 2019, 125, 177-180.	2.0	3
300	The impact of gene expression profile testing on confidence in chemotherapy decisions and prognostic expectations. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 417-427.	1.1	4
301	Impact of 21-Gene Expression Assay on Staging Estrogen Receptor-Positive HER2-Negative Breast Cancer. <i>Clinical Breast Cancer</i> , 2019, 19, e261-e269.	1.1	3
302	Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers. <i>Journal of Surgical Oncology</i> , 2019, 119, 175-186.	0.8	32
303	Molecular Diagnostics in Cytopathology. , 2019, , .		0
304	Molecular Diagnostics in Breast Cytology. , 2019, , 301-336.		0
305	EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer. <i>Breast</i> , 2019, 43, 74-80.	0.9	7
306	21-Gene Recurrence Score Testing in HER2-positive Patients. <i>Clinical Breast Cancer</i> , 2019, 19, 126-130.	1.1	2
307	The association of socioeconomic status with receipt of neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 179-188.	1.1	12
308	Validation of the 21-gene test as a predictor of clinical response to neoadjuvant hormonal therapy for ER+, HER2-negative breast cancer: the TransNEOS study. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 123-133.	1.1	77
309	Multifocal/Multicentric Ipsilateral Invasive Breast Carcinomas with Similar Histology: Is Multigene Testing of All Individual Foci Necessary?. <i>Annals of Surgical Oncology</i> , 2019, 26, 329-335.	0.7	9
310	Prognostic Value of the Detection of Lymphovascular Invasion in Hormone Receptor-Positive Early Breast Cancer in the Era of Molecular Profiling. <i>Oncology</i> , 2019, 96, 14-24.	0.9	10
311	Re: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 318-319.	3.0	1
312	Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2020, 112, 154-160.	3.0	27
313	Modifiable risk factors for advanced vs . early breast cancer in the French E3N cohort. <i>International Journal of Cancer</i> , 2020, 146, 850-860.	2.3	5
314	Relationship Between Hereditary Cancer Syndromes and Oncotype DX Recurrence Score. <i>Clinical Breast Cancer</i> , 2020, 20, 125-130.	1.1	5
315	Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy. <i>JAMA Oncology</i> , 2020, 6, 367.	3.4	100
316	Adjuvant Chemotherapy for Older Patients With Breast Cancer: When Is the Pain Worth the Gain?. <i>Journal of the National Cancer Institute</i> , 2020, 112, 551-552.	3.0	3

#	ARTICLE	IF	CITATIONS
317	Multigene assays in early breast cancer: Insights from recent phase 3 studies. <i>European Journal of Surgical Oncology</i> , 2020, 46, 656-666.	0.5	20
318	Absolute Improvements in Freedom From Distant Recurrence to Tailor Adjuvant Endocrine Therapies for Premenopausal Women: Results From TEXT and SOFT. <i>Journal of Clinical Oncology</i> , 2020, 38, 1293-1303.	0.8	93
319	Improving Adjuvant Endocrine Treatment Tailoring in Premenopausal Women With Hormone Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1258-1267.	0.8	33
320	Deep-learning approach to identifying cancer subtypes using high-dimensional genomic data. <i>Bioinformatics</i> , 2020, 36, 1476-1483.	1.8	84
321	RNA sequencing for research and diagnostics in clinical oncology. <i>Seminars in Cancer Biology</i> , 2020, 60, 311-323.	4.3	56
322	Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 889-892.	0.9	9
323	Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor-Positive Early Breast Cancer. <i>Clinical Breast Cancer</i> , 2020, 20, 98-107.e1.	1.1	15
324	Simulation of Chemotherapy Effects in Older Breast Cancer Patients With High Recurrence Scores. <i>Journal of the National Cancer Institute</i> , 2020, 112, 574-581.	3.0	14
325	Comparison of 21-gene assay and St.Gallen International Expert Consensus in the treatment decision for patients with early invasive breast cancers. <i>Cancer Biology and Therapy</i> , 2020, 21, 108-112.	1.5	0
326	Hormone Effects on Tumors. , 2020, , 667-693.		2
327	Impact of 21-gene recurrence score testing on adjuvant chemotherapy decision making in older patients with breast cancer. <i>Journal of Geriatric Oncology</i> , 2020, 11, 843-849.	0.5	5
328	Impact of 21-Gene Expression Assay on Clinical Outcomes in Node-Negative T1b Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 1671-1678.	0.7	10
329	Talking the Talk About Tumor Genomic Testing. <i>Journal of the National Cancer Institute</i> , 2020, 112, 436-437.	3.0	1
330	Reply to A. Katz. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-103.	0.8	0
331	Is It Appropriate to Use the Result of an Unplanned, Exploratory, Nonstatistically Significant Subgroup Analysis to Support a Treatment Recommendation in an ASCO Treatment Guideline?. <i>Journal of Clinical Oncology</i> , 2020, 38, 102-102.	0.8	1
332	Validation of the OncoMasTR Risk Score in Estrogen Receptor-Positive/HER2-Negative Patients: A TransATAC study. <i>Clinical Cancer Research</i> , 2020, 26, 623-631.	3.2	10
333	Breast conserving therapy is associated with improved overall survival compared to mastectomy in early-stage, lymph node-negative breast cancer. <i>Radiotherapy and Oncology</i> , 2020, 142, 186-194.	0.3	38
334	Association Between 21-Gene Assay Recurrence Score and Locoregional Recurrence Rates in Patients With Node-Positive Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 505.	3.4	51

#	ARTICLE	IF	CITATIONS
335	Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 187-195.	1.1	8
336	Cytotoxic chemotherapy: clinical aspects. <i>Medicine</i> , 2020, 48, 97-102.	0.2	10
337	Evaluation of the 12-Gene Molecular Score and the 21-Gene Recurrence Score as Predictors of Response to Neo-adjuvant Chemotherapy in Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 765-771.	0.7	19
338	Change in 21-gene Recurrence Score result after exposure to neo-adjuvant endocrine therapy in patients with operable breast cancer. <i>Breast Journal</i> , 2020, 26, 1449-1451.	0.4	0
339	Evaluation of the Cunningham Panel, a pediatric autoimmune neuropsychiatric disorder associated with streptococcal infection (PANDAS) and pediatric acute-onset neuropsychiatric syndrome (PANS): Changes in antineuronal antibody titers parallel changes in patient symptoms. <i>Journal of Neuroimmunology</i> , 2020, 339, 577138.	1.1	38
340	Considering adjuvant therapy for stage II melanoma. <i>Cancer</i> , 2020, 126, 1166-1174.	2.0	32
341	Nodal positivity decreases with age in women with early-stage, hormone receptor-positive breast cancer. <i>Cancer</i> , 2020, 126, 1193-1201.	2.0	12
342	Genomics and the History of Precision Oncology. <i>Surgical Oncology Clinics of North America</i> , 2020, 29, 35-49.	0.6	23
343	Procalcitonin. <i>Critical Care Clinics</i> , 2020, 36, 23-40.	1.0	104
344	Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information. <i>Clinical Breast Cancer</i> , 2020, 20, 61-67.	1.1	7
345	Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 101-109.	3.2	14
346	Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study. <i>Breast</i> , 2020, 49, 233-241.	0.9	8
347	Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older. <i>Breast Cancer Research and Treatment</i> , 2020, 179, 687-697.	1.1	13
348	Prognostic and predictive markers for adjuvant therapy. <i>Current Opinion in Obstetrics and Gynecology</i> , 2020, 32, 100-105.	0.9	0
349	Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2020, 21, 33-43.	5.1	105
350	Advancing the Science of Cancer in Latinos. , 2020, , .		5
351	Prognostic Impact of the 21-Gene Recurrence Score Assay Among Young Women With Node-Negative and Node-Positive ER-Positive/HER2-Negative Breast Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 725-733.	0.8	46
352	Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG) Tj ETQq1 1 0.784314 rBT /Over		

#	ARTICLE	IF	CITATIONS
353	Association of Diabetes and Other Clinical and Sociodemographic Factors With Guideline-concordant Breast Cancer Treatment for Breast Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 101-106.	0.6	3
354	Precision medicine in an imprecise and complex world: Magic bullets, hype, and the fuzzy line between health and disease. <i>Journal of Evaluation in Clinical Practice</i> , 2020, 26, 1534-1538.	0.9	5
355	Spatially multiplexed RNA in situ hybridization to reveal tumor heterogeneity. <i>Nucleic Acids Research</i> , 2020, 48, e17-e17.	6.5	23
356	Outcome of adjuvant chemotherapy in elderly patients with early-stage, hormone receptor-positive, HER2-negative breast cancer. <i>Breast Journal</i> , 2020, 26, 2026-2030.	0.4	3
357	Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result?. <i>Breast Journal</i> , 2020, 26, 2199-2202.	0.4	3
358	Proteomic analysis of circulating extracellular vesicles identifies potential markers of breast cancer progression, recurrence, and response. <i>Science Advances</i> , 2020, 6, .	4.7	58
359	The role of adjuvant chemotherapy in stage III male breast cancer: a SEER-based analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095835.	1.4	9
360	Two-Stage Adaptive Design for Prognostic Biomarker Signatures With a Survival Endpoint. <i>Statistics in Biopharmaceutical Research</i> , 2020, , 1-10.	0.6	0
361	The Evolution of Our Understanding of the Biology of Cancer Is the Key to Avoiding Overdiagnosis and Overtreatment. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 2463-2474.	1.1	10
362	Development and Validation of a Next-Generation Sequencing-Based Multigene Assay to Predict the Prognosis of Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 6513-6522.	3.2	6
363	Road Map to Safe and Well-Designed De-escalation Trials of Systemic Adjuvant Therapy for Solid Tumors. <i>Journal of Clinical Oncology</i> , 2020, 38, 4120-4129.	0.8	32
364	Side effects of adjuvant chemotherapy and their impact on outcome in elderly breast cancer patients: a cohort study. <i>Future Science OA</i> , 2020, 6, FSO617.	0.9	7
366	A biobank analysis of prognostic biomarkers of the systemic inflammatory response in patients presenting with malignancy of undefined primary origin. <i>European Journal of Cancer</i> , 2020, 139, 1-9.	1.3	4
367	Transcriptomics and solid tumors: The next frontier in precision cancer medicine. <i>Seminars in Cancer Biology</i> , 2022, 84, 50-59.	4.3	36
368	Landmark trials in the medical oncology management of early stage breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 278-292.	0.8	6
369	Prognostic and Predictive Factors in Metastatic Renal Cell Carcinoma. <i>Cancer Journal (Sudbury, Mass)</i> Tj ETQq1 1 0,784314 rgBT /Over	1.0	10
370	Integrated Multiparametric Radiomics and Informatics System for Characterizing Breast Tumor Characteristics with the OncotypeDX Gene Assay. <i>Cancers</i> , 2020, 12, 2772.	1.7	18
371	What happened to the US cancer cooperative groups? A status update ten years after the Institute of Medicine report. <i>Cancer</i> , 2020, 126, 5022-5029.	2.0	9

#	ARTICLE	IF	CITATIONS
372	Clinical utility of genomic signatures in young breast cancer patients: a systematic review. <i>Npj Breast Cancer</i> , 2020, 6, 46.	2.3	29
373	Breast cancer in the young patient: review of therapy and treatment considerations. <i>Breast Cancer Management</i> , 2020, 9, BMT39.	0.2	0
374	Considerations for feature selection using gene pairs and applications in large-scale dataset integration, novel oncogene discovery, and interpretable cancer screening. <i>BMC Medical Genomics</i> , 2020, 13, 148.	0.7	6
375	Inter-tumor genomic heterogeneity of breast cancers: comprehensive genomic profile of primary early breast cancers and relapses. <i>Breast Cancer Research</i> , 2020, 22, 107.	2.2	32
376	Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016. <i>BMC Cancer</i> , 2020, 20, 847.	1.1	5
377	Comparison of breast cancer prognostic tests CanAssist Breast and Oncotype DX. <i>Cancer Medicine</i> , 2020, 9, 7810-7818.	1.3	9
378	Genomic Predictors for Radiation Sensitivity and Toxicity in Breast Cancer—From Promise to Reality. <i>Current Breast Cancer Reports</i> , 2020, 12, 255-265.	0.5	1
380	Advances in the Molecular Taxonomy of Breast Cancer. <i>Archives of Medical Research</i> , 2020, 51, 777-783.	1.5	8
381	Management of hormone receptor-positive, HER2-negative early breast cancer. <i>Seminars in Oncology</i> , 2020, 47, 187-200.	0.8	24
382	The 21-Gene Recurrence Score Assay and Prediction of Chemotherapy Benefit: A Propensity Score-Matched Analysis of the SEER Database. <i>Cancers</i> , 2020, 12, 1829.	1.7	7
383	The Influence of Histologic Grade on Outcomes of Elderly Women With Early Stage Breast Cancer Treated With Breast Conserving Surgery With or Without Radiotherapy. <i>Clinical Breast Cancer</i> , 2020, 20, e701-e710.	1.1	7
384	Cost-effectiveness analyses demonstrate that observation is superior to sentinel lymph node biopsy for postmenopausal women with HR+ breast cancer and negative axillary ultrasound. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 251-262.	1.1	6
385	Update Breast Cancer 2020 Part 3 – Early Breast Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1105-1114.	0.8	12
386	WNT4 secreted by tumor tissues promotes tumor progression in colorectal cancer by activation of the Wnt/ β -catenin signalling pathway. <i>Journal of Experimental and Clinical Cancer Research</i> , 2020, 39, 251.	3.5	34
387	Comparison of comfort and complications in breast cancer patients of implantable venous access port (IVAP) with ultrasound guided internal jugular vein (IJV) and axillary vein/subclavian vein (AxV/SCV) puncture: a randomized controlled study protocol. <i>Annals of Palliative Medicine</i> , 2020, 9, 4323-4331.	0.5	4
388	Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 130.	2.2	7
389	Addition of chemotherapy to local therapy in women aged 70 years or older with triple-negative breast cancer: a propensity-matched analysis. <i>Lancet Oncology</i> , The, 2020, 21, 1611-1619.	5.1	45
390	Reimagining T Staging Through Artificial Intelligence and Machine Learning Image Processing Approaches in Digital Pathology. <i>JCO Clinical Cancer Informatics</i> , 2020, 4, 1039-1050.	1.0	10

#	ARTICLE	IF	CITATIONS
391	Prognostic Model and Nomogram for Estimating Survival of Small Breast Cancer: A SEER-based Analysis. <i>Clinical Breast Cancer</i> , 2021, 21, e497-e505.	1.1	10
392	Neoadjuvant chemotherapy for luminal a breast cancer: Factors predictive of histopathologic response and oncologic outcome. <i>American Journal of Surgery</i> , 2021, 222, 368-376.	0.9	13
393	The run-in phase of the prospective WSG-ADAPT HR+/HER2- trial demonstrates the feasibility of a study design combining static and dynamic biomarker assessments for individualized therapy in early breast cancer. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592097313.	1.4	18
394	Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database. <i>Frontiers in Oncology</i> , 2020, 10, 1583.	1.3	10
395	Differential impact of prognostic parameters in hormone receptor- positive lobular breast cancer. <i>Cancer</i> , 2020, 126, 4847-4858.	2.0	33
396	Time to rethink vascular access in patients with breast cancer. <i>British Journal of Nursing</i> , 2020, 29, S32-S38.	0.3	2
397	Peritumoural stroma collagen organization of invasive ductal carcinoma assessed by polarized light microscopy differs between OncotypeDX risk group. <i>Journal of Biophotonics</i> , 2020, 13, e202000188.	1.1	6
398	Primary 21-Gene Recurrence Score and Disease Outcome in Loco-Regional and Distant Recurrent Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 1315.	1.3	3
399	Single Hormone Receptor-Positive Breast Cancers Have Distinct Characteristics and Survival. <i>Annals of Surgical Oncology</i> , 2020, 27, 4687-4694.	0.7	21
400	The Potential Use of Tumour-Based Prognostic and Predictive Tools in Older Women with Primary Breast Cancer: A Narrative Review. <i>Oncology and Therapy</i> , 2020, 8, 231-250.	1.0	2
401	Molecular biology of breast cancer. , 2020, , 449-461.		0
402	Luminal Breast Cancer: The Head of Janus in Breast Oncology. <i>Breast Care</i> , 2020, 15, 325-326.	0.8	0
403	Concordance of breast cancer biomarker status between routine immunohistochemistry/in situ hybridization and Oncotype DX qRT-PCR with investigation of discordance, a study of 591 cases. <i>Human Pathology</i> , 2020, 104, 54-65.	1.1	2
404	A system for risk stratification and prioritization of breast cancer surgeries delayed by the COVID-19 pandemic: preparing for re-entry. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 515-524.	1.1	11
405	Big Data Approaches in Heart Failure Research. <i>Current Heart Failure Reports</i> , 2020, 17, 213-224.	1.3	13
406	A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation. <i>Lancet Oncology</i> , The, 2020, 21, 1455-1464.	5.1	52
407	Genomic expression assay testing among American Indian and Alaska Native women with breast cancer. <i>Cancer</i> , 2020, 126, 5222-5229.	2.0	2
408	Tailoring precision immunotherapy: coming to a clinic soon?. <i>ESMO Open</i> , 2020, 5, e000631.	2.0	8

#	ARTICLE	IF	CITATIONS
409	A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection. <i>Neurosurgery</i> , 2021, 88, 202-210.	0.6	19
410	Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. <i>PLoS ONE</i> , 2020, 15, e0238593.	1.1	2
411	Genomic Signatures in Luminal Breast Cancer. <i>Breast Care</i> , 2020, 15, 355-365.	0.8	20
414	CDK4/6 Inhibition in Early-Stage Breast Cancer: The New Standard?. <i>Journal of Clinical Oncology</i> , 2020, 38, 3977-3979.	0.8	6
415	Beyond Chemotherapies: Recent Strategies in Breast Cancer Treatment. <i>Cancers</i> , 2020, 12, 2634.	1.7	7
417	Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. <i>JAMA Network Open</i> , 2020, 3, e2013973.	2.8	5
418	Characteristics and Outcomes for Secondary Breast Cancer in Childhood, Adolescent, and Young Adult Cancer Survivors Treated with Radiation. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2020, 29, 1767-1774.	1.1	6
419	The Long and Winding Road for Breast Cancer Biomarkers to Reach Clinical Utility. <i>Clinical Cancer Research</i> , 2020, 26, 5543-5545.	3.2	6
420	Racial and ethnic disparities in 21-gene recurrence scores, chemotherapy, and survival among women with hormone receptor-positive, node-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 915-925.	1.1	12
421	Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 683-687.	1.1	2
422	Four cycles of docetaxel and cyclophosphamide as adjuvant chemotherapy in node negative breast cancer: A real-world study. <i>Breast</i> , 2020, 54, 1-7.	0.9	3
424	Discordance in 21-gene recurrence scores between paired breast cancer samples is inversely associated with patient age. <i>Breast Cancer Research</i> , 2020, 22, 90.	2.2	11
425	Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 325-334.	1.1	18
426	Prognostic significance of residual nodal disease after neoadjuvant endocrine therapy for hormone receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2020, 6, 35.	2.3	27
427	Intratumoral heterogeneity of second-harmonic generation scattering from tumor collagen and its effects on metastatic risk prediction. <i>BMC Cancer</i> , 2020, 20, 1217.	1.1	10
428	Impact of Commercialized Genomic Tests on Adjuvant Treatment Decisions in Early Stage Breast Cancer Patients. <i>Journal of Oncology</i> , 2020, 2020, 1-7.	0.6	3
429	Predictability of 21-Gene Recurrence Score Assay by Using Pathological and Immunohistochemical Parameters in Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2020, 14, 117822342097784.	0.6	0
430	Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2557-2570.	13.9	146

#	ARTICLE	IF	CITATIONS
431	Residual Axillary Burden After Neoadjuvant Chemotherapy (NACT) in Early Breast Cancer in Patients with a priori Clinically Occult Nodal Metastases – a transSENTINA Analysis. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1229-1236.	0.8	3
432	The menstrual cycle is an under-appreciated factor in premenopausal breast cancer diagnosis and treatment. <i>Current Opinion in Endocrine and Metabolic Research</i> , 2020, 15, 37-42.	0.6	3
433	23P Oncotype DX RS correlation with clinicopathologic risk factors and chemotherapy: Follow up based on TAILORx study. <i>Annals of Oncology</i> , 2020, 31, S1250.	0.6	0
434	Pan-cancer prognostic models of clinical outcomes: statistical exercise or clinical tools?. <i>Annals of Oncology</i> , 2020, 31, 1427-1429.	0.6	2
435	Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial. <i>Breast Cancer Research</i> , 2020, 22, 111.	2.2	15
436	Blood molecular markers associated with COVID-19 immunopathology and multi-organ damage. <i>EMBO Journal</i> , 2020, 39, e105896.	3.5	123
437	A Systematic Review of the Value Assessment Frameworks Used within Health Technology Assessment of Omics Technologies and Their Actual Adoption from HTA Agencies. <i>International Journal of Environmental Research and Public Health</i> , 2020, 17, 8001.	1.2	5
438	MYC Targets Scores Are Associated with Cancer Aggressiveness and Poor Survival in ER-Positive Primary and Metastatic Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8127.	1.8	71
439	Low Overall Survival in Women With De Novo Metastatic Breast Cancer: Does This Reflect Tumor Biology or a Lack of Access to Health Care?. <i>JCO Global Oncology</i> , 2020, 6, 679-687.	0.8	8
441	Prediction of Oncotype DX recurrence score using deep multi-layer perceptrons in estrogen receptor-positive, HER2-negative breast cancer. <i>Breast Cancer</i> , 2020, 27, 1007-1016.	1.3	25
442	The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real-world early-stage breast cancer. <i>Cancer Medicine</i> , 2020, 9, 4603-4612.	1.3	3
443	Utility of Oncotype DX in Male Breast Cancer Patients and Impact on Chemotherapy Administration: A Comparative Study with Female Patients. <i>Annals of Surgical Oncology</i> , 2020, 27, 3605-3611.	0.7	7
444	p53 and BLC2 Immunohistochemical Expression Across Molecular Subtypes in 1099 Early Breast Cancer Patients With Long-Term Follow-up: An Observational Study. <i>Clinical Breast Cancer</i> , 2020, 20, e761-e770.	1.1	4
445	Risk factors of distant metastasis after surgery among different breast cancer subtypes: a hospital-based study in Indonesia. <i>World Journal of Surgical Oncology</i> , 2020, 18, 117.	0.8	17
446	Does the Sequence of Anthracycline and Taxane Matter? The NeoSAMBA Trial. <i>Oncologist</i> , 2020, 25, 758-764.	1.9	4
447	Do 21-Gene Recurrence Score Influence Chemotherapy Decisions in T1bN0 Breast Cancer Patients?. <i>Frontiers in Oncology</i> , 2020, 10, 708.	1.3	2
448	Multigene testing in breast cancer: What have we learned from the 21-gene recurrence score assay?. <i>Breast Journal</i> , 2020, 26, 1199-1207.	0.4	8
449	EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 137-146.	1.1	18

#	ARTICLE	IF	CITATIONS
450	Time trends of neoadjuvant chemotherapy for early breast cancer. <i>International Journal of Cancer</i> , 2020, 147, 3049-3058.	2.3	26
451	Association of 21-Gene Assay (OncotypeDX) Testing and Receipt of Chemotherapy in the Medicare Breast Cancer Patient Population Following Initial Adoption. <i>Clinical Breast Cancer</i> , 2020, 20, 487-494.e1.	1.1	1
452	Efficacy of neoadjuvant endocrine therapy compared with neoadjuvant chemotherapy in pre-menopausal patients with oestrogen receptor-positive and HER2-negative, lymph node-positive breast cancer. <i>Breast Cancer Research</i> , 2020, 22, 54.	2.2	32
453	If you don't measure it, you can't improve it: Success and shortcomings of genomic assays in early breast cancer. <i>Cancer</i> , 2020, 126, 3922-3925.	2.0	0
454	Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunohistochemistry Analysis. <i>Clinical Breast Cancer</i> , 2020, 20, e600-e611.	1.1	3
455	Quantitative assessment of distant recurrence risk in early stage breast cancer using a nonlinear combination of pathological, clinical and imaging variables. <i>Journal of Biophotonics</i> , 2020, 13, e201960235.	1.1	0
457	Prognostic potential of automated Ki67 evaluation in breast cancer: different hot spot definitions versus true global score. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 161-175.	1.1	29
458	Molecular characterization of breast cancer needle core biopsy specimens by the 21-gene Breast Recurrence Score test. <i>Journal of Surgical Oncology</i> , 2020, 122, 611-618.	0.8	17
459	Personalised medicine and the decision to withhold chemotherapy in early breast cancer with intermediate risk of recurrence – a systematic review and meta-analysis. <i>European Journal of Clinical Pharmacology</i> , 2020, 76, 1199-1211.	0.8	2
460	Barriers to Clinical Trial Accrual: Perspectives of Community-Based Providers. <i>Clinical Breast Cancer</i> , 2020, 20, 395-401.e3.	1.1	7
461	The Effect of Adjuvant Treatment in Small Node-negative HER2-positive Breast Cancer: Which Subgroup Will Benefit?. <i>Clinical Breast Cancer</i> , 2020, 20, 503-510.	1.1	2
462	Predictive Value of Molecular Subtypes in Premenopausal Women with Hormone Receptor-positive Early Breast Cancer: Results from the ABCSG Trial 5. <i>Clinical Cancer Research</i> , 2020, 26, 5682-5688.	3.2	4
463	Aim for Clinical Utility, Not Just Predictive Accuracy. <i>Epidemiology</i> , 2020, 31, 359-364.	1.2	17
464	RDCN-based predictive model for the prognosis of breast cancer. <i>Experimental Hematology and Oncology</i> , 2020, 9, 13.	2.0	12
465	Adjuvant endocrine treatment for estrogen receptor (ER)-positive/HER2-negative breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 33-33.	0.4	7
466	Pharmacological management of male breast cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1493-1504.	0.9	3
467	Overview of Breast Cancer and Implications of Overtreatment of Early-Stage Breast Cancer: An Indian Perspective. <i>JCO Global Oncology</i> , 2020, 6, 789-798.	0.8	44
468	Impact of chemotherapy, radiotherapy, and endocrine therapy on sick leave in women with early-stage breast cancer during a 5-year period: a population-based cohort study. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 699-707.	1.1	8

#	ARTICLE	IF	CITATIONS
469	Propensity score analysis of the prognostic value of genomic assays for breast cancer in diverse populations using the National Cancer Data Base. <i>Cancer</i> , 2020, 126, 4013-4022.	2.0	23
470	A new clinical-genomic model to predict 10-year recurrence risk in primary operable breast cancer patients. <i>Scientific Reports</i> , 2020, 10, 4861.	1.6	7
471	Adjuvant Chemotherapy for Patients with Breast Cancer Based on Clinical and Evolving Oncotype DX Criteria. <i>Breast Care</i> , 2020, 15, 642-647.	0.8	1
472	The impact of 21-gene Recurrence Score test and classic clinical-pathologic factors in guiding adjuvant therapy for HER2-negative, ER-positive, early-stage breast cancer: A retrospective study. <i>Breast Journal</i> , 2020, 26, 1064-1066.	0.4	0
473	Cognitive Impairment in Patients With Breast Cancer: Understanding the Impact of Chemotherapy and Endocrine Therapy. <i>Journal of Clinical Oncology</i> , 2020, 38, 1871-1874.	0.8	10
474	Biomarkers of neoadjuvant/adjuvant chemotherapy for breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 27-27.	0.4	37
475	Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. <i>Cancers</i> , 2020, 12, 712.	1.7	3
476	The healthcare value of the Magee Decision Algorithm [®] : use of Magee Equations [®] and mitosis score to safely forgo molecular testing in breast cancer. <i>Modern Pathology</i> , 2020, 33, 1563-1570.	2.9	27
477	Decision-making of Adjuvant Chemotherapy for Breast Cancer Patients with Discordant Risk Classifications between Clinical-Pathological Factors and 21-gene Recurrence Score. <i>Journal of Cancer</i> , 2020, 11, 2509-2517.	1.2	1
478	Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. <i>Medical Sciences (Basel, Switzerland)</i> , 2020, 8, 18.	1.3	72
479	Tumor Microenvironment. <i>Cancer Treatment and Research</i> , 2020, , .	0.2	12
480	Breast cancer diagnosis based on lipid profiling by probe electrospray ionization mass spectrometry. <i>British Journal of Surgery</i> , 2020, 107, 632-635.	0.1	22
481	Comprehensive Transcriptomic Profiling Identifies Breast Cancer Patients Who May Be Spared Adjuvant Systemic Therapy. <i>Clinical Cancer Research</i> , 2020, 26, 171-182.	3.2	14
482	The impact of Oncotype DX breast cancer assay results on clinical practice: a UK experience. <i>Breast Cancer Research and Treatment</i> , 2020, 180, 809-817.	1.1	24
483	Comparison of Estrogen receptors, Progesterone receptors and HER2-neu immunohistochemistry results in breast cancer with those of Oncotype Dx. <i>Annals of Diagnostic Pathology</i> , 2020, 47, 151556.	0.6	2
484	Deep learning-based survival prediction for multiple cancer types using histopathology images. <i>PLoS ONE</i> , 2020, 15, e0233678.	1.1	143
485	4. Supportivtherapie. , 2020, , 127-216.		0
486	The history, present situation, and future directions of neoadjuvant chemotherapy for HER2-negative breast cancer. <i>Chinese Clinical Oncology</i> , 2020, 9, 29-29.	0.4	9

#	ARTICLE	IF	CITATIONS
487	Impact of progesterone receptor status on response to neoadjuvant chemotherapy in estrogen receptor-positive breast cancer patients. <i>Journal of Surgical Oncology</i> , 2020, 122, 861-868.	0.8	2
488	Oncotype DX Breast Recurrence Score®: A Review of its Use in Early-Stage Breast Cancer. <i>Molecular Diagnosis and Therapy</i> , 2020, 24, 621-632.	1.6	33
489	Case 22-2020: A 62-Year-Old Woman with Early Breast Cancer during the Covid-19 Pandemic. <i>New England Journal of Medicine</i> , 2020, 383, 262-272.	13.9	12
490	Technical Validity of a Customized Assay of Sensitivity to Endocrine Therapy Using Sections from Fixed Breast Cancer Tissue. <i>Clinical Chemistry</i> , 2020, 66, 934-945.	1.5	5
491	Question Prompt List to Support Patient-Provider Communication in the Use of the 21-Gene Recurrence Test: Feasibility, Acceptability, and Outcomes. <i>JCO Oncology Practice</i> , 2020, 16, e1085-e1097.	1.4	11
492	Impact of Recurrence Score on Type and Duration of Chemotherapy in Breast Cancer. <i>Current Oncology</i> , 2020, 27, 86-92.	0.9	1
493	Distribution of the 21-Gene Breast Recurrence Score in Patients with Primary Breast Cancer in Germany. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 619-627.	0.8	7
494	The Landmark Series: Neoadjuvant Endocrine Therapy for Breast Cancer. <i>Annals of Surgical Oncology</i> , 2020, 27, 3393-3401.	0.7	14
495	Current State of the Art in the Adjuvant Systemic Treatment of Premenopausal Patients With Early Breast Cancer. <i>Clinical Medicine Insights: Oncology</i> , 2020, 14, 117955492093181.	0.6	7
496	Sarcopenia and monocyte-to-lymphocyte ratio as prognostic factors in early-stage breast cancer. <i>Annals of Translational Medicine</i> , 2020, 8, 737-737.	0.7	1
497	Novel radiation therapy approaches for breast cancer treatment. <i>Seminars in Oncology</i> , 2020, 47, 209-216.	0.8	29
499	Strategies to Improve Recruitment to a De-escalation Trial: A Mixed-Methods Study of the OPTIMA Prelim Trial in Early Breast Cancer. <i>Clinical Oncology</i> , 2020, 32, 382-389.	0.6	3
500	The Evolving Complexity of Treating Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer: Special Considerations in Older Breast Cancer Patients Part I: Early-Stage Disease. <i>Drugs and Aging</i> , 2020, 37, 331-348.	1.3	3
501	A multidisciplinary expert opinion on CINV and RINV, unmet needs and practical real-life approaches. <i>Expert Opinion on Drug Safety</i> , 2020, 19, 187-204.	1.0	5
502	Maximizing Breast Cancer Therapy with Awareness of Potential Treatment-Related Blood Disorders. <i>Oncologist</i> , 2020, 25, 391-397.	1.9	13
503	Clinical vs genomic risks in breast cancer in 2019: Breast pathologist's appellate review of the controversial results from TAILORx trial. <i>Breast Journal</i> , 2020, 26, 1447-1448.	0.4	0
504	Commercially Available Gene Expression Assays as Predictive Tools for Adjuvant Radiotherapy? A Critical Review. <i>Breast Care</i> , 2020, 15, 118-127.	0.8	10
505	Standard Anthracycline Based Versus Docetaxel-Capecitabine in Early High Clinical and/or Genomic Risk Breast Cancer in the EORTC 10041/BIG 3-04 MINDACT Phase III Trial. <i>Journal of Clinical Oncology</i> , 2020, 38, 1186-1197.	0.8	10

#	ARTICLE	IF	CITATIONS
506	RNA expression and risk of venous thromboembolism in lung cancer. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2020, 4, 117-123.	1.0	9
507	Programmed death-ligand 1 gene expression is a prognostic marker in early breast cancer and provides additional prognostic value to 21-gene and 70-gene signatures in estrogen receptor-positive disease. <i>Molecular Oncology</i> , 2020, 14, 951-963.	2.1	18
508	Adherence to Adjuvant Aromatase Inhibitor Therapy Among Postmenopausal Hispanic/Latino Women With Breast Cancer. <i>Anticancer Research</i> , 2020, 40, 857-864.	0.5	12
509	Use of the 21-Gene Recurrence Score to Predict Clinical Outcomes in Early Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, 584.	3.4	0
510	Current concepts in breast cancer genomics: An evidence based review by the CGC breast cancer working group. <i>Cancer Genetics</i> , 2020, 244, 11-20.	0.2	4
511	Trends in utilization of sentinel node biopsy and adjuvant radiation in women ≥ 70 . <i>Breast Journal</i> , 2020, 26, 1321-1329.	0.4	6
512	MAGI1, a New Potential Tumor Suppressor Gene in Estrogen Receptor Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 223.	1.7	15
513	Genomic profiling in oncology clinical practice. <i>Clinical and Translational Oncology</i> , 2020, 22, 1430-1439.	1.2	4
514	Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. <i>Journal of Clinical Oncology</i> , 2020, 38, 1346-1366.	0.8	673
515	Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update. <i>Archives of Pathology and Laboratory Medicine</i> , 2020, 144, 545-563.	1.2	205
516	Case-Based Review and Clinical Guidance on the Use of Genomic Assays for Early-Stage Breast Cancer: Breast Cancer Therapy Expert Group (BCTEG). <i>Clinical Breast Cancer</i> , 2020, 20, 183-193.	1.1	13
517	Is there an association between body mass index and 21-gene recurrence score?. <i>Surgical Oncology</i> , 2020, 34, 74-79.	0.8	4
518	Prognostic DNA methylation markers for hormone receptor breast cancer: a systematic review. <i>Breast Cancer Research</i> , 2020, 22, 13.	2.2	29
519	Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer. <i>JAMA Oncology</i> , 2020, 6, e196400.	3.4	32
520	The prognostic and predictive role of 21-gene recurrence scores in hormone receptor-positive early-stage breast cancer. <i>Journal of Surgical Oncology</i> , 2020, 122, 144-154.	0.8	7
521	Mucinous carcinoma with micropapillary features is morphologically, clinically and genetically distinct from pure mucinous carcinoma of breast. <i>Modern Pathology</i> , 2020, 33, 1945-1960.	2.9	19
522	Molecular profiling in breast cancer—ready for clinical routine?. <i>Memo - Magazine of European Medical Oncology</i> , 2020, 13, 445-449.	0.3	7
523	ESO—ESMO 4th International Consensus Guidelines for Breast Cancer in Young Women (BCY4). <i>Annals of Oncology</i> , 2020, 31, 674-696.	0.6	172

#	ARTICLE	IF	CITATIONS
524	Review of precision cancer medicine: Evolution of the treatment paradigm. <i>Cancer Treatment Reviews</i> , 2020, 86, 102019.	3.4	327
525	Being Precise About Precision Medicine: What Should Value Frameworks Incorporate to Address Precision Medicine? A Report of the Personalized Precision Medicine Special Interest Group. <i>Value in Health</i> , 2020, 23, 529-539.	0.1	59
526	National Cancer Institute: Restructuring to Support the Clinical Trials of the Future. <i>Seminars in Oncology Nursing</i> , 2020, 36, 151003.	0.7	4
527	Prognostic impact of ACTN4 gene copy number alteration in hormone receptor-positive, HER2-negative, node-negative invasive breast carcinoma. <i>British Journal of Cancer</i> , 2020, 122, 1811-1817.	2.9	8
528	Informative censoring â€” a neglected cause of bias in oncology trials. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 327-328.	12.5	43
529	Characterization of Hypoxia Signature to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Glioma Groups. <i>Frontiers in Oncology</i> , 2020, 10, 796.	1.3	118
530	Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 487-497.	1.1	272
531	Executable cancer models: successes and challenges. <i>Nature Reviews Cancer</i> , 2020, 20, 343-354.	12.8	43
532	ASO Author Reflections: No Profiling in Male Breast Cancer: Where We are and Where We Should Be. <i>Annals of Surgical Oncology</i> , 2020, 27, 3612-3613.	0.7	0
533	Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study. <i>Cancer Communications</i> , 2020, 40, 181-193.	3.7	18
534	Update Breast Cancer 2020 Part 2 â€” Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 391-398.	0.8	12
535	G2M Cell Cycle Pathway Score as a Prognostic Biomarker of Metastasis in Estrogen Receptor (ER)-Positive Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2921.	1.8	100
536	Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institutionâ€™s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer. <i>Breast</i> , 2020, 51, 120-126.	0.9	20
537	Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDx study. <i>Breast</i> , 2020, 52, 1-7.	0.9	8
538	Model Combining Tumor Molecular and Clinicopathologic Risk Factors Predicts Sentinel Lymph Node Metastasis in Primary Cutaneous Melanoma. <i>JCO Precision Oncology</i> , 2020, 4, 319-334.	1.5	67
539	Patient-Reported Cognitive Impairment Among Women With Early Breast Cancer Randomly Assigned to Endocrine Therapy Alone Versus Chemoendocrine Therapy: Results From TAILORx. <i>Journal of Clinical Oncology</i> , 2020, 38, 1875-1886.	0.8	59
540	Scalp cooling for hair loss prevention in female Japanese breast cancer patients receiving (neo)adjuvant chemotherapy. <i>Supportive Care in Cancer</i> , 2021, 29, 437-443.	1.0	6
541	Optimizing Survival Analysis of XGBoost for Ties to Predict Disease Progression of Breast Cancer. <i>IEEE Transactions on Biomedical Engineering</i> , 2021, 68, 148-160.	2.5	68

#	ARTICLE	IF	CITATIONS
542	Effect of adjuvant chemotherapy in patients with ER+%/HER2- breast cancer, assessed by propensity score matching: significance of nuclear grade and nodal status. <i>Breast Cancer</i> , 2021, 28, 40-47.	1.3	1
543	Prognostic and predictive parameters in breast pathology: a pathologist's primer. <i>Modern Pathology</i> , 2021, 34, 94-106.	2.9	14
544	Response to neoadjuvant chemotherapy and the 21-gene Breast Recurrence Score test in young women with estrogen receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 157-165.	1.1	12
545	The use of genomic tests in patients with breast cancer in Lombardy: a successful healthcare model. <i>Tumori</i> , 2021, 107, 166-170.	0.6	5
546	Adjuvant Chemotherapy for Low-Clinical-Risk Breast Cancer Defined by Modified Version of Adjuvant! Online: A Propensity Score Matched SEER Analysis. <i>Breast Care</i> , 2021, 16, 156-162.	0.8	1
547	Magee Equations ^{â„¢} and response to neoadjuvant chemotherapy in ER+/HER2-negative breast cancer: a multi-institutional study. <i>Modern Pathology</i> , 2021, 34, 77-84.	2.9	14
548	A Gene-Expression Predictor for Efficacy of Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma. <i>Journal of the National Cancer Institute</i> , 2021, 113, 471-480.	3.0	17
549	Zinc distribution within breast cancer tissue of different intrinsic subtypes. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 195-205.	0.8	17
550	Oncotype DX testing in node-positive breast cancer strongly impacts chemotherapy use at a comprehensive cancer center. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 215-227.	1.1	10
551	Identification of blood protein biomarkers for breast cancer staging by integrative transcriptome and proteome analyses. <i>Journal of Proteomics</i> , 2021, 230, 103991.	1.2	16
553	Oncoplastic Breast-Conserving Surgery: Can We Reduce Rates of Mastectomy and Chemotherapy Use in Patients with Traditional Indications for Mastectomy?. <i>Annals of Surgical Oncology</i> , 2021, 28, 2199-2209.	0.7	8
554	Race, Ethnicity, and Clinical Outcomes in Hormone Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer in the Randomized TAILORx Trial. <i>Journal of the National Cancer Institute</i> , 2021, 113, 390-399.	3.0	62
555	Predicted Chemotherapy Benefit for Breast Cancer Patients With Germline Pathogenic Variants in Cancer Susceptibility Genes. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkaa083.	1.4	3
556	Perspective: A potential role for NUS in metabolite- based in vitro diagnostics. <i>Magnetic Resonance in Chemistry</i> , 2021, 59, 257-263.	1.1	3
557	Genomic Aberrations and Late Recurrence in Postmenopausal Women with Hormone Receptor- positive Early Breast Cancer: Results from the SOLE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 504-512.	3.2	5
558	The 21-gene recurrence score in node-positive, hormone receptor-positive, HER2-negative breast cancer: a cautionary tale from an NCDB analysis. <i>Breast Cancer Research and Treatment</i> , 2021, 185, 667-676.	1.1	11
559	21-gene recurrence score testing utilization among older women from different races: A population-based study. <i>Journal of Geriatric Oncology</i> , 2021, 12, 206-211.	0.5	4
560	A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma. <i>Annals of Oncology</i> , 2021, 32, 250-260.	0.6	45

#	ARTICLE	IF	CITATIONS
561	Deep learning in cancer pathology: a new generation of clinical biomarkers. <i>British Journal of Cancer</i> , 2021, 124, 686-696.	2.9	291
562	Updates on the treatment of invasive breast cancer: Quo Vadimus?. <i>Maturitas</i> , 2021, 145, 64-72.	1.0	7
563	Endocrine Therapy for Breast Cancer. <i>Journal for Nurse Practitioners</i> , 2021, 17, 177-181.	0.4	1
564	Breast cancer tumor heterogeneity has only little impact on the estimation of the Oncotype DX® recurrence score using Magee Equations and Magee Decision Algorithm. <i>Human Pathology</i> , 2021, 108, 51-59.	1.1	1
565	Relationships between pathological factors and long-term outcomes in patients enrolled in two prospective randomized controlled trials comparing the efficacy of oral tegafurâ€“uracil with CMF (NÂ·SAS-BCÂ01 trial and CUBC trial). <i>Breast Cancer Research and Treatment</i> , 2021, 186, 135-147.	1.1	1
566	Breast cancer, screening and diagnostic tools: All you need to know. <i>Critical Reviews in Oncology/Hematology</i> , 2021, 157, 103174.	2.0	55
567	Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 557-564.	0.8	69
568	Delay in surgery is associated with axillary upstaging of clinically node negative breast cancer patients. <i>Journal of Surgical Oncology</i> , 2021, 123, 854-865.	0.8	7
569	Relationship of Oncotype Dx score with tumor grade, size, nodal status, proliferative marker Ki67 and Nottingham Prognostic Index in early breast cancer tumors in Saudi Population. <i>Annals of Diagnostic Pathology</i> , 2021, 51, 151674.	0.6	7
570	Identification and Complete Validation of Prognostic Gene Signatures for Human Papillomavirus-Associated Cancers: Integrated Approach Covering Different Anatomical Locations. <i>Journal of Virology</i> , 2021, 95, .	1.5	4
571	Breast Cancer Index Predicts Extended Endocrine Benefit to Individualize Selection of Patients with HR+ Early-stage Breast Cancer for 10 Years of Endocrine Therapy. <i>Clinical Cancer Research</i> , 2021, 27, 311-319.	3.2	58
572	Carboxymethyl chitosan based redox-responsive micelle for near-infrared fluorescence image-guided photo-chemotherapy of liver cancer. <i>Carbohydrate Polymers</i> , 2021, 253, 117284.	5.1	15
573	Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement. <i>American Journal of Transplantation</i> , 2021, 21, 460-474.	2.6	67
574	Molecular Biology in the Breast Clinicsâ€“Current status and future perspectives. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 7-20.	0.3	0
575	CanAssist Breast Impacting Clinical Treatment Decisions in Early-Stage HR+ Breast Cancer Patients: Indian Scenario. <i>Indian Journal of Surgical Oncology</i> , 2021, 12, 21-29.	0.3	12
576	The clinical utility of gene expression assays in breast cancer patients with 0â€“3 involved lymph nodes. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110384.	1.4	4
577	Systemic Therapy for the Treatment of Breast Cancer. , 2021, , 81-87.		0
578	Developing a clinical-pathologic model to predict genomic risk of recurrence in patients with hormone receptor positive, human epidermal growth factor receptor-2 negative, node negative breast cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 28, 100401.	0.7	2

#	ARTICLE	IF	CITATIONS
579	Concordance of the 21-gene assay between core needle biopsy and resection specimens in early breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 327-342.	1.1	14
580	Recent advances in neoadjuvant therapy for breast cancer. <i>Faculty Reviews</i> , 2021, 10, 2.	1.7	8
581	A novel immune prognostic index for stratification of high-risk patients with early breast cancer. <i>Scientific Reports</i> , 2021, 11, 128.	1.6	5
582	Is radiomic MRI a feasible alternative to OncotypeDX® recurrence score testing? A systematic review and meta-analysis. <i>BJS Open</i> , 2021, 5, .	0.7	6
583	Postmenopausal Women with HR +/- HER2 - Early Breast Cancer, 1-3 Positive Nodes, and a Low Risk of Recurrence Can Safely Forego Chemotherapy. <i>Oncologist</i> , 2021, 26, S11-S12.	1.9	2
584	Planning Adjuvant Treatment. , 2021, , 569-577.		0
585	Invasive lobular carcinoma of the breast: the increasing importance of this special subtype. <i>Breast Cancer Research</i> , 2021, 23, 6.	2.2	64
586	Adrenocortical carcinoma: current state of the art, ongoing controversies, and future directions in diagnosis and treatment. <i>Therapeutic Advances in Chronic Disease</i> , 2021, 12, 204062232110331.	1.1	15
587	Update on the most promising biomarkers of response to immune checkpoint inhibitors in clear cell renal cell carcinoma. <i>World Journal of Urology</i> , 2021, 39, 1377-1385.	1.2	15
588	The Global Landscape of Treatment Standards for Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1143-1155.	3.0	13
589	Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer. <i>Computational and Structural Biotechnology Journal</i> , 2021, 19, 4101-4109.	1.9	436
591	Clinical Impact of a Novel Model Predictive of Oncotype DX Recurrence Score in Breast Cancer. <i>In Vivo</i> , 2021, 35, 2439-2444.	0.6	2
592	Hoping for the Worst? A Paradoxical Preference for Bad News. <i>Journal of Consumer Research</i> , 2021, 48, 270-288.	3.5	3
593	Adaptation of international coronavirus disease 2019 and breast cancer guidelines to local context. <i>World Journal of Clinical Oncology</i> , 2021, 12, 31-42.	0.9	3
594	Multi-protein spatial signatures in ductal carcinoma in situ (DCIS) of breast. <i>British Journal of Cancer</i> , 2021, 124, 1150-1159.	2.9	11
595	Evaluating the Clinical Utility of Routine Sentinel Lymph Node Biopsy and the Value of Adjuvant Chemotherapy in Elderly Patients Diagnosed With Oestrogen Receptor Positive, Clinically Node Negative Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2021, 15, 117822342110222.	0.6	3
596	Surgeon and medical oncologist peer network effects on the uptake of the 21-gene breast cancer recurrence score assay. <i>Cancer Medicine</i> , 2021, 10, 1253-1263.	1.3	4
597	Current Achievements and Applications of Transcriptomics in Personalized Cancer Medicine. <i>International Journal of Molecular Sciences</i> , 2021, 22, 1422.	1.8	64

#	ARTICLE	IF	CITATIONS
598	Impact of the COVID-19 Pandemic on Breast Cancer Mortality in the US: Estimates From Collaborative Simulation Modeling. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1484-1494.	3.0	92
599	Tumor Microenvironment Features as Predictive Biomarkers of Response to Immune Checkpoint Inhibitors (ICI) in Metastatic Clear Cell Renal Cell Carcinoma (mccRCC). <i>Cancers</i> , 2021, 13, 231.	1.7	42
600	The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 1320-1325.	0.7	13
601	Concordance Between 21-Gene Recurrence Scores in Multifocal or Multicentric Breast Carcinomas Differs by Age and Histologic Subtype. <i>Annals of Surgical Oncology</i> , 2021, 28, 4256-4262.	0.7	5
602	Value of a 21-gene expression assay on core biopsy to predict neoadjuvant chemotherapy response in breast cancer: systematic review and meta-analysis. <i>British Journal of Surgery</i> , 2021, 108, 24-31.	0.1	28
603	Oncotype DX and Prosigna in breast cancer patients: A comparison study. <i>Cancer Treatment and Research Communications</i> , 2021, 26, 100306.	0.7	6
604	Recommendations from the European Commission Initiative on Breast Cancer for multigene testing to guide the use of adjuvant chemotherapy in patients with early breast cancer, hormone receptor positive, HER-2 negative. <i>British Journal of Cancer</i> , 2021, 124, 1503-1512.	2.9	24
605	How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients. <i>Current Oncology</i> , 2021, 28, 800-812.	0.9	5
606	A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age. <i>Journal of Translational Medicine</i> , 2021, 19, 75.	1.8	3
607	Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management. <i>Journal of Personalized Medicine</i> , 2021, 11, 156.	1.1	1
608	Concordance between results of inexpensive statistical models and multigene signatures in patients with ER+/HER2 ⁻ early breast cancer. <i>Modern Pathology</i> , 2021, 34, 1297-1309.	2.9	5
609	Refining breast cancer prognosis by incorporating age at diagnosis into clinical prognostic staging: introduction of a novel online calculator. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 805-814.	1.1	5
610	Molecular Biomarkers for Contemporary Therapies in Hormone Receptor-Positive Breast Cancer. <i>Genes</i> , 2021, 12, 285.	1.0	18
611	Patient-Reported Outcomes Bridge an Important Gap in Identifying Risk for Early Endocrine Therapy Discontinuation. <i>Journal of the National Cancer Institute</i> , 2021, 113, 945-947.	3.0	6
612	Recent Advances in Integrative Multi-Omics Research in Breast and Ovarian Cancer. <i>Journal of Personalized Medicine</i> , 2021, 11, 149.	1.1	16
613	Systematic evaluation of scoring methods for Ki67 as a surrogate for 21-gene recurrence score. <i>Npj Breast Cancer</i> , 2021, 7, 13.	2.3	10
614	The Level of Agreement Among Medical Oncologists on Adjuvant Chemotherapy Decision for Breast Cancer in Pre and Post-Oncotype DX Settings. <i>Cureus</i> , 2021, 13, e13298.	0.2	0
616	Characterizing patient-oncologist communication in genomic tumor testing: The 21-gene recurrence score as an exemplar. <i>Patient Education and Counseling</i> , 2021, 104, 250-256.	1.0	3

#	ARTICLE	IF	CITATIONS
617	Validation of the GenesWell BCT Score in Young Asian Women With HR+/HER2 ⁻ Early Breast Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 588728.	1.3	2
618	eTumorMetastasis: A Network-based Algorithm Predicts Clinical Outcomes Using Whole-exome Sequencing Data of Cancer Patients. <i>Genomics, Proteomics and Bioinformatics</i> , 2021, 19, 973-985.	3.0	6
619	In modern times, how important are breast cancer stage, grade and receptor subtype for survival: a population-based cohort study. <i>Breast Cancer Research</i> , 2021, 23, 17.	2.2	31
620	Concordance of the molecular subtype classification between core needle biopsy and surgical specimen in primary breast cancer. <i>Archives of Gynecology and Obstetrics</i> , 2021, 304, 783-790.	0.8	5
621	Targeting transcription of MCL-1 sensitizes HER2-amplified breast cancers to HER2 inhibitors. <i>Cell Death and Disease</i> , 2021, 12, 179.	2.7	11
622	Background Parenchymal Enhancement on Breast MRI as a Prognostic Surrogate: Correlation With Breast Cancer Oncotype Dx Score. <i>Frontiers in Oncology</i> , 2020, 10, 595820.	1.3	9
623	Neoadjuvant Endocrine Therapy in Breast Cancer Management: State of the Art. <i>Cancers</i> , 2021, 13, 902.	1.7	6
624	The multigene classifiers 95GC/42GC/155GC for precision medicine in ER ⁺ positive HER2 ⁻ negative early breast cancer. <i>Cancer Science</i> , 2021, 112, 1369-1375.	1.7	7
625	FGFR1 amplification or overexpression and hormonal resistance in luminal breast cancer: rationale for a triple blockade of ER, CDK4/6, and FGFR1. <i>Breast Cancer Research</i> , 2021, 23, 21.	2.2	22
626	Development and validation for research assessment of Oncotype DX [®] Breast Recurrence Score, EndoPredict [®] and Prosigna [®] . <i>Npj Breast Cancer</i> , 2021, 7, 15.	2.3	11
627	The IHC4+C score: an affordable and reproducible non-molecular decision-aid in hormone receptor-positive breast cancer. Does it still hold value for patients in 2020?. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2021, 17, 368-376.	0.7	2
628	Genomic Assays in Node Positive Breast Cancer Patients: A Review. <i>Frontiers in Oncology</i> , 2020, 10, 609100.	1.3	13
629	Are restricted mean survival time methods especially useful for noninferiority trials?. <i>Clinical Trials</i> , 2021, 18, 188-196.	0.7	7
631	Multifocality, Multicentricity, and Bilaterality of Breast Cancer. , 0, , .		0
632	Reconsidering the Meaning of Curing Primary Breast Cancer as a Systemic Disease. <i>Frontiers in Oncology</i> , 2021, 11, 639420.	1.3	0
633	Lymphovascular invasion, race, and the 21-gene recurrence score in early estrogen receptor-positive breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 20.	2.3	12
634	Clinicopathological correlates, oncological impact, and validation of Oncotype DX [®] in a European Tertiary Referral Centre. <i>Breast Journal</i> , 2021, 27, 521-528.	0.4	22
635	A Clinicogenetic Prognostic Classifier for Prediction of Recurrence and Survival in Asian Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 645853.	1.3	4

#	ARTICLE	IF	CITATIONS
636	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. <i>Cells</i> , 2021, 10, 648.	1.8	47
637	Novel evolutionary dynamics of small populations in breast cancer adjuvant and neoadjuvant therapy. <i>Npj Breast Cancer</i> , 2021, 7, 26.	2.3	7
638	Neoadjuvant endocrine therapy use in early stage breast cancer during the covid-19 pandemic. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 249-258.	1.1	20
639	The oncogene AAMDC links PI3K-AKT-mTOR signaling with metabolic reprogramming in estrogen receptor-positive breast cancer. <i>Nature Communications</i> , 2021, 12, 1920.	5.8	19
640	A qualitative study to evaluate physician attitudes regarding omission of surgery among exceptional responders to neoadjuvant systemic therapy for breast cancer (NRG-CC006). <i>Breast Cancer Research and Treatment</i> , 2021, 187, 777-784.	1.1	4
641	Personalization in Modern Radiation Oncology: Methods, Results and Pitfalls. <i>Personalized Interventions and Breast Cancer. Frontiers in Oncology</i> , 2021, 11, 616042.	1.3	7
642	Personalized Decision Making on Genomic Testing in Early Breast Cancer: Expanding the MINDACT Trial with Decision-Analytic Modeling. <i>Medical Decision Making</i> , 2021, 41, 354-365.	1.2	1
643	Integrating Adjuvant Radiation with Post-Neoadjuvant Therapies in Early Breast Cancer. <i>Current Oncology Reports</i> , 2021, 23, 58.	1.8	1
644	Comprehensive Association Analysis of 21-Gene Recurrence Score and Obesity in Chinese Breast Cancer Patients. <i>Frontiers in Oncology</i> , 2021, 11, 619840.	1.3	5
645	Cancer Cell Intrinsic and Immunologic Phenotypes Determine Clinical Outcomes in Basal-like Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3079-3093.	3.2	8
646	Adequacy of early-stage breast cancer systemic adjuvant treatment to Saint Gallen-2013 statement: the MCC-Spain study. <i>Scientific Reports</i> , 2021, 11, 5375.	1.6	1
647	On the design and the analysis of stratified biomarker trials in the presence of measurement error. <i>Statistics in Medicine</i> , 2021, 40, 2783-2799.	0.8	0
648	The Impact of Genomic Profiling on Adjuvant Therapy Recommendation in Postmenopausal Women with ER-Positive, T1-2 Breast Cancer: Can Genomic Profiling Eliminate the Need for Sentinel Lymph Node Biopsy?. <i>Clinical Breast Cancer</i> , 2021, 21, e731-e737.	1.1	2
650	Association of Race/Ethnicity and the 21-Gene Recurrence Score With Breast Cancer-Specific Mortality Among US Women. <i>JAMA Oncology</i> , 2021, 7, 370.	3.4	64
651	A Four-Gene-Based Prognostic Model Predicts Overall Survival in Patients With Cutaneous Melanoma. <i>Frontiers in Oncology</i> , 2021, 11, 639874.	1.3	10
652	Pleomorphic adenoma of the breast: A potential morphologic and molecular pitfall in the era of genomic risk stratification. <i>Current Problems in Cancer Case Reports</i> , 2021, 3, 100047.	0.1	2
654	Exploring the effects of genomic testing on fear of cancer recurrence among breast cancer survivors. <i>Psycho-Oncology</i> , 2021, 30, 1322-1331.	1.0	3
655	Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 583-592.	1.1	2

#	ARTICLE	IF	CITATIONS
656	Effects of PIM3 in prognosis of colon cancer. <i>Clinical and Translational Oncology</i> , 2021, 23, 2163-2170.	1.2	3
659	The avoidable casualties in America's war on cancer. <i>Cancer</i> , 2021, 127, 2390-2392.	2.0	0
660	Selection of neoadjuvant treatment based on the 21-GENE test results in luminal breast cancer. <i>Breast</i> , 2021, 56, 35-41.	0.9	13
661	Invited Commentary. <i>Journal of the American College of Surgeons</i> , 2021, 232, 491-492.	0.2	0
662	Precision Oncology via NMR-Based Metabolomics: A Review on Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2021, 22, 4687.	1.8	23
663	70-gene signature as an aid for treatment decisions in early breast cancer: updated results of the phase 3 randomised MINDACT trial with an exploratory analysis by age. <i>Lancet Oncology</i> , The, 2021, 22, 476-488.	5.1	179
664	Genomic Correlates of DNA Damage in Breast Cancer Subtypes. <i>Cancers</i> , 2021, 13, 2117.	1.7	3
665	We have to talk about it: Bringing fertility into the conversation for young women with breast cancer. <i>Cancer</i> , 2021, 127, 2873-2876.	2.0	1
666	Leveraging Single-Cell Approaches in Cancer Precision Medicine. <i>Trends in Cancer</i> , 2021, 7, 359-372.	3.8	18
667	Multigene tests for breast cancer: the physician's perspective. <i>Oncotarget</i> , 2021, 12, 936-947.	0.8	9
668	Real-world analysis of clinical and economic impact of 21-gene recurrence score (RS) testing in early-stage breast cancer (ESBC) in Ireland. <i>Breast Cancer Research and Treatment</i> , 2021, 188, 789-798.	1.1	6
669	Breast cancer patients' insurance status and residence zip code correlate with early discontinuation of endocrine therapy: An analysis of the ECOG-ACRIN TAILORx trial. <i>Cancer</i> , 2021, 127, 2545-2552.	2.0	20
670	Innovative Approaches in the Battle Against Cancer Recurrence: Novel Strategies to Combat Dormant Disseminated Tumor Cells. <i>Frontiers in Oncology</i> , 2021, 11, 659963.	1.3	29
671	Long-Term Outcomes in a Multicenter, Prospective Cohort Evaluating the Prognostic 31-Gene Expression Profile for Cutaneous Melanoma. <i>JCO Precision Oncology</i> , 2021, 5, 589-601.	1.5	20
672	The Proper Ki-67 Cut-Off in Hormone Responsive Breast Cancer: A Monoinstitutional Analysis with Long-Term Follow-Up. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 213-217.	1.0	10
673	Genetic Testing and De-escalation of Contralateral Prophylactic Mastectomy. <i>Annals of Surgical Oncology</i> , 2021, 28, 4764-4766.	0.7	2
674	Factors associated with chemotherapy benefit in breast cancer patients with midrange Oncotype DX breast recurrence scores. <i>Cancer Letters</i> , 2021, 503, 213-219.	3.2	3
675	Breast-conserving Surgery Without Radiation Therapy for Invasive Cancer. <i>Clinical Breast Cancer</i> , 2021, 21, 112-119.	1.1	5

#	ARTICLE	IF	CITATIONS
676	Using multiple imputation to classify potential outcomes subgroups. <i>Statistical Methods in Medical Research</i> , 2021, 30, 1428-1444.	0.7	0
677	An <i>in vivo</i> genome-wide shRNA screen identifies BCL6 as a targetable biomarker of paclitaxel resistance in breast cancer. <i>Molecular Oncology</i> , 2021, 15, 2046-2064.	2.1	5
678	Comparison of hormone-induced mRNA and protein biomarker expression changes in breast cancer cells. <i>Breast Cancer Research and Treatment</i> , 2021, 187, 681-693.	1.1	0
679	The impact of progesterone receptor negativity on oncological outcomes in oestrogen-receptor-positive breast cancer. <i>BJS Open</i> , 2021, 5, .	0.7	19
680	Annual Screening Mammography Associated With Lower Stage Breast Cancer Compared With Biennial Screening. <i>American Journal of Roentgenology</i> , 2021, 217, 40-47.	1.0	11
681	Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry. <i>Frontiers in Oncology</i> , 2021, 11, 596364.	1.3	14
683	Current Landscape of Targeted Therapy in Hormone Receptor-Positive and HER2-Negative Breast Cancer. <i>Current Oncology</i> , 2021, 28, 1803-1822.	0.9	24
684	PONDx: real-life utilization and decision impact of the 21-gene assay on clinical practice in Italy. <i>Npj Breast Cancer</i> , 2021, 7, 47.	2.3	18
685	Breast cancer dormancy: need for clinically relevant models to address current gaps in knowledge. <i>Npj Breast Cancer</i> , 2021, 7, 66.	2.3	35
686	Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. <i>Molecular Diagnosis and Therapy</i> , 2021, 25, 409-424.	1.6	33
687	Breast cancer. <i>Lancet</i> , The, 2021, 397, 1750-1769.	6.3	731
688	Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1744-1750.	3.0	7
689	Highlights of the 17th St. Gallen International Breast Cancer Conference 2021: customising local and systemic therapies. <i>Ecancermedicalscience</i> , 2021, 15, 1236.	0.6	8
690	Mammograms and Mortality: How Has the Evidence Evolved?. <i>Journal of Economic Perspectives</i> , 2021, 35, 119-140.	2.7	8
691	Influence of the competing risk of death on estimates of disease recurrence in trials of adjuvant endocrine therapy for early-stage breast cancer: A secondary analysis of MA.27, MA.17 and MA.17R. <i>European Journal of Cancer</i> , 2021, 149, 117-127.	1.3	7
692	The Present and Future of Neoadjuvant Endocrine Therapy for Breast Cancer Treatment. <i>Cancers</i> , 2021, 13, 2538.	1.7	14
693	Update Breast Cancer 2021 Part 1 – Prevention and Early Stages. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 526-538.	0.8	10
694	Tissue-Based Biomarkers for the Risk Stratification of Men With Clinically Localized Prostate Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 676716.	1.3	14

#	ARTICLE	IF	CITATIONS
695	The use of genomic assays reduces rates of chemotherapy: a single-institution experience. Irish Journal of Medical Science, 2021, , 1.	0.8	1
696	Discovery of Î²-carboline-(phenylsulfonyl)furoxan hybrids as potential anti-breast cancer agents. Bioorganic and Medicinal Chemistry Letters, 2021, 40, 127952.	1.0	14
697	Staging of the Axilla in Breast Cancer and the Evolving Role of Axillary Ultrasound. Breast Cancer: Targets and Therapy, 2021, Volume 13, 311-323.	1.0	6
698	Challenges in Adjuvant Therapy for Premenopausal Women Diagnosed With Luminal Breast Cancers. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2021, 41, e47-e61.	1.8	12
699	Identifying Prognostic Significance of RCL1 and Four-Gene Signature as Novel Potential Biomarkers in HCC Patients. Journal of Oncology, 2021, 2021, 1-20.	0.6	5
702	De-escalation of Systemic Therapy for Early-Stage, Node-Negative Her2+ and Triple-Negative Breast Cancer. Current Breast Cancer Reports, 2021, 13, 151-156.	0.5	1
703	Disease recurrence and oncological outcome of patients treated surgically with curative intent for estrogen receptor positive, lymph node negative breast cancer. Surgical Oncology, 2021, 37, 101531.	0.8	21
704	Clinical and Psychosocial Challenges of Breast Cancer in Adolescent and Young Adult Women Under the Age of 40 Years. JCO Oncology Practice, 2021, 17, 317-319.	1.4	3
705	What Is the Optimal Model to Estimate the Benefits of Chemotherapy in Patients With Hormone Receptorâ€“Positive, HER2-Negative, Node-Negative Breast Cancer?. Journal of Clinical Oncology, 2021, 39, 1946-1947.	0.8	1
706	A 95-gene signature stratifies recurrence risk of invasive disease in ER-positive, HER2-negative, node-negative breast cancer with intermediate 21-gene signature recurrence scores. Breast Cancer Research and Treatment, 2021, 189, 455-461.	1.1	6
707	A Neoadjuvant Chemotherapy Trial for Early Breast Cancer is Impacted by COVID-19: Addressing Vaccination and Cancer Trials Through Education, Equity, and Outcomes. Clinical Cancer Research, 2021, 27, 4486-4490.	3.2	7
708	Molecular Genomic Assessment Using a Blood-based mRNA Signature (NETest) is Cost-effective and Predicts Neuroendocrine Tumor Recurrence With 94% Accuracy. Annals of Surgery, 2021, 274, 481-490.	2.1	22
709	Undercutting efforts of precision medicine: roadblocks to minority representation in breast cancer clinical trials. Breast Cancer Research and Treatment, 2021, 187, 605-611.	1.1	4
710	Lack of prognostic impact of sentinel node micro-metastases in endocrine receptor-positive early breast cancer: results from a large multicenter cohortâ†. ESMO Open, 2021, 6, 100151.	2.0	13
711	Reply to K. Ando et al. Journal of Clinical Oncology, 2021, 39, 1947-1948.	0.8	0
712	Update Breast Cancer 2021 Part 3 â€“ Current Developments in the Treatment of Early Breast Cancer: Review and Assessment of Specialised Treatment Scenarios by an International Expert Panel. Geburtshilfe Und Frauenheilkunde, 2021, 81, 654-665.	0.8	4
713	Perineural invasion as a risk factor for locoregional recurrence of invasive breast cancer. Scientific Reports, 2021, 11, 12781.	1.6	17
714	Will the Use of Biomarkers Improve Bladder Cancer Radiotherapy Delivery?. Clinical Oncology, 2021, 33, e264-e273.	0.6	4

#	ARTICLE	IF	CITATIONS
715	NGS in Lung, Breast, and Unknown Primary Cancer in Colombia: A Multidisciplinary Consensus on Challenges and Opportunities. <i>JCO Global Oncology</i> , 2021, 7, 1012-1023.	0.8	7
716	When the World Throws You a Curve Ball: Lessons Learned in Breast Cancer Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2021, 41, e79-e89.	1.8	3
717	Receipt of guideline-concordant care among young adult women with breast cancer. <i>Cancer</i> , 2021, 127, 3325-3333.	2.0	3
718	Efficacy of adjuvant chemotherapy stratified by age and the 21-gene recurrence score in estrogen receptor-positive breast cancer. <i>BMC Cancer</i> , 2021, 21, 707.	1.1	1
719	Ovarian cycle stage critically affects 21-gene recurrence scores in Mmtv-Pytm mouse mammary tumours. <i>BMC Cancer</i> , 2021, 21, 736.	1.1	3
720	Adjuvant chemotherapy and survival outcome in node-negative breast cancer with a 21-gene recurrence score of 26-30. <i>Future Oncology</i> , 2021, 17, 2183-2192.	1.1	1
721	Expert review on systemic treatment in the St. Gallen International Breast Cancer Conference 2021. <i>Translational Breast Cancer Research</i> , 0, 2, 17-17.	0.4	2
722	Genomically Guided Breast Radiation Therapy: A Review of the Current Data and Future Directions. <i>Advances in Radiation Oncology</i> , 2021, 6, 100731.	0.6	7
723	Comparative survival analysis of multiparametric tests when molecular tests disagree: A TEAM Pathology study. <i>Npj Breast Cancer</i> , 2021, 7, 90.	2.3	0
724	Artificial intelligence for clinical oncology. <i>Cancer Cell</i> , 2021, 39, 916-927.	7.7	136
725	Highlights of the San Antonio Breast Cancer Symposium 2020: part 2. <i>Future Oncology</i> , 2021, 17, 2699-2703.	1.1	0
726	Introduction to the key contents of the Chinese Society of Breast Surgery Practice Guideline 2021. <i>Translational Breast Cancer Research</i> , 0, 2, 18-18.	0.4	0
727	Evaluation of multiple transcriptomic gene risk signatures in male breast cancer. <i>Npj Breast Cancer</i> , 2021, 7, 98.	2.3	4
728	Discordance in Oncotype DX Breast Recurrence Score® Results for Bilateral Breast Cancer. <i>Annals of Surgical Oncology</i> , 2021, 28, 8711-8716.	0.7	1
729	Targeting DNA Damage Response and Repair to Enhance Therapeutic Index in Cisplatin-Based Cancer Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8199.	1.8	48
730	Updated interpretation for early breast cancer in The Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines. <i>Translational Breast Cancer Research</i> , 0, 2, 24-24.	0.4	1
731	Substantial Reduction in Adjuvant Chemotherapy With the Use of the 21-Gene Test to Manage Early Breast Cancer in a Public Hospital in Brazil. <i>JCO Global Oncology</i> , 2021, 7, 1003-1011.	0.8	10
732	Learning from BISCAY: The future of biomarker-based trial design in bladder cancer. <i>Cancer Cell</i> , 2021, 39, 910-912.	7.7	4

#	ARTICLE	IF	CITATIONS
733	Financial Toxicity During Breast Cancer Treatment: A Qualitative Analysis to Inform Strategies for Mitigation. <i>JCO Oncology Practice</i> , 2021, 17, e1413-e1423.	1.4	24
734	Prediction of quality of life in early breast cancer upon completion of adjuvant chemotherapy. <i>Npj Breast Cancer</i> , 2021, 7, 92.	2.3	8
735	Is the 21-Gene Recurrence Score on Core Needle Biopsy Equivalent to Surgical Specimen in Early-Stage Breast Cancer? A Comparison of Gene Expression Between Paired Core Needle Biopsy and Surgical Specimens. <i>Annals of Surgical Oncology</i> , 2021, 28, 5588-5596.	0.7	10
736	Oestrogen receptor activity in hormone-dependent breast cancer during chemotherapy. <i>EBioMedicine</i> , 2021, 69, 103451.	2.7	7
737	Prognosis and Chemotherapy Use in Breast Cancer Patients with Multiple Lymphatic Micrometastases: An NCDB Analysis. <i>Annals of Surgical Oncology</i> , 2021, 28, 8717-8727.	0.7	5
738	Using knockoffs for controlled predictive biomarker identification. <i>Statistics in Medicine</i> , 2021, 40, 5453-5473.	0.8	5
739	Risk evaluation of early-stage hormone receptor-positive and human epidermal growth factor receptor 2-negative breast cancer patients: a population-based study from Taiwan. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 807-815.	1.1	0
740	Estrogen receptor-low breast cancer: Biology chaos and treatment paradox. <i>Cancer Communications</i> , 2021, 41, 968-980.	3.7	23
741	Prognostic value of the 6-gene OncoMasTR test in hormone receptor-positive HER2-negative early-stage breast cancer: Comparative analysis with standard clinicopathological factors. <i>European Journal of Cancer</i> , 2021, 152, 78-89.	1.3	2
742	Architecting for Artificial Intelligence with Emerging Nanotechnology. <i>ACM Journal on Emerging Technologies in Computing Systems</i> , 2021, 17, 1-33.	1.8	3
743	Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use. <i>Breast Cancer Research</i> , 2021, 23, 74.	2.2	27
744	Metal organic framework-coated gold nanorod as an on-demand drug delivery platform for chemo-photothermal cancer therapy. <i>Journal of Nanobiotechnology</i> , 2021, 19, 219.	4.2	32
745	Is oestrogen receptor-negative/progesterone receptor-positive (ER ⁻ /PR+) a real pathological entity?. <i>Ecancermedalscience</i> , 2021, 15, 1278.	0.6	4
746	Practice-Changing Use of the 21-Gene Test for the Management of Patients With Early-Stage Breast Cancer in Latin America. <i>JCO Global Oncology</i> , 2021, 7, 1364-1373.	0.8	3
747	Association of Modifiable Risk Factors With Early Discontinuation of Adjuvant Endocrine Therapy. <i>JAMA Oncology</i> , 2021, 7, 1196.	3.4	13
748	Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0. <i>Journal of Clinical Oncology</i> , 2021, 39, 2720-2731.	0.8	52
749	Deep learning from HE slides predicts the clinical benefit from adjuvant chemotherapy in hormone receptor-positive breast cancer patients. <i>Scientific Reports</i> , 2021, 11, 17363.	1.6	7
750	18F-fluorodeoxyglucose (FDG) PET or 18F-fluorothymidine (FLT) PET to assess early response to aromatase inhibitors (AI) in women with ER+ operable breast cancer in a window-of-opportunity study. <i>Breast Cancer Research</i> , 2021, 23, 88.	2.2	11

#	ARTICLE	IF	CITATIONS
751	Secondary Invasive Breast Events among Patients with Hormone-Positive Breast Cancer and High-Risk Oncotype DX Recurrence Scores 26–30 and ≥31. <i>Oncology</i> , 2021, 99, 699-702.	0.9	1
752	CDKN1C as a prognostic biomarker correlated with immune infiltrates and therapeutic responses in breast cancer patients. <i>Journal of Cellular and Molecular Medicine</i> , 2021, 25, 9390-9401.	1.6	10
753	Response to Induction Neoadjuvant Hormonal Therapy Using Upfront 21-Gene Breast Recurrence Score Assay—Results From the SAFIA Phase III Trial. <i>JCO Global Oncology</i> , 2021, 7, 811-819.	0.8	7
754	Molecular Testing in Breast Cancer. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1422-1432.	1.2	14
755	Application of the 21-Gene Recurrence Score in Patients with Early HR-Positive/HER2-Negative Breast Cancer: Chemotherapy and Survival Rate According to Clinical Risk. <i>Cancers</i> , 2021, 13, 4003.	1.7	2
756	Clinical utility of the 21-gene assay in predicting response to neoadjuvant endocrine therapy in breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2021, 58, 113-120.	0.9	28
757	Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study. <i>ESMO Open</i> , 2021, 6, 100207.	2.0	3
758	The 21-Gene Recurrence Score in Special Histologic Subtypes of Breast Cancer: A Population-Based Study. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, . .	1.2	1
759	The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer. <i>Discover Oncology</i> , 2021, 12, 26.	0.8	2
760	Hormone receptor-positive breast cancer and black race: does sex matter?. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 111-119.	1.1	0
761	Top 3 Abstracts concerning hormone-receptor-positive early breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 2021, 14, 252-256.	0.3	1
762	Breast Cancer in Jamaica: Stage, Grade and Molecular Subtype Distributions Across Age Blocks, the Implications for Screening and Treatment. <i>World Journal of Oncology</i> , 2021, 12, 93-103.	0.6	10
763	Correlation of manual semi-quantitative and automated quantitative Ki-67 proliferative index with OncotypeDX™ recurrence score in invasive breast carcinoma. <i>Breast Disease</i> , 2021, 41, 1-11.	0.4	2
764	The Impact of Exogenous Estrogen Exposure on the Characteristics and Outcome of Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Early-Stage Breast Cancer. <i>Oncology</i> , 2021, 99, 713-721.	0.9	0
765	Diverse Distribution and Gene Expression on the 21-Gene Recurrence Assay in Breast Cancer Patients with Locoregional Recurrence Versus Distant Metastasis. <i>Cancer Management and Research</i> , 2021, Volume 13, 6279-6289.	0.9	3
766	Mucin expression, epigenetic regulation and patient survival: A toolkit of prognostic biomarkers in epithelial cancers. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2021, 1876, 188538.	3.3	15
767	Predictive markers based on transcriptome modules for vinorelbine-based adjuvant chemotherapy for lung adenocarcinoma patients. <i>Lung Cancer</i> , 2021, 158, 115-125.	0.9	2
768	Do hospital type or caseload make a difference in chemotherapy treatment patterns for early breast cancer? Results from 104 German institutions, 2008–2017. <i>Breast</i> , 2021, 58, 63-71.	0.9	2

#	ARTICLE	IF	CITATIONS
769	The Role of MicroRNA as Clinical Biomarkers for Breast Cancer Surgery and Treatment. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8290.	1.8	29
770	Identifying Clinicopathological Factors Associated with Oncotype DX® 21-Gene Recurrence Score: A Real-World Retrospective Cohort Study of Breast Cancer Patients in Quebec City, Canada. <i>Journal of Personalized Medicine</i> , 2021, 11, 858.	1.1	4
771	Chemotherapy is a risk factor of lymphopenia before adjuvant radiotherapy in breast cancer. <i>Cancer Reports</i> , 2021, , e1525.	0.6	4
772	Collagen fiber orientation disorder from H&E images is prognostic for early stage breast cancer: clinical trial validation. <i>Npj Breast Cancer</i> , 2021, 7, 104.	2.3	26
773	Prognostic Significance of O-GlcNAc and PKM2 in Hormone Receptor-Positive and HER2-Nonenriched Breast Cancer. <i>Diagnostics</i> , 2021, 11, 1460.	1.3	3
774	Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: the pathologists' perspective. <i>Annals of Oncology</i> , 2021, 32, 1316-1321.	0.6	4
775	Advancement of prognostic models in breast cancer: a narrative review. <i>Gland Surgery</i> , 2021, 10, 2815-2831.	0.5	7
776	Neoadjuvant Endocrine Therapy in Clinical Practice. <i>JAMA Oncology</i> , 2021, 7, 1700.	3.4	23
777	Oncotype®DX 21-gene test has a low recurrence score in both pure and mixed mucinous breast carcinoma. <i>Oncology Letters</i> , 2021, 22, 771.	0.8	4
778	Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, 190, 183-188.	1.1	5
779	Histologic Discordance Between Primary Tumor and Nodal Metastasis in Breast Cancer: Solving a Clinical Conundrum in the Era of Genomics. <i>Oncologist</i> , 2021, 26, 1000-1005.	1.9	1
780	The WISDOM study: a new approach to screening can and should be tested. <i>Breast Cancer Research and Treatment</i> , 2021, 189, 593-598.	1.1	19
781	Ki67 as Proliferative Marker in Patients with Early Breast Cancer and Its Association with Clinicopathological Factors. <i>Oncology</i> , 2021, 99, 780-789.	0.9	13
782	Using Breast Cancer Gene Expression Signatures in Clinical Practice: Unsolved Issues, Ongoing Trials and Future Perspectives. <i>Cancers</i> , 2021, 13, 4840.	1.7	13
783	Lack of predictive tools for conventional and targeted cancer therapy: Barriers to biomarker development and clinical translation. <i>Advanced Drug Delivery Reviews</i> , 2021, 176, 113854.	6.6	12
784	OncotypeDX® Recurrence Score in BRCA mutation carriers: a systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2021, 154, 209-216.	1.3	10
785	Mammography-based radiomics for predicting the risk of breast cancer recurrence: a multicenter study. <i>British Journal of Radiology</i> , 2021, 94, 20210348.	1.0	11
786	Development and Validation of a Simulation Model-Based Clinical Decision Tool: Identifying Patients Where 21-Gene Recurrence Score Testing May Change Decisions. <i>Journal of Clinical Oncology</i> , 2021, 39, 2893-2902.	0.8	7

#	ARTICLE	IF	CITATIONS
787	Breast cancer immunotherapy: Current biomarkers and the potential of inÂvitro assays. Current Opinion in Biomedical Engineering, 2022, 21, 100348.	1.8	2
788	Adherence to Endocrine Therapy and Racial Outcome Disparities in Breast Cancer. Oncologist, 2021, 26, 910-915.	1.9	13
789	Squamousness gain defines pancreatic ductal adenocarcinoma hepatic metastases phenotype, and gemcitabine response. European Journal of Cancer, 2021, 155, 42-53.	1.3	1
791	Clinical practice guidelines for multigene assays in patients with early-stage breast cancer. Chinese Medical Journal, 2021, Publish Ahead of Print, 2269-2271.	0.9	0
792	Evaluation of risk stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy. Breast Cancer Research and Treatment, 2021, 189, 737-745.	1.1	3
794	Impact of the 21-Gene Recurrence Score Assay on the Treatment of Estrogen Receptor-Positive, HER2-Negative, Breast Cancer Patients With 1-3 Positive Nodes: A Prospective Clinical Utility Study. Clinical Breast Cancer, 2022, 22, e74-e79.	1.1	8
795	Systematic tissue collection during clinical breast biopsy is feasible, safe and enables high-content translational analyses. Npj Precision Oncology, 2021, 5, 85.	2.3	1
796	Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). Cancer Treatment Reviews, 2021, 99, 102241.	3.4	29
797	Comparison of multiple oncotype DX Â® from the same patient. Breast Journal, 2021, 27, 828-831.	0.4	0
798	Impact of the menstrual cycle on commercial prognostic gene signatures in oestrogen receptor-positive primary breast cancer. Breast Cancer Research and Treatment, 2021, 190, 295-305.	1.1	1
799	Comparison of the Metastasis Predictive Potential of mRNA and Long Non-Coding RNA Profiling in Systemically Untreated Breast Cancer. Cancers, 2021, 13, 4907.	1.7	0
800	Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Annals of Oncology, 2021, 32, 1216-1235.	0.6	354
801	Tumour-infiltrating lymphocytes in non-invasive breast cancer: A systematic review and meta-analysis. Breast, 2021, 59, 183-192.	0.9	10
802	Role of epidermal growth factor receptor signaling in a Pt(II)-resistant human breast cancer cell line. Biochemical Pharmacology, 2021, 192, 114702.	2.0	3
803	Mucinous carcinoma in an octogenarian: Treatment and management of breast cancer in the elderly. Radiology Case Reports, 2021, 16, 3201-3207.	0.2	2
804	Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer. Breast, 2021, 60, 62-69.	0.9	88
805	The impact of tumor detection method on genomic and clinical risk and chemotherapy recommendation in early hormone receptor positive breast cancer. Breast, 2021, 60, 78-85.	0.9	0
806	Next-Generation Sequencing-Based Biomarkers in Breast Cancer. Advances in Experimental Medicine and Biology, 2021, 1187, 323-335.	0.8	2

#	ARTICLE	IF	CITATIONS
807	Podoplanin expression in cancer-associated fibroblasts predicts unfavorable prognosis in node-negative breast cancer patients with hormone receptor-positive/HER2-negative subtype. <i>Breast Cancer</i> , 2021, 28, 822-828.	1.3	8
808	ASO Author Reflections: Age Is an Important Determinant of Concordance Between 21-Gene Recurrence Scores in Multiple Ipsilateral Breast Carcinomas. <i>Annals of Surgical Oncology</i> , 2021, 28, 4263-4264.	0.7	1
809	Determination of hypoxia signature to predict prognosis and the tumor immune microenvironment in melanoma. <i>Molecular Omics</i> , 2021, 17, 307-316.	1.4	20
810	Breast cancer staging in population-based registries: an alert to the quality of information. <i>Mastology</i> , 0, 31, .	0.1	1
811	Germline Genetics in Cancer: The New Frontier. , 2021, , 379-385.		0
812	The implementation of a commercially available multi-gene profile test for breast cancer characterization in a department of pathology: what have we learned from the first 100 cases?. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2021, 478, 1079-1087.	1.4	3
813	Residual risk stratification of Taiwanese breast cancers following curative therapies with the extended concurrent genes signature. <i>Breast Cancer Research and Treatment</i> , 2021, 186, 475-485.	1.1	4
814	Design and Implementing Pharmacogenomics Study in Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2019, 1168, 43-77.	0.8	3
815	Patients'™ perceptions of 70-gene signature testing: commonly changing the initial inclination to undergo or forego chemotherapy and reducing decisional conflict. <i>Breast Cancer Research and Treatment</i> , 2020, 182, 107-115.	1.1	2
816	Prognostic value of the 21-gene recurrence score in ER-positive, HER2-negative, node-positive breast cancer was similar in node-negative diseases: a single-center study of 800 patients. <i>Frontiers of Medicine</i> , 2021, 15, 621-628.	1.5	3
817	Feasibility of Measuring Preferences for Chemotherapy Among Early-Stage Breast Cancer Survivors Using a Direct Rank Ordering Multicriteria Decision Analysis Versus a Time Trade-Off. <i>Patient</i> , 2020, 13, 557-566.	1.1	2
818	Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis. <i>Breast</i> , 2020, 54, 319-327.	0.9	8
819	Gene expression signatures: A tool for analysis of breast cancer prognosis and therapy. <i>Critical Reviews in Oncology/Hematology</i> , 2020, 151, 102964.	2.0	23
820	The molecular landscape of Asian breast cancers reveals clinically relevant population-specific differences. <i>Nature Communications</i> , 2020, 11, 6433.	5.8	37
821	Molecular Subtypes of Breast Cancer: A Review for Breast Radiologists. <i>Journal of Breast Imaging</i> , 2021, 3, 12-24.	0.5	82
822	21-Gene Assay and Breast Cancer Mortality in Ductal Carcinoma In Situ. <i>Journal of the National Cancer Institute</i> , 2021, 113, 572-579.	3.0	17
823	Ki67 Immunohistochemistry Quantification in Breast Carcinoma: A Comparison of Visual Estimation, Counting, and ImmunoRatio. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2021, 29, 105-111.	0.6	16
825	Do we still need breast cancer screening in the era of targeted therapies and precision medicine?. <i>Insights Into Imaging</i> , 2020, 11, 105.	1.6	31

#	ARTICLE	IF	CITATIONS
826	Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center. Journal of the Egyptian National Cancer Institute, 2020, 32, 13.	0.6	4
827	Partial Breast Irradiation Is the Preferred Standard of Care for a Majority of Women With Early-Stage Breast Cancer. Journal of Clinical Oncology, 2020, 38, 2268-2272.	0.8	14
828	Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer. World Journal of Clinical Cases, 2019, 7, 1937-1953.	0.3	5
829	The Effect of the New Eighth Edition Breast Cancer Staging System on 100 Consecutive Patients. Journal of Clinical Medicine Research, 2019, 11, 407-414.	0.6	4
830	The impact of COVID-19 on and recommendations for breast cancer care: the Singapore experience. Endocrine-Related Cancer, 2020, 27, R307-R327.	1.6	23
831	Molecular downstaging: a new paradigm for neoadjuvant endocrine therapy. Annals of Translational Medicine, 2020, 8, 1694-1694.	0.7	2
832	Multigene expression signatures in early hormone receptor positive HER2 negative breast cancer. Radiology and Oncology, 2019, 53, 285-292.	0.6	7
833	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 2019, 23, 1-328.	1.3	35
834	Six versus 12 months™ adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCT. Health Technology Assessment, 2020, 24, 1-190.	1.3	11
835	Unmet Clinical Need: Developing Prognostic Biomarkers and Precision Medicine to Forecast Early Tumor Relapse, Detect Chemo-Resistance and Improve Overall Survival in High-Risk Breast Cancer. Annals of Breast Cancer and Therapy, 2020, 4, 48-57.	0.8	11
836	Expression of miR-221 and miR-489 in breast cancer patients and their relationship with prognosis. Oncology Letters, 2020, 19, 1523-1529.	0.8	6
837	Clinicopathological characteristics, adjuvant chemotherapy decision and disease outcome in patients with breast cancer with a 21-gene recurrence score of 26-30. Oncology Letters, 2020, 20, 1545-1556.	0.8	4
838	Validation of a Risk Score Incorporating Tumor Characteristics into the American Joint Committee on Cancer Anatomic Stage for Breast Cancer. Journal of Breast Cancer, 2019, 22, 260.	0.8	2
839	Breast Cancer Statistics in Korea in 2017: Data from a Breast Cancer Registry. Journal of Breast Cancer, 2020, 23, 115.	0.8	94
840	A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miMO Hormone Receptor-Positive, Human Epidermal Growth Factor 2 (HER2)-Negative Breast Cancer. Cancer Research and Treatment, 2019, 51, 1073-1085.	1.3	23
841	Impact of 21-Gene Recurrence Score on Chemotherapy Decision in Invasive Ductal Carcinoma of Breast with Nodal Micrometastases. Cancer Research and Treatment, 2019, 51, 1437-1448.	1.3	4
842	Cost effectiveness of Gene Expression Profiling in Patients with Early-Stage Breast Cancer in a Middle-Income Country, Turkey: Results of a Prospective Multicenter Study. The Journal of Breast Health, 2019, 15, 183-190.	0.4	20
843	The Oncotype Dx Assay in ER-Positive, HER2-Negative Breast Cancer Patients: A Real Life Experience from a Single Cancer Center. The Journal of Breast Health, 2019, 15, 163-170.	0.4	13

#	ARTICLE	IF	CITATIONS
844	The Correlation of Magee Equations™ and Oncotype DX® Recurrence Score From Core Needle Biopsy Tissues in Predicting Response to Neoadjuvant Chemotherapy in ER+ and HER2- Breast Cancer. The Journal of Breast Health, 2020, 16, 117-123.	0.4	3
845	Predictive markers of endocrine response in breast cancer. World Journal of Experimental Medicine, 2018, 8, 1-7.	0.9	18
846	Prospective Validation of a Genomic Assay in Breast Cancer: The 70-gene MammaPrint Assay and the MINDACT Trial. Acta Medica Academica, 2019, 48, 18.	0.3	23
847	NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. Journal of the National Comprehensive Cancer Network: JNCCN, 2021, 19, 484-493.	2.3	186
848	The Utility of Oncotype DX for Adjuvant Chemotherapy Treatment Decisions in Estrogen Receptor-positive, Human Epidermal Growth Factor Receptor 2-negative, Node-negative Breast Cancer. Cureus, 2020, 12, e7269.	0.2	8
849	How Does Invasive Breast Cancer Oncotype Dx Recurrence Score on Core Needle Biopsies Influence Neoadjuvant Treatment Decision? A Descriptive Study. Technology in Cancer Research and Treatment, 2021, 20, 153303382110350.	0.8	1
850	Locoregional and Locally Advanced Breast Cancer. UNIPA Springer Series, 2021, , 429-466.	0.1	0
851	Optimal Endocrine Therapy in Premenopausal Women: A Pragmatic Approach to Unanswered Questions. JCO Oncology Practice, 2022, 18, 211-216.	1.4	10
852	Liquid Biopsies for Molecular Biology-Based Radiotherapy. International Journal of Molecular Sciences, 2021, 22, 11267.	1.8	4
853	Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Cancers, 2021, 13, 5168.	1.7	1
854	Breast Cancer Disparities and the Impact of Geography. Surgical Oncology Clinics of North America, 2022, 31, 81-90.	0.6	5
855	Predicting cancer outcomes with radiomics and artificial intelligence in radiology. Nature Reviews Clinical Oncology, 2022, 19, 132-146.	12.5	221
856	Patientâ€Derived Organoids Can Guide Personalizedâ€Therapies for Patients with Advanced Breast Cancer. Advanced Science, 2021, 8, e2101176.	5.6	42
857	The impact of Oncotype <sc>DX</sc> testing on adjuvant chemotherapy decision making in 1â€3 node positive breast cancer. Cancer Reports, 2022, 5, e1546.	0.6	3
858	Reply to Significance of 21-Gene Nonconcordant Recurrence Scores in Patients with Multifocal or Multicentric Breast Carcinomas. Annals of Surgical Oncology, 2021, 28, 793-794.	0.7	0
859	MicroRNA Expression Profiles and Breast Cancer Chemotherapy. International Journal of Molecular Sciences, 2021, 22, 10812.	1.8	30
860	Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica, 2022, 107, 358-370.	1.7	10
861	Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patientâ€reported outcomes substudy. Cancer, 2021, , .	2.0	3

#	ARTICLE	IF	CITATIONS
890	Features, Outcomes, and Management Strategies of Male Breast Cancer: A Single Institution Comparison to Well-Matched Female Controls. <i>The Journal of Breast Health</i> , 2020, 16, 201-207.	0.4	3
891	Regional Nodal Management in Patients With Clinically Node-Negative Breast Cancer Undergoing Upfront Surgery. <i>Journal of Clinical Oncology</i> , 2020, 38, 2273-2280.	0.8	5
892	The 70-gene signature test as a prognostic and predictive biomarker in patients with invasive lobular breast cancer. <i>Breast Cancer Research and Treatment</i> , 2021, , 1.	1.1	9
893	Molecular genetic predictors of metastatic lesions of regional lymph nodes in patients with breast cancer. <i>Opuholi Zenskoj Reproktivnoy Sistemy</i> , 2021, 17, 24-36.	0.1	0
894	DeepMiner: Discovering Interpretable Representations for Mammogram Classification and Explanation. , 2021, 3, .		4
895	Molecular Basis of Breast Cancer. , 2022, , 3-15.		0
896	Adjuvant Therapy. , 2022, , 435-438.		0
897	Impact of Different Modules of 21-Gene Assay in Early Breast Cancer Patients. <i>Frontiers in Endocrinology</i> , 2021, 12, 759338.	1.5	2
899	Personalized Management of Cancers of Various Organs/Systems. , 2021, , 509-602.		0
901	Association of mammography and ultrasound features with MammaPrint in patients with estrogen receptor-positive, HER2-negative, node-positive invasive breast cancer. <i>Acta Radiologica</i> , 2021, 62, 1592-1600.	0.5	2
902	Changing paradigms in breast cancer treatment. <i>European Journal of Translational and Clinical Medicine</i> , 2020, 3, 53-63.	0.0	2
903	A novel gene signature associated with poor response to chemoradiotherapy in patients with locally advanced cervical cancer. <i>Journal of Gynecologic Oncology</i> , 2022, 33, .	1.0	5
904	High-Cost Patients and Preventable Spending: A Population-Based Study. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 23-31.	2.3	10
905	Breast Cancer Diagnosis and Management. , 2020, , 313-328.		0
906	Pragmatic Trials and Approaches to Transforming Care. <i>Success in Academic Surgery</i> , 2020, , 59-76.	0.1	1
907	The Immune Landscape in Women Cancers. <i>Cancer Treatment and Research</i> , 2020, 180, 215-249.	0.2	3
908	Tryptophanyl-tRNA Synthetase Sensitizes Hormone Receptor-Positive Breast Cancer to Docetaxel-Based Chemotherapy. <i>Journal of Breast Cancer</i> , 2020, 23, 599.	0.8	3
909	Endocrine Treatment of Young Patients with EBC. , 2020, , 113-126.		0

#	ARTICLE	IF	CITATIONS
910	Correlation of Preoperative Axillary Lymph Node Status to Final Histology After Axillary Surgery for Breast Cancer. <i>Journal of Clinical and Medical Images and Short Reports</i> , 2020, 05, .	0.0	0
911	General recommendations for the management of breast cancer (St. Gallen Expert Consensus) <i>Tj ETQq1 1 0.784314 rgBT /Overlock 10</i> <i>Reproduktivnoy Sistemy</i> , 2020, 15, 50-57.	0.1	0
912	Correlation between Oncotype DX, PREDICT and the Nottingham Prognostic Index: Implications for the management of early breast cancer. <i>Cureus</i> , 2020, 12, e7552.	0.2	4
913	Supervised machine learning model to predict oncotype DX risk category in patients over age 50. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 423-430.	1.1	6
914	How to Perform Repeat Sentinel Node Biopsy Safely After a Previous Mastectomy: Technical Features and Oncologic Outcomes. <i>Annals of Surgical Oncology</i> , 2022, 29, 1750-1760.	0.7	7
916	Should we target "intermediate expression" of HER2 in older estrogen receptor positive patients?. <i>Translational Cancer Research</i> , 2020, 9, 4056-4059.	0.4	1
917	Adjuvant Chemotherapy in Early Breast Cancer. , 2021, , 143-155.		0
918	Risk Stratification for Adjuvant Treatment in Early Breast Cancer. , 2021, , 131-142.		0
919	Options of precision medicine in clinical oncological practice. <i>Onkologie (Czech Republic)</i> , 2020, 14, 178-181.	0.0	0
920	Gene Expression Profiling Tests for Early-Stage Invasive Breast Cancer: A Health Technology Assessment. <i>Ontario Health Technology Assessment Series</i> , 2020, 20, 1-234.	3.0	8
921	Immune responses during neoadjuvant chemotherapy in triple negative breast cancer. <i>EXCLI Journal</i> , 2020, 19, 1295-1296.	0.5	0
922	ZNF217: the cerberus who fails to guard the gateway to lethal malignancy. <i>American Journal of Cancer Research</i> , 2021, 11, 3378-3405.	1.4	0
923	Translation of Precision Medicine Research Into Biomarker-Informed Care in Radiation Oncology. <i>Seminars in Radiation Oncology</i> , 2022, 32, 42-53.	1.0	4
924	Mammakarzinom. , 2022, , 340-351.		0
925	Electrochemical determination of epirubicin in the presence of topotecan as essential anti-cancer compounds using paste electrode amplified with Pt/SWCNT nanocomposite and a deep eutectic solvent. <i>Chemosphere</i> , 2022, 289, 133060.	4.2	6
926	Development of a Prognostic Model Based on the Identification of EMT-Related lncRNAs in Triple-Negative Breast Cancer. <i>Journal of Oncology</i> , 2021, 2021, 1-18.	0.6	4
927	Is the oncotype DX test useful in elderly breast cancer patients: a subgroup analysis of real-life Italian PONDx study. <i>Breast Cancer Research and Treatment</i> , 2022, 191, 477-480.	1.1	5
928	Treatment of Premenopausal Women: Finding the Right-Sized Endocrine Therapy. <i>JCO Oncology Practice</i> , 2021, , OP2100720.	1.4	0

#	ARTICLE	IF	CITATIONS
929	Evaluation of PD-L1 and tumor infiltrating lymphocytes in paired pretreatment biopsies and post neoadjuvant chemotherapy surgical specimens of breast carcinoma. <i>Scientific Reports</i> , 2021, 11, 22478.	1.6	8
931	Analysis of Adjuvant Chemotherapy on Pathological Remission of Breast Cancer. <i>Computational and Mathematical Methods in Medicine</i> , 2021, 2021, 1-8.	0.7	1
932	Biomarker and multigene assay testing in ER positive, HER-2 negative breast carcinomas: An international guidelines-based approach. <i>Human Pathology Reports</i> , 2021, 26, 300574.	0.1	5
934	Distribution, Chemotherapy Use, and Outcome of the 21-Gene Recurrence Score Between Chinese and White breast Cancer in the United States. <i>Clinical Breast Cancer</i> , 2022, 22, 279-287.	1.1	3
935	Validation of the 21-Gene Recurrence Score Assay in Patients with Hormone Receptor-Positive, HER2-Negative Breast Cancer and 0 to 3 Positive Lymph Nodes â€œ Risk Pattern and Outcomes on a Community Level. <i>Breast Care</i> , 0, , .	0.8	0
936	Development of novel agents for the treatment of early estrogen receptor positive breast cancer. <i>Breast</i> , 2022, 62, S34-S42.	0.9	8
937	Establishment and Validation of a Gene Signature-Based Prognostic Model to Improve Survival Prediction in Adrenocortical Carcinoma Patients. <i>International Journal of Endocrinology</i> , 2021, 2021, 1-12.	0.6	1
938	<i>TP53</i> mutations are associated with primary endocrine resistance in luminal early breast cancer. <i>Cancer Medicine</i> , 2021, 10, 8581-8594.	1.3	14
939	21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer. <i>New England Journal of Medicine</i> , 2021, 385, 2336-2347.	13.9	363
940	Lymphovascular invasion has a significant prognostic impact in patients with early breast cancer, results from a large, national, multicenter, retrospective cohort study. <i>ESMO Open</i> , 2021, 6, 100316.	2.0	36
941	Genomic Expression Profiling in Melanoma and the Road to Clinical Practice. <i>Annals of Surgical Oncology</i> , 2022, 29, 764-766.	0.7	3
942	Impact of the EndoPredict genomic assay on treatment decisions for oestrogen receptor-positive early breast cancer patients: benefits of physician selective testing. <i>Breast Cancer Research and Treatment</i> , 2021, 191, 501.	1.1	1
943	Impact of TAILORx on chemotherapy prescribing and 21-gene recurrence score-guided treatment costs in a population-based cohort of patients with breast cancer. <i>Cancer</i> , 2022, 128, 665-674.	2.0	8
944	Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2- breast cancer: Available Evidence and Clinical Implications. <i>Cancer Treatment Reviews</i> , 2021, 102, 102323.	3.4	17
945	The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma. <i>Genomics</i> , 2021, 114, 95-106.	1.3	1
946	Outcome without any adjuvant systemic treatment in stage I ER+/HER2- breast cancer patients included in the MINDACT trial. <i>Annals of Oncology</i> , 2021, , .	0.6	9
948	Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110595.	1.4	10
949	Integrating pathomics with radiomics and genomics for cancer prognosis: A brief review. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association, Beijing Institute for Cancer Research</i> , 2021, 33, 563-573.	0.7	23

#	ARTICLE	IF	CITATIONS
950	Low RUFY3 expression level is associated with lymph node metastasis in older women with invasive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 19-32.	1.1	4
951	Mammakarzinom: Update 2019. , 0, , .		0
953	Precision Medicine: Technological Impact into Breast Cancer Diagnosis, Treatment and Decision Making. <i>Journal of Personalized Medicine</i> , 2021, 11, 1348.	1.1	5
954	Epigenetic Reprogramming and Landscape of Transcriptomic Interactions: Impending Therapeutic Interference of Triple-Negative Breast Cancer in Molecular Medicine. <i>Current Molecular Medicine</i> , 2022, 22, 835-850.	0.6	3
955	Utilization of neoadjuvant chemotherapy in high-risk, node-negative early breast cancer. <i>Cancer Medicine</i> , 2022, 11, 1099-1108.	1.3	6
956	Utility of Oncotype DX score in clinical management for T1 estrogen receptor positive, HER2 negative, and lymph node negative breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 509-516.	1.1	4
957	Somatic and Germline Genomic Alterations in Very Young Women with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 2339-2348.	3.2	20
958	Outcome of Patients With an Ultralow-Risk 70-Gene Signature in the MINDACT Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 1335-1345.	0.8	28
959	Factors Associated With the Decision to Decline Chemotherapy in Patients With Early-stage, ER+/HER2-Breast Cancer and High-risk Scoring on Genomic Assays. <i>Clinical Breast Cancer</i> , 2022, 22, 367-373.	1.1	2
960	Oncotype DX Risk Recurrence Score and Total Mortality for Early-Stage Breast Cancer by Race/Ethnicity. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2022, 31, 821-830.	1.1	10
961	Gene Expression Profiling in Early Breast Cancer—Patient Stratification Based on Molecular and Tumor Microenvironment Features. <i>Biomedicines</i> , 2022, 10, 248.	1.4	11
962	How we treat HR-positive, HER2-negative early breast cancer. <i>Future Oncology</i> , 2022, 18, 1003-1022.	1.1	11
963	Circulating Tumor Cells and Breast Cancer: The Long and Winding Road Behind and Before Us. <i>Annals of Surgical Oncology</i> , 2022, 29, 2747.	0.7	1
964	The 21-gene recurrence score in early non-ductal breast cancer: a National Cancer Database analysis. <i>Npj Breast Cancer</i> , 2022, 8, 4.	2.3	11
965	Sentinel lymph node biopsy in patients with ductal carcinoma <i>in situ</i> : systematic review and meta-analysis. <i>BJS Open</i> , 2022, 6, .	0.7	9
966	Terapia personalizada en c�ncer de mama precoz. Implicancias pr�cticas. <i>Revista M�dica Cl�nica Las Condes</i> , 2022, 33, 17-24.	0.2	0
967	Classification of Breast Cancer. , 2022, , 71-85.		1
968	Individualizing Adjuvant Therapy in Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Node-Positive Breast Cancer. <i>JCO Oncology Practice</i> , 2022, , OP2100780.	1.4	1

#	ARTICLE	IF	CITATIONS
969	Linking Structural Racism and Discrimination and Breast Cancer Outcomes: A Social Genomics Approach. <i>Journal of Clinical Oncology</i> , 2022, 40, 1407-1413.	0.8	17
970	The Utility of the Oncotype DX Test for Breast Cancer Patients in an Australian Multidisciplinary Setting. <i>Breast Journal</i> , 2022, 2022, 1-7.	0.4	2
971	Refining risk stratification in HR-positive/HER2-negative early breast cancer: how to select patients for treatment escalation?. <i>Breast Cancer Research and Treatment</i> , 2022, 192, 465-484.	1.1	6
972	Adjuvant chemotherapy in patients with invasive lobular carcinoma and use of the 21-gene recurrence score: A National Cancer Database analysis. <i>Cancer</i> , 2022, , .	2.0	13
973	Development and validation of a prognostic and predictive 32-gene signature for gastric cancer. <i>Nature Communications</i> , 2022, 13, 774.	5.8	52
974	Abemaciclib: The First FDA-Approved CDK4/6 Inhibitor for the Adjuvant Treatment of HR+ HER2~ Early Breast Cancer. <i>Annals of Pharmacotherapy</i> , 2022, 56, 1258-1266.	0.9	4
975	Comparative analysis of molecular signatures reveals a hybrid approach in breast cancer: Combining the Nottingham Prognostic Index with gene expressions into a hybrid signature. <i>PLoS ONE</i> , 2022, 17, e0261035.	1.1	7
976	Pathobiologic Stratification of Oncotype DX Recurrence Scores and Comparative Validation of 3 Surrogate Models. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 1258-1267.	1.2	1
977	Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor~positive breast cancer. <i>JCI Insight</i> , 2022, 7, .	2.3	17
978	Clinical outcomes and Oncotype DX Breast Recurrence Score~ in early~stage <sc>BRCA</sc>-associated hormone receptor~positive breast cancer. <i>Cancer Medicine</i> , 2022, 11, 1474-1483.	1.3	5
979	Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. <i>Frontiers in Oncology</i> , 2021, 11, 667397.	1.3	11
980	Management of breast cancer: basic principles. <i>Surgery</i> , 2022, 40, 113-120.	0.1	2
981	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology). <i>Breast Cancer Research and Treatment</i> , 2022, 193, 555-564.	1.1	5
982	Why Precision Oncology Is Not Very Precise (and Why This Should Not Surprise Us). <i>Human Perspectives in Health Sciences and Technology</i> , 2022, , 3-21.	0.2	4
983	Oncotype DX Recurrence Score in premenopausal women. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210810.	1.4	4
984	Are we closer to being able to select patients with node-positive hormone receptor-positive breast cancer who can safely omit chemotherapy?. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210847.	1.4	4
985	Stratification of Prognosis by Biological Features Following Neoadjuvant Chemotherapy in Luminal Breast Cancer. <i>In Vivo</i> , 2022, 36, 859-864.	0.6	0
986	AKR1B10 as a Potential Novel Serum Biomarker for Breast Cancer: A Pilot Study. <i>Frontiers in Oncology</i> , 2022, 12, 727505.	1.3	3

#	ARTICLE	IF	CITATIONS
987	Early Changes in Quantitative Ultrasound Imaging Parameters during Neoadjuvant Chemotherapy to Predict Recurrence in Patients with Locally Advanced Breast Cancer. <i>Cancers</i> , 2022, 14, 1247.	1.7	6
988	Assessment of Racial Disparity in Survival Outcomes for Early Hormone Receptor-Positive Breast Cancer After Adjusting for Insurance Status and Neighborhood Deprivation. <i>JAMA Oncology</i> , 2022, 8, 579.	3.4	27
989	Potential Refinement of Recurrence Score by pSTAT3 Status. <i>Genes</i> , 2022, 13, 438.	1.0	1
990	Breast cancer management in 2021: A primer for the obstetrics and gynecology. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2022, 82, 30-45.	1.4	18
991	Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, 19.	2.3	4
992	Association of Adjuvant Hormone Therapy Timing With Overall Survival Among Patients With Hormone Receptor-Positive Human Epidermal Growth Factor Receptor-2-Negative Early Breast Cancer Without Chemotherapy. <i>JAMA Network Open</i> , 2022, 5, e2145934.	2.8	4
993	Validation of the Prognostic Stage from the American Joint Committee on Cancer 8th Staging Manual in Luminal B-Like Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. <i>Cancer Management and Research</i> , 2022, Volume 14, 719-728.	0.9	1
994	Breast cancer-specific mortality in early breast cancer as defined by high-risk clinical and pathologic characteristics. <i>PLoS ONE</i> , 2022, 17, e0264637.	1.1	17
995	Particle Therapy for Breast Cancer. <i>Cancers</i> , 2022, 14, 1066.	1.7	9
996	Outcome analysis of primary breast cancer patients who declined adjuvant chemotherapy—results from the prospective multi-center BRENDA II study. <i>Breast Cancer</i> , 2022, , 1.	1.3	0
997	Molecular profiling leading to personalized treatment in breast cancer. <i>Memo - Magazine of European Medical Oncology</i> , 0, , 1.	0.3	1
998	Genome-wide identification and analysis of prognostic features in human cancers. <i>Cell Reports</i> , 2022, 38, 110569.	2.9	48
999	Androgen receptor expression and its prognostic value in T1N0 luminal/HER2- breast cancer. <i>Future Oncology</i> , 2022, , .	1.1	0
1000	A single-cell analysis of breast cancer cell lines to study tumour heterogeneity and drug response. <i>Nature Communications</i> , 2022, 13, 1714.	5.8	65
1003	Comparison of comfort and complications of Implantable Venous Access Port (IVAP) with ultrasound guided Internal Jugular Vein (IJV) and Axillary Vein/Subclavian Vein (AxV/SCV) puncture in breast cancer patients: a randomized controlled study. <i>BMC Cancer</i> , 2022, 22, 248.	1.1	9
1004	Prognostic Value of Stromal Tumor-Infiltrating Lymphocytes in Young, Node-Negative, Triple-Negative Breast Cancer Patients Who Did Not Receive (neo)Adjuvant Systemic Therapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2361-2374.	0.8	45
1005	Breast Radiotherapy after Oncoplastic Surgery—A Multidisciplinary Approach. <i>Cancers</i> , 2022, 14, 1685.	1.7	2
1006	Feasibility of Adjuvant Treatment with Abemaciclib—Real-World Data from a Large German Breast Center. <i>Journal of Personalized Medicine</i> , 2022, 12, 382.	1.1	5

#	ARTICLE	IF	CITATIONS
1007	Survival outcomes after neoadjuvant letrozole and palbociclib versus third generation chemotherapy for patients with high-risk oestrogen receptor-positive HER2-negative breast cancer. <i>European Journal of Cancer</i> , 2022, 166, 300-308.	1.3	11
1008	The impact of age and nodal status on variations in oncotype DX testing and adjuvant treatment. <i>Npj Breast Cancer</i> , 2022, 8, 27.	2.3	7
1009	High RRM2 expression has poor prognosis in specific types of breast cancer. <i>PLoS ONE</i> , 2022, 17, e0265195.	1.1	5
1010	Total circulating microRNA level as an independent prognostic marker for risk stratification in breast cancer. <i>British Journal of Cancer</i> , 2022, 127, 156-162.	2.9	8
1011	Low correlation between Ki67 assessed by qRT-PCR in Oncotype Dx score and Ki67 assessed by Immunohistochemistry. <i>Scientific Reports</i> , 2022, 12, 3617.	1.6	2
1012	Evaluating Regional Nodal Irradiation Allocation and Association with Oncologic Outcomes in NSABP B-18, B-27, B-40, and B-41. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 542-551.	0.4	7
1013	Surgery, Chemotherapy and Radiotherapy May Promote Cancer Growth Speeds and Shorten Patient Lives. <i>Global Journal of Cancer Therapy</i> , 2022, 8, 046-049.	0.4	2
1014	Population-based estimates of overtreatment with adjuvant systemic therapy in early breast cancer patients with data from the Netherlands and the USA. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 161-173.	1.1	7
1015	SEOM-GETTHI clinical guideline for the practical management of molecular platforms (2021). <i>Clinical and Translational Oncology</i> , 2022, 24, 693-702.	1.2	1
1016	Higher risk tumor features are not associated with higher nodal stage in patients with estrogen receptor-positive, node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 429-436.	1.1	1
1017	Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction. <i>Breast</i> , 2022, 63, 61-70.	0.9	3
1021	Unmet challenges in systemic therapy for early stage breast cancer. <i>Breast</i> , 2022, 62, S67-S69.	0.9	1
1022	Association Between Neutrophil-Lymphocyte Ratio and Oncotype Dx Recurrence Score in Early-Stage Hormonal Receptor-Positive, HER2-Negative, Node-Negative Breast Cancer. <i>Cancer Management and Research</i> , 2021, Volume 13, 9411-9420.	0.9	0
1023	Breast cancerâ€”The catalyst of contemporary trials design. <i>Journal of Surgical Oncology</i> , 2022, 125, 7-16.	0.8	0
1025	Treatment and Survivorship Interventions to Prevent Poor Body Image Outcomes in Breast Cancer Survivors. <i>Breast Cancer: Targets and Therapy</i> , 2021, Volume 13, 701-709.	1.0	5
1026	Simulation modeling of breast cancer endocrine therapy duration by patient and tumor characteristics. <i>Cancer Medicine</i> , 2022, 11, 297-307.	1.3	2
1028	De-escalating axillary surgery in early-stage breast cancer. <i>Breast</i> , 2022, 62, S43-S49.	0.9	22
1029	Current status of AYA-generation breast cancer: trends worldwide and in Japan. <i>International Journal of Clinical Oncology</i> , 2022, 27, 16-24.	1.0	3

#	ARTICLE	IF	CITATIONS
1030	Can Systems Biology Advance Clinical Precision Oncology?. <i>Cancers</i> , 2021, 13, 6312.	1.7	10
1031	The clinician's perspective on the 21-gene assay in early breast cancer. <i>Oncotarget</i> , 2021, 12, 2514-2530.	0.8	4
1032	Adjuvant and neoadjuvant therapy of ER+ / HER2- breast cancer. <i>Medical Alphabet</i> , 2021, 1, 7-12.	0.0	1
1034	Update Mammakarzinom 2021 Teil 1 - Prävention und frühe Krankheitsstadien. <i>Senologie - Zeitschrift für Mammadiagnostik Und -therapie</i> , 2021, 18, 377-390.	0.0	0
1035	A Canadian national guideline on the neoadjuvant treatment of invasive breast cancer, including patient assessment, systemic therapy, and local management principles. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 1-20.	1.1	8
1036	Anthracyclines in the treatment of patients with early breast cancer. <i>ESMO Open</i> , 2022, 7, 100461.	2.0	4
1037	Definition of High-Risk Early Hormone-Positive HER2-Negative Breast Cancer: A Consensus Review. <i>Cancers</i> , 2022, 14, 1898.	1.7	20
1038	Identification of a combined apoptosis and hypoxia gene signature for predicting prognosis and immune infiltration in breast cancer. <i>Cancer Medicine</i> , 2022, 11, 3886-3901.	1.3	9
1039	Value of the 21-gene expression assay in predicting locoregional recurrence rates in estrogen receptor-positive breast cancer: a systematic review and network meta-analysis. <i>Breast Cancer Research and Treatment</i> , 2022, 193, 535-544.	1.1	7
1040	Endocrine Therapy Response and 21-Gene Expression Assay for Therapy Guidance in HR+/HER2- Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2557-2567.	0.8	49
1041	Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. <i>Current Oncology</i> , 2022, 29, 2599-2616.	0.9	5
1042	Indian Perspective On 17th St. Gallen: Customizing Local and Systemic Therapies for Indian Women with Breast Cancer. <i>Indian Journal of Surgery</i> , 0, , .	0.2	0
1043	A retrospective analysis of changes in distant and breast cancer related disease-free survival events in adjuvant breast cancer trials over time. <i>Scientific Reports</i> , 2022, 12, 6352.	1.6	3
1044	Testing Endocrine Response for Managing Primary Estrogen Receptor-Positive Breast Cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 2520-2523.	0.8	6
1045	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2022, 40, 1816-1837.	0.8	139
1064	Distribution and influence of the 21-gene recurrence score on chemotherapy decision-making in special type of breast cancer.. <i>American Journal of Cancer Research</i> , 2021, 11, 6188-6199.	1.4	0
1066	Combining TMEM Doorway Score and MenaCalc Score Improves the Prediction of Distant Recurrence Risk in HR+/HER2- Breast Cancer Patients. <i>Cancers</i> , 2022, 14, 2168.	1.7	2
1067	A narrative review of five multigenetic assays in breast cancer. <i>Translational Cancer Research</i> , 2022, 11, 897-907.	0.4	7

#	ARTICLE	IF	CITATIONS
1068	Oncobiology and treatment of breast cancer in young women. <i>Cancer and Metastasis Reviews</i> , 2022, 41, 749-770.	2.7	11
1069	Behaviour within a Clinical Trial and Implications for Mammography Guidelines. <i>Review of Economic Studies</i> , 2023, 90, 432-462.	2.9	3
1072	A hierarchical approach to combine histological grade and immunohistochemical factors to identify high-risk luminal breast cancers. <i>Ecancermedicalsecience</i> , 0, 16, .	0.6	0
1073	Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. <i>Annals of Oncology</i> , 2022, 33, 702-712.	0.6	24
1074	PAM50 subtyping and ROR score add long-term prognostic information in premenopausal breast cancer patients. <i>Npj Breast Cancer</i> , 2022, 8, 61.	2.3	5
1075	A look at current and potential treatment approaches for hormone receptorâ€­positive, HER2â€­negative early breast cancer. <i>Cancer</i> , 2022, 128, 2209-2223.	2.0	4
1076	Relevance of the 21-gene expression assay in male breast cancer: A systematic review and meta-analysis. <i>Breast</i> , 2022, 64, 41-46.	0.9	3
1078	Gene expression signatures in early breast cancer: Better together with clinicopathological features. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103708.	2.0	10
1079	Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67. <i>Annals of Surgical Oncology</i> , 2022, 29, 5747-5756.	0.7	9
1080	Treatment of Breast Cancer in Young Adults. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2022, 42, 795-806.	1.8	8
1081	Conventional and digital Ki67 evaluation and their correlation with molecular prognosis and morphological parameters in luminal breast cancer. <i>Scientific Reports</i> , 2022, 12, 8176.	1.6	2
1082	Precision medicine â€­ A new era in multidisciplinary care. <i>Cancer Treatment and Research Communications</i> , 2022, 32, 100577.	0.7	0
1083	Use of a convolutional neural network-based mammographic evaluation to predict breast cancer recurrence among women with hormone receptor-positive operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2022, , .	1.1	2
1084	Limiting systemic endocrine overtreatment in postmenopausal breast cancer patients with an ultralow classification of the 70-gene signature. <i>Breast Cancer Research and Treatment</i> , 2022, , .	1.1	2
1085	Addressing the problem of overtreatment in breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 535-548.	1.1	4
1086	Predicting Differences in Treatment Response and Survival Time of Lung Adenocarcinoma Patients Based on a Prognostic Risk Model of Glycolysis-Related Genes. <i>Frontiers in Genetics</i> , 2022, 13, .	1.1	1
1087	Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. <i>Cancers</i> , 2022, 14, 2615.	1.7	7
1088	Multi-Omics Approaches for the Prediction of Clinical Endpoints after Immunotherapy in Non-Small Cell Lung Cancer: A Comprehensive Review. <i>Biomedicines</i> , 2022, 10, 1237.	1.4	7

#	ARTICLE	IF	CITATIONS
1089	Personalizing Adjuvant Endocrine Therapy for Early-Stage Hormone Receptor-Positive Breast Cancer. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2022, , 60-72.	1.8	15
1090	Impact of genomic assays on treatment and outcomes in locally advanced breast cancer. Breast Cancer Research and Treatment, 0, , .	1.1	0
1091	Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database. Breast Cancer, 2022, 29, 889-898.	1.3	3
1092	Breast Cancer-Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature). Cancers, 2022, 14, 2569.	1.7	94
1093	Independent validation of stromal uPA in ABCSG-08: Level 1b evidence for the prognostic value of uPA immunohistochemistry. Breast, 2022, , .	0.9	0
1094	Codelivery of Gemcitabine and MUC1 Inhibitor Using PEG-PCL Nanoparticles for Breast Cancer Therapy. Molecular Pharmaceutics, 2022, 19, 2429-2440.	2.3	11
1095	Overdetection of Breast Cancer. Current Oncology, 2022, 29, 3894-3910.	0.9	7
1096	Targeted Assessment of Mucosal Immune Gene Expression Predicts Clinical Outcomes in Children with Ulcerative Colitis. Journal of Crohn's and Colitis, 2022, 16, 1735-1750.	0.6	2
1097	Lack of Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in Early Breast Cancer. Breast Care, 2022, 17, 546-553.	0.8	0
1098	Breast cancer recurrence and survival rates in patients who underwent breast-conserving surgery under non-mechanically ventilated anesthesia. Cancer Reports, 2023, 6, .	0.6	2
1102	Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. Targeted Oncology, 2022, 17, 355-368.	1.7	1
1103	Update on prognostic and predictive biomarkers of breast cancer. Seminars in Diagnostic Pathology, 2022, 39, 322-332.	1.0	20
1104	Chemotherapy Regimens Received by Women with BRCA1/2 Pathogenic Variants for Early-Stage Breast Cancer Treatment. JNCI Cancer Spectrum, 0, , .	1.4	0
1105	Going Beyond Bibliometrics: A system to track the progress and impact of biomedical research funded by Susan G. Komen. Clinical and Translational Science, 0, , .	1.5	1
1106	Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis. Frontiers in Cell and Developmental Biology, 0, 10, .	1.8	4
1107	Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update Q and A. JCO Oncology Practice, 0, , .	1.4	2
1108	Ovarian Function Suppression: A Deeper Consideration of the Role in Early Breast Cancer and its Potential Impact on Patient Outcomes: A Consensus Statement from an International Expert Panel. Oncologist, 2022, 27, 722-731.	1.9	6
1109	ENDORSE: a prognostic model for endocrine therapy in estrogen-receptor-positive breast cancers. Molecular Systems Biology, 2022, 18, .	3.2	5

#	ARTICLE	IF	CITATIONS
1110	Breast Cancer with Low Recurrence Score on Oncotype DX®: Interplay Between Early Recurrence, Lobular Histology and BRCA Mutation. <i>Oncology and Therapy</i> , 0, , .	1.0	0
1111	Evaluation of Breast Problems. <i>Clinical Obstetrics and Gynecology</i> , 0, Publish Ahead of Print, .	0.6	0
1112	MiRNAs in renal cell carcinoma. <i>Clinical and Translational Oncology</i> , 2022, 24, 2055-2063.	1.2	4
1113	Systemic Treatment of Breast Cancer. 1st Central-Eastern European Professional Consensus Statement on Breast Cancer. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	12
1114	Age at initial diagnosis and prognosis of breast cancer: a nationwide multicenter retrospective study in China. <i>Annals of Translational Medicine</i> , 2022, 10, 813-813.	0.7	1
1115	Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 0, 10, .	1.8	12
1116	Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes. <i>Annals of Surgical Oncology</i> , 2022, 29, 7674-7682.	0.7	2
1117	Breast Cancer Subtypes Based on Hypoxia-Related Gene Sets Identify Potential Therapeutic Agents. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
1118	Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical NO ER+/HER2 ⁺ Breast Cancer. <i>Annals of Surgical Oncology</i> , 2022, 29, 7662-7669.	0.7	5
1119	The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study. <i>Annals of Surgical Oncology</i> , 2022, 29, 7739-7747.	0.7	6
1120	Impact of the 21-Gene Recurrence Score Assay on Treatment Decisions and Cost in Patients with Node-Positive Breast Cancer: A Multicenter Study in Quebec. <i>Oncologist</i> , 0, , .	1.9	0
1121	A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score®. <i>Journal of Personalized Medicine</i> , 2022, 12, 1117.	1.1	0
1122	From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. <i>Cancers</i> , 2022, 14, 3469.	1.7	5
1124	Radiological predictive factors on preoperative multimodality imaging are related to Oncotype DX recurrence score in estrogen-positive/human epidermal growth factor receptor 2-negative invasive breast cancer: a cross-sectional study. <i>Annals of Nuclear Medicine</i> , 2022, 36, 853-864.	1.2	3
1125	ASO Author Reflections: Can Genomic Recurrence Score Replace SLNB in Postmenopausal Women with ER+/HER2 ⁺ Breast Cancer?. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
1126	Using menopause status and 21-gene expression assay to inform chemotherapy benefit in node-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	1
1127	CACA Guidelines for Holistic Integrative Management of Breast Cancer. , 2022, 1, .		2
1128	Rethinking breast cancer follow-up based on individual risk and recurrence management. <i>Cancer Treatment Reviews</i> , 2022, 109, 102434.	3.4	14

#	ARTICLE	IF	CITATIONS
1129	Chemotherapy and gene expression profiling in older early luminal breast cancer patients: An International Society of Geriatric Oncology systematic review. <i>European Journal of Cancer</i> , 2022, 172, 158-170.	1.3	4
1130	21-Gene recurrence score predictive for prognostic benefit of radiotherapy in patients age ≥70 with T1N0 ER/PR+HER2- breast cancer treated with breast conserving surgery and endocrine therapy. <i>Radiotherapy and Oncology</i> , 2022, 174, 37-43.	0.3	5
1131	Axillary Staging Is Not Justified in Postmenopausal Clinically Node-Negative Women Based on Nodal Disease Burden. <i>Annals of Surgical Oncology</i> , 2023, 30, 92-97.	0.7	7
1132	Copy number heterogeneity identifies ER+ breast cancer patients that do not benefit from adjuvant endocrine therapy. <i>British Journal of Cancer</i> , 0, , .	2.9	0
1133	Emerging Trends in Bioinformatics for Breast Cancer Molecular Research. , 2022, , 86-108.		0
1134	Evaluating the Role of Circulating MicroRNAs to Aid Therapeutic Decision Making for Neoadjuvant Chemotherapy in Breast Cancer. <i>Annals of Surgery</i> , 2022, 276, 905-912.	2.1	16
1135	Guidelines for breast cancer treatment in Bosnia and Herzegovina. <i>Bosnian Journal of Basic Medical Sciences</i> , 0, , .	0.6	1
1136	Clinical Utility of Genomic Assay in Node-Positive Early-Stage Breast Cancer. <i>Current Oncology</i> , 2022, 29, 5139-5149.	0.9	1
1137	Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	0
1138	Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk. <i>Annals of Surgical Oncology</i> , 2022, 29, 6254-6264.	0.7	2
1140	The Oncotype DX Recurrence Score's Impact on the Management of Oestrogen-Positive/Human Epidermal Growth Factor Receptor 2-Negative, Low-Burden Axillary Status Breast Cancer (REHAB) Tj ETQqO 0 0 rgB0, Overlock 10 Tf 50		
1141	What Is the Role of Neoadjuvant Endocrine Therapy for Breast Cancer?. <i>Advances in Surgery</i> , 2022, 56, 275-286.	0.6	2
1142	Optimal Choice of Neoadjuvant Chemotherapy for HER2-Negative Breast Cancer: Clinical Insights. <i>Cancer Management and Research</i> , 0, Volume 14, 2493-2506.	0.9	3
1143	Predictive Biomarkers of Response to Neoadjuvant Chemotherapy in Breast Cancer: Current and Future Perspectives for Precision Medicine. <i>Cancers</i> , 2022, 14, 3876.	1.7	20
1144	Correlation of the Ki67 Working Group prognostic risk categories with the Oncotype <sc>DX</sc> Recurrence Score in early breast cancer. <i>Cancer</i> , 2022, 128, 3602-3609.	2.0	3
1145	Regional Variations in Clinical Trial Outcomes in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 879-886.e2.	2.3	2
1146	RNA sequencing-based single sample predictors of molecular subtype and risk of recurrence for clinical assessment of early-stage breast cancer. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	20
1147	Breast Cancer Disparities Related to Young Age at Diagnosis. <i>Current Breast Cancer Reports</i> , 2022, 14, 174-179.	0.5	1

#	ARTICLE	IF	CITATIONS
1148	Utility of Genomic Platforms in Treatment Decisions in Axilla-Positive Breast Cancer. <i>Clinical Breast Cancer</i> , 2022, , .	1.1	0
1149	The potential of predictive and prognostic breast MRI (P2-bMRI). <i>European Radiology Experimental</i> , 2022, 6, .	1.7	7
1150	Predictive value of immune genomic signatures from breast cancer cohorts containing data for both response to neoadjuvant chemotherapy and prognosis after surgery. <i>Breast Cancer</i> , 0, , .	1.3	0
1152	Discordant Endorsement of Prostate Cancer Biomarkers Across Major Guidelines. <i>European Urology Focus</i> , 2022, 8, 919-921.	1.6	2
1153	ESOâ€“ESMO fifth international consensus guidelines for breast cancer in young women (BCY5). <i>Annals of Oncology</i> , 2022, 33, 1097-1118.	0.6	46
1154	A novel age-related gene expression signature associates with proliferation and disease progression in breast cancer. <i>British Journal of Cancer</i> , 2022, 127, 1865-1875.	2.9	5
1155	Prognostic and predictive biomarkers with therapeutic targets in breast cancer: A 2022 update on current developments, evidence, and recommendations. <i>Journal of Oncology Pharmacy Practice</i> , 2023, 29, 1343-1360.	0.5	3
1156	The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 178, 103781.	2.0	3
1157	Dual-phase FDG PET/CT for predicting prognosis in operable breast cancer. <i>Breast</i> , 2022, 65, 98-103.	0.9	2
1158	Tailoring neoadjuvant treatment of HR-positive/HER2-negative breast cancers: Which role for gene expression assays?. <i>Cancer Treatment Reviews</i> , 2022, 110, 102454.	3.4	14
1159	Overview of non-coding RNAs in breast cancers. <i>Translational Oncology</i> , 2022, 25, 101512.	1.7	5
1160	Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score. <i>Wspolczesna Onkologia</i> , 2022, 26, 139-143.	0.7	7
1162	Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4435-4443.	3.2	3
1163	Ten-year follow-up of the observational RASTER study, prospective evaluation of the 70-gene signature in ER-positive, HER2-negative, node-negative, early breast cancer. <i>European Journal of Cancer</i> , 2022, 175, 169-179.	1.3	3
1164	Does the 21-gene recurrence score have clinical utility in HR+/HER2+ breast cancer?. <i>Breast</i> , 2022, 66, 49-53.	0.9	1
1165	Therapeutic advances in metastatic pancreatic cancer: a focus on targeted therapies. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211180.	1.4	13
1166	Real-world utilization of the 21-gene assay in taiwanese female patients with early-stage breast cancer: Experience from a single institute. <i>Journal of Cancer Research and Practice</i> , 2022, 9, 87.	0.2	0
1167	Prediction of Axillary Lymph Node Metastasis by Combined 5-Immunohistochemistry in Hormone Receptors Positive Breast Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0

#	ARTICLE	IF	CITATIONS
1168	The Clinical Research and Latest Application of Genomic Assays in Early-Stage Breast Cancer. Technology in Cancer Research and Treatment, 2022, 21, 153303382211174.	0.8	0
1169	Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. Advances in Experimental Medicine and Biology, 2022, , 171-194.	0.8	2
1170	Diagnostic Applications of Nuclear Medicine: Breast Cancer. , 2022, , 715-741.		0
1171	Role of 21-Gene Recurrence Score in Predicting Prognostic Benefit of Radiation Therapy After Breast-Conserving Surgery for T1N0 Breast Cancer. Practical Radiation Oncology, 2023, 13, e230-e238.	1.1	4
1172	Omission of axillary surgery for ipsilateral breast tumor recurrence with negative nodes after previous breast-conserving surgery: is it oncologically safe?. Breast Cancer Research and Treatment, 2022, 196, 97-109.	1.1	2
1173	Hospital Rurality and Gene Expression Profiling for Early-Stage Breast Cancer among Iowa Residents (2010â€“2018). Breast Journal, 2022, 2022, 1-11.	0.4	1
1174	A unique gene signature predicting recurrence-free survival in stage IA lung adenocarcinoma. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 1554-1564.e1.	0.4	1
1175	Transcriptomics in Tumor and Normal Lung Tissues Identify Patients With Early-Stage Nonâ€“Small-Cell Lung Cancer With High Risk of Postsurgery Recurrence Who May Benefit From Adjuvant Therapies. JCO Precision Oncology, 2022, , .	1.5	0
1176	The Impact of Chemotherapy Prescription on Long-Term Survival Outcomes in Early-Stage Invasive Lobular Carcinoma â€“ A Systematic Review and Meta-Analysis. Clinical Breast Cancer, 2022, , .	1.1	3
1177	Cost and Clinical Benefits Associated with Oncotype DX® Test in Patients with Early-Stage HR+/HER2- Node-Negative Breast Cancer in the Netherlands. International Journal of Breast Cancer, 2022, 2022, 1-12.	0.6	3
1178	Breast cancer: an upâ€“toâ€“date review and future perspectives. Cancer Communications, 2022, 42, 913-936.	3.7	70
1180	The Future of Diagnostic Excellence. JAMA - Journal of the American Medical Association, 2022, 328, 1039.	3.8	1
1182	Five decades of progress in surgical oncology: Breast. Journal of Surgical Oncology, 2022, 126, 852-859.	0.8	0
1183	Plasma Copy Number Alteration-Based Prognostic and Predictive Multi-Gene Risk Score in Metastatic Castration-Resistant Prostate Cancer. Cancers, 2022, 14, 4714.	1.7	0
1184	Combined Focused Next-Generation Sequencing Assays to Guide Precision Oncology in Solid Tumors: A Retrospective Analysis from an Institutional Molecular Tumor Board. Cancers, 2022, 14, 4430.	1.7	7
1185	The Story of the Magee Equations: The Ultimate in Applied Immunohistochemistry. Applied Immunohistochemistry and Molecular Morphology, 0, Publish Ahead of Print, .	0.6	1
1186	Big data in basic and translational cancer research. Nature Reviews Cancer, 2022, 22, 625-639.	12.8	67
1187	Cost-Effectiveness Analysis of the Oncotype DX Breast Recurrence Score® Test in Node-Negative Early Breast Cancer. ClinicoEconomics and Outcomes Research, 0, Volume 14, 619-633.	0.7	1

#	ARTICLE	IF	CITATIONS
1188	Emerging Targeted Therapies for Early Breast Cancer. <i>Drugs</i> , 2022, 82, 1437-1451.	4.9	5
1189	Breast Cancer Statistics, 2022. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 524-541.	157.7	611
1190	Surgical Management of the Axilla in Breast Cancer: Evolving but Still Necessary. <i>Annals of Surgical Oncology</i> , 0, , .	0.7	4
1191	Real-world outcomes for Chinese breast cancer patients with tumor location of central and nipple portion. <i>Frontiers in Surgery</i> , 0, 9, .	0.6	3
1192	Prospective Study Investigating the Efficacy and Safety of a Scalp Cooling Device for the Prevention of Alopecia in Women Undergoing (Neo)Adjuvant Chemotherapy for Breast Cancer. <i>Current Oncology</i> , 2022, 29, 7218-7228.	0.9	2
1193	Extended adjuvant endocrine treatment for premenopausal women: A Delphi approach to guide clinical practice. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
1194	Ensuring equitable access to cancer care for Black patients in Canada. <i>Cmaj</i> , 2022, 194, E1416-E1419.	0.9	1
1195	Can We Forgo Sentinel Lymph Node Biopsy in Women Aged ≥ 50 Years with Early-Stage Hormone-Receptor-Positive HER2-Negative Special Histologic Subtype Breast Cancer?. <i>Annals of Surgical Oncology</i> , 2023, 30, 1042-1050.	0.7	5
1196	Optimizing pathological assessment of breast cancer in Brazil: recommendations from a multidisciplinary working group on the tumor-tissue journey. <i>Surgical and Experimental Pathology</i> , 2022, 5, .	0.2	0
1197	Preoperative Hormone Therapy in the Treatment of Breast Cancer: What Do We Know So Far?. <i>Kreativna i Hirurģi i Onkologi</i> , 2022, 12, 199-204.	0.1	0
1198	Genome-Wide DNA Methylation and Gene Expression Profiling Characterizes Molecular Subtypes of Esophagus Squamous Cell Carcinoma for Predicting Patient Survival and Immunotherapy Efficacy. <i>Cancers</i> , 2022, 14, 4970.	1.7	5
1199	Recurrence Score® Result Impacts Treatment Decisions in Hormone Receptor-Positive, HER2-Negative Patients with Early Breast Cancer in a Real-World Setting—Results of the IRMA Trial. <i>Cancers</i> , 2022, 14, 5365.	1.7	6
1200	Genomic Profiling and Liquid Biopsies for Breast Cancer. <i>Surgical Clinics of North America</i> , 2022, , .	0.5	0
1201	Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age. <i>Breast Cancer Research and Treatment</i> , 2022, 196, 565-570.	1.1	0
1202	Clinical Trials in Breast Cancer. <i>Surgical Clinics of North America</i> , 2023, 103, 17-33.	0.5	0
1203	Correlation between Ferroptosis-Related Gene Signature and Immune Landscape, Prognosis in Breast Cancer. <i>Journal of Immunology Research</i> , 2022, 2022, 1-19.	0.9	2
1205	Diversity, Equity, and Inclusion in Clinical Trials. <i>Surgical Oncology Clinics of North America</i> , 2023, 32, 221-232.	0.6	2
1206	Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score® result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2+, node-positive early breast cancer. <i>Breast Cancer Research</i> , 2022, 24, .	2.2	2

#	ARTICLE	IF	CITATIONS
1207	Clinical Trials That Have Informed the Modern Management of Breast Cancer. <i>Surgical Oncology Clinics of North America</i> , 2022, , .	0.6	0
1208	Comparison of the Nottingham Prognostic Index and OncotypeDX® recurrence score in predicting outcome in estrogen receptor positive breast cancer. <i>Breast</i> , 2022, 66, 227-235.	0.9	3
1209	Characterization of 5-inflammatory-gene signature to affect the immune status and predict prognosis in breast cancer. <i>Central-European Journal of Immunology</i> , 2022, 47, 218-233.	0.4	1
1212	Precision Medicine in Breast Cancer: Do MRI Biomarkers Identify Patients Who Truly Benefit from the Oncotype DX Recurrence Score® Test?. <i>Diagnostics</i> , 2022, 12, 2730.	1.3	0
1213	Integrative prognostic analysis of tumor-infiltrating lymphocytes, CD8, CD20, programmed cell death-ligand 1, and tertiary lymphoid structures in patients with early-stage triple-negative breast cancer who did not receive adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2023, 197, 287-297.	1.1	4
1215	Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. <i>Npj Breast Cancer</i> , 2022, 8, .	2.3	4
1217	Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER+ breast cancer. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	1
1218	ĐŸŃĐĐ¼Đ³Đ½Đ¾ŃŃ,Đ,ŃĐĐŃĐ°Ń•Đ,Đ;ŃĐĐĐĐ,Đ°Ń,Đ,Đ²Đ½Đ°Ń•Đ-Đ½Đ°ŃĐ,Đ¼Đ¾ŃŃ,ŃĐĐ¼Đ°ŃĐ°ĐŃĐ° Đ¼Đ;ŃĐĐ		
1219	Prognostic Comparison between Oncotype DX® and a 23-Gene Classifier, RecurIndex®, on the Taiwan Breast Cancer Population. <i>Diagnostics</i> , 2022, 12, 2850.	1.3	0
1220	De-Escalating Breast Cancer Therapy. <i>Surgical Clinics of North America</i> , 2023, 103, 83-92.	0.5	2
1221	Race, ethnicity, and clinical outcomes in hormone receptor-positive, human epidermal growth factor 2 negative (HER2-), node negative breast cancer in the randomized TAILORx trial: gaps in biologic and social determinants of health. <i>Annals of Translational Medicine</i> , 2022, .	0.7	0
1222	Gene expression signatures in older patients with breast cancer: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103884.	2.0	2
1223	Cytotoxic chemotherapy: clinical aspects. <i>Medicine</i> , 2023, 51, 23-27.	0.2	0
1224	Efficacy of chemotherapy in patients with HR+/HER2- Invasive lobular breast cancer. <i>Cancer Treatment and Research Communications</i> , 2023, 34, 100666.	0.7	0
1225	Shear-wave elastography-based nomograms predicting 21-gene recurrence score for adjuvant chemotherapy decisions in patients with breast cancer. <i>European Journal of Radiology</i> , 2023, 158, 110638.	1.2	1
1226	Neoadjuvant endocrine therapy for luminal breast tumors: State of the art, challenges and future perspectives. <i>Critical Reviews in Oncology/Hematology</i> , 2023, 181, 103900.	2.0	6
1227	Breast Cancer Pathology in the Era of Genomics. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 33-50.	0.9	2
1228	Surgical Management of the Axilla for Breast Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2023, 37, 51-77.	0.9	4

#	ARTICLE	IF	CITATIONS
1229	Adjuvant Systemic Therapy for Postmenopausal, Hormone Receptor-Positive Early Breast Cancer. Hematology/Oncology Clinics of North America, 2023, 37, 89-102.	0.9	2
1230	A Review of Gene Expression Profiling in Early-Stage ER+/HER2- Breast Cancer With A Focus on The PAM50 Risk of Recurrence Assay. European Medical Journal Oncology, 0, , 2-13.	0.0	3
1231	Prediction with Precision: Does TAILORx Make Chemotherapy a Personalised Treatment?. European Medical Journal Oncology, 0, , 50-57.	0.0	0
1233	Multiparametric MR Imaging Radiomics Signatures for Assessing the Recurrence Risk of ER+/HER2- Breast Cancer Quantified With a Gene Recurrence Score. Journal of Magnetic Resonance Imaging, 2023, 58, 444-453.	1.9	2
1234	Clinical Utility of Genomic Recurrence Risk Stratification in Early, Hormone-Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Real-World Experience. Clinical Breast Cancer, 2022, , .	1.1	2
1235	Breast Cancer Dataset, Classification and Detection Using Deep Learning. Healthcare (Switzerland), 2022, 10, 2395.	1.0	10
1236	Favorable locoregional control in clinically node-negative hormone-receptor positive breast cancer with low 21-gene recurrence scores: a single-institution study with 10-year follow-up. BMC Cancer, 2022, 22, .	1.1	1
1237	Association between ki67 antigen and other clinicopathological factors with the Oncotype DX Score in luminal breast cancer. Obstetrics & Gynecology International Journal, 2022, 13, 368-372.	0.0	0
1238	Phosphoproteomic analysis of neoadjuvant breast cancer suggests that increased sensitivity to paclitaxel is driven by CDK4 and filamin A. Nature Communications, 2022, 13, .	5.8	5
1239	Clinically oriented prediction of patient response to targeted and immunotherapies from the tumor transcriptome. Med, 2023, 4, 15-30.e8.	2.2	4
1241	Comparing Genetic Risk and Clinical Risk Classification in Luminal-like Breast Cancer Patients Using a 23-Gene Classifier. Cancers, 2022, 14, 6263.	1.7	0
1242	A 10 year service evaluation of the survival of 439 patients with early oestrogen receptor positive breast cancer who underwent initial OncotypeDX A® testing to guide adjuvant chemotherapy decisions. Cancer Treatment and Research Communications, 2023, 34, 100671.	0.7	1
1243	Post Treatment Mastalgia is a Common Complaint but not an Indication of Recurrence or Second Primary Breast Cancer. Clinical Breast Cancer, 2023, 23, 330-337.	1.1	0
1244	Right Sizing Systemic Therapy for Patients with Breast Cancer. Where are we Today?. Current Breast Cancer Reports, 0, , .	0.5	0
1245	Load and release of gambogic acid via dual-target ellipsoidal-Fe ₃ O ₄ @SiO ₂ @mSiO ₂ -C ₁₈ @dopamine hydrochloride-graphene quantum dots-folic acid and its inhibition to VX2 tumor cells. Nanotechnology, 2023, 34, 105101.	1.3	3
1246	The effect of non-oncology drugs on clinical and genomic risk in early luminal breast cancer. ESMO Open, 2022, 7, 100648.	2.0	1
1247	Development and validation of an AI-enabled digital breast cancer assay to predict early-stage breast cancer recurrence within 6 years. Breast Cancer Research, 2022, 24, .	2.2	6
1248	Predicting tumour radiosensitivity to deliver precision radiotherapy. Nature Reviews Clinical Oncology, 2023, 20, 83-98.	12.5	37

#	ARTICLE	IF	CITATIONS
1249	Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer. <i>Cancers</i> , 2023, 15, 148.	1.7	3
1250	RecurIndex assay as an aid for adjuvant chemotherapy decisions in HR-positive HER2-negative breast cancer patients. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	0
1251	Borderline indications for ovarian suppression: addressing uncertainties with patients. <i>Future Oncology</i> , 0, , .	1.1	0
1252	Prognostic factors and adjuvant systemic therapy for patients with HER2-positive T1N0 breast cancer: evidence from a real-world study with long-term follow-up. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
1254	Association of tumor immune microenvironment profiling and 21-gene recurrence assay in early breast cancer patients. <i>European Journal of Medical Research</i> , 2022, 27, .	0.9	1
1255	Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: innovative hospitals are early adopters of a de-escalating approach. <i>International Journal of Cancer</i> , 0, , .	2.3	1
1256	Preventing metastatic recurrence in low-risk ER/PR+ breast cancer patients—a retrospective clinical study exploring the evolving challenge of persistence with adjuvant endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 31-41.	1.1	0
1257	Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. <i>Journal of Clinical Oncology</i> , 2023, 41, 1841-1848.	0.8	7
1258	Cost-effectiveness analysis of Oncotype DX from a Brazilian private medicine perspective: a GBECAM multicenter retrospective study. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592211417.	1.4	0
1259	Predictive and prognostic biomarker testing in invasive breast cancer. <i>Diagnostic Histopathology</i> , 2023, , .	0.2	0
1260	Prognostic significance of pretreatment 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with T2N1 hormone receptor-positive, ERBB2-negative breast cancer who underwent adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	3
1261	POLARized Risk for Local Recurrence on the Basis of Tumor Biology: Is It That Simple?. <i>Journal of Clinical Oncology</i> , 2023, 41, 1511-1513.	0.8	4
1262	Retarding breast tumor growth with nanoparticle-facilitated intravenous delivery of BRCA1 and BRCA2 tumor suppressor genes. <i>Scientific Reports</i> , 2023, 13, .	1.6	0
1263	Un accès équitable aux soins contre le cancer pour les personnes noires au Canada. <i>Cmaj</i> , 2023, 195, E51-E55.	0.9	0
1264	Targeted Endocrine Agents should be the Dominant Systemic Therapies Prescribed in Luminal A Breast Cancer. <i>Breast Cancer: Basic and Clinical Research</i> , 2023, 17, 117822342211454.	0.6	0
1265	Evaluation oncotype DX [®] 21-gene recurrence score and clinicopathological parameters: a single institutional experience. <i>Histopathology</i> , 2023, 82, 755-766.	1.6	7
1266	Survival Benefit of Chemotherapy According to 21-Gene Recurrence Score in Young Women with Breast Cancer. <i>Annals of Surgical Oncology</i> , 2023, 30, 2130-2139.	0.7	0
1267	Neoadjuvant endocrine therapy in postmenopausal women with HR+/HER2- breast cancer. <i>Expert Review of Anticancer Therapy</i> , 2023, 23, 67-86.	1.1	2

#	ARTICLE	IF	CITATIONS
1268	Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family. <i>Gene</i> , 2023, 857, 147179.	1.0	0
1269	Adjuvant Therapy in Breast Cancer Patients With Microscopic Residual Disease. <i>Journal of Surgical Research</i> , 2023, 285, 114-120.	0.8	0
1270	Evaluating the Role of Circulating MicroRNAs in Predicting Long-Term Survival Outcomes in Breast Cancer: A Prospective, Multicenter Clinical Trial. <i>Journal of the American College of Surgeons</i> , 2023, 236, 317-327.	0.2	8
1271	The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy. <i>Biomedicines</i> , 2023, 11, 98.	1.4	2
1272	MRI-Based Radiomics Approach Predicts Tumor Recurrence in ER+HER2~Early Breast Cancer Patients. <i>Journal of Digital Imaging</i> , 0, .	1.6	0
1273	The central role of pathology labs in breast cancer precision oncology: a call for action. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	0
1274	Prognostic Tests in Early-Stage Hormone Receptor+Positive Breast Cancer: An Opportunity to Refine Personalized Cancer Care. <i>Journal of Clinical Oncology</i> , 2023, 41, 1816-1819.	0.8	1
1275	Chemotherapy refusal and subsequent survival in healthy older women with high genomic risk estrogen receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 198, 309-319.	1.1	0
1276	Axillary lymph node dissection: Dead or still alive?. <i>Breast</i> , 2023, 69, 469-475.	0.9	5
1277	The Rochester Modified Magee Algorithm (RoMMA): An Outcomes Based Strategy for Clinical Risk-Assessment and Risk-Stratification in ER Positive, HER2 Negative Breast Cancer Patients Being Considered for Oncotype DX® Testing. <i>Cancers</i> , 2023, 15, 903.	1.7	1
1278	Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer. <i>Cancers</i> , 2023, 15, 1087.	1.7	5
1279	Adherence Disparities and Utilization Trends of Oncotype Dx Assay: A National Cancer Database Study. <i>Journal of Surgical Research</i> , 2023, 286, 65-73.	0.8	0
1280	Establishment and validation of a multigene model to predict the risk of relapse in hormone receptor-positive early-stage Chinese breast cancer patients. <i>Chinese Medical Journal</i> , 2023, 136, 184-193.	0.9	1
1281	Provision of Fertility Preservation for Young Women with Early-Stage Breast Cancer. <i>Advances in Reproductive Sciences</i> , 2023, 11, 23-35.	0.3	0
1282	Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	9
1283	Racial and Ethnic Disparities in Locoregional Recurrence Among Patients With Hormone Receptor+Positive, Node-Negative Breast Cancer. <i>JAMA Surgery</i> , 2023, 158, 583.	2.2	12
1284	Prognostic and predictive impact of gene expression in node+positive early breast cancer patients receiving dose-dense versus standard-dose adjuvant chemotherapy. <i>Molecular Oncology</i> , 2023, 17, 1060-1075.	2.1	0
1285	Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100~000 women from 86 randomised trials. <i>Lancet, The</i> , 2023, 401, 1277-1292.	6.3	23

#	ARTICLE	IF	CITATIONS
1286	Progranulin and Breast Cancer Mortality: 13-Year Follow-Up of a Cohort Study. <i>Breast Cancer: Targets and Therapy</i> , 0, Volume 15, 251-261.	1.0	0
1287	Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer. <i>BMC Cancer</i> , 2023, 23, .	1.1	2
1288	Molecular Testing for Diagnostics, Prognostication, and Treatment Stratification in Cancers. <i>Cancer Journal (Sudbury, Mass)</i> , 2023, 29, 3-8.	1.0	0
1289	The Biomarker Ki-67: Promise, Potential, and Problems in Breast Cancer. <i>Applied Immunohistochemistry and Molecular Morphology</i> , 2023, 31, 478-484.	0.6	2
1290	Adjuvant Chemotherapy De-Escalation with Genomic Assay Protocol in Patients with Early Breast Cancer: A Single-Centre Prospective Cohort Study. <i>Acta Medica Portuguesa</i> , 2023, 36, 487-495.	0.2	0
1291	A systematic and comprehensive analysis of T cell exhaustion related to therapy in lung adenocarcinoma tumor microenvironment. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	1
1292	Molecular profiling in contemporary breast cancer management. <i>British Journal of Surgery</i> , 2023, 110, 743-745.	0.1	2
1293	Lessons from other fields of medicine, Part 1: Breast cancer. <i>Handbook of Clinical Neurology / Edited By P J Vinken and C W Bruyn</i> , 2023, , 101-118.	1.0	2
1294	Association of Social Determinants and Tumor Biology With Racial Disparity in Survival From Early-Stage, Hormone-Dependent Breast Cancer. <i>JAMA Oncology</i> , 2023, 9, 536.	3.4	8
1296	Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes. <i>Frontiers in Endocrinology</i> , 0, 14, .	1.5	2
1297	How I treat endocrine-dependent metastatic breast cancer. <i>ESMO Open</i> , 2023, 8, 100882.	2.0	6
1298	Association of Neighborhood-Level Household Income With 21-Gene Recurrence Score and Survival Among Patients With Estrogen Receptorâ€“Positive Breast Cancer. <i>JAMA Network Open</i> , 2023, 6, e230179.	2.8	1
1299	Survival Nomogram for Patients With Locally Advanced Breast Cancer Undergoing Immediate Breast Reconstruction: A SEER Population-Based Study. <i>Clinical Breast Cancer</i> , 2023, , .	1.1	0
1300	Effect of Epirubicin Plus Paclitaxel vs Epirubicin and Cyclophosphamide Followed by Paclitaxel on Disease-Free Survival Among Patients With Operable <i>ERBB2</i>-Negative and Lymph Nodeâ€“Positive Breast Cancer. <i>JAMA Network Open</i> , 2023, 6, e230122.	2.8	1
1301	PROCURE European consensus on breast cancer multigene signatures in early breast cancer management. <i>Npj Breast Cancer</i> , 2023, 9, .	2.3	0
1303	Impact of the 21-Gene Assay in Patients with High-Clinical Risk ER-Positive and HER2-Negative Early Breast Cancer: Results of the KARMA Dx Study. <i>Cancers</i> , 2023, 15, 1529.	1.7	0
1304	Molecular Profiling in Early ERâ€“+â€“Breast Cancer to Aid Systemic Therapy Decisions. <i>Current Oncology Reports</i> , 2023, 25, 491-500.	1.8	1
1305	Genetic Considerations in the Locoregional Management of Breast Cancer: a Review of Current Evidence. <i>Current Breast Cancer Reports</i> , 2023, 15, 48-57.	0.5	0

#	ARTICLE	IF	CITATIONS
1306	Integrative Pan-Cancer Genomic and Transcriptomic Analyses of Refractory Metastatic Cancer. <i>Cancer Discovery</i> , 2023, 13, 1116-1143.	7.7	11
1307	Uncharted waters: Significance of fall in Ki67 index after short-term preoperative endocrine therapy in early breast cancers. <i>Breast Disease</i> , 2023, 42, 27-36.	0.4	0
1308	Multigene signatures for early breast cancer in clinical practice: A report of the Lombardy genomic assays for breast cancer working group. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
1309	The innovative model based on artificial intelligence algorithms to predict recurrence risk of patients with postoperative breast cancer. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	1
1310	Impact of de-escalating systemic therapy guided by 21-gene assay on locoregional recurrence after partial-breast irradiation. <i>Brachytherapy</i> , 2023, , .	0.2	0
1311	Tâ€cell exhaustion: A potential target biomarker of the tumour microenvironment affecting oesophageal adenocarcinoma. <i>Journal of Gene Medicine</i> , 2023, 25, .	1.4	2
1312	Comprehensive analysis of nicotinamide metabolism-related signature for predicting prognosis and immunotherapy response in breast cancer. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	1
1313	Leveraging transcriptomics for precision diagnosis: Lessons learned from cancer and sepsis. <i>Frontiers in Genetics</i> , 0, 14, .	1.1	7
1314	Impact of the 12-gene recurrence score in influencing adjuvant chemotherapy prescription in mismatch repair proficient stage II/III colonic carcinomaâ€”a systematic review and meta-analysis. <i>International Journal of Colorectal Disease</i> , 2023, 38, .	1.0	0
1315	Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy. <i>Therapeutic Advances in Medical Oncology</i> , 2023, 15, 175883592211386.	1.4	1
1316	Chromatin Remodeling Enzyme Cluster Predicts Prognosis and Clinical Benefit of Therapeutic Strategy in Breast Cancer. <i>International Journal of Molecular Sciences</i> , 2023, 24, 5583.	1.8	1
1318	Systemic therapy for hormone receptorâ€positive/human epidermal growth factor receptor 2â€negative early stage and metastatic breast cancer. <i>Ca-A Cancer Journal for Clinicians</i> , 2023, 73, 480-515.	157.7	23
1319	Phase III study of long-term prognosis of estrogen receptor-positive early breast cancer treated with neoadjuvant endocrine therapy with/without adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 0, , .	1.1	0
1320	Predicting Breast Cancer Events in Ductal Carcinoma In Situ (DCIS) Using Generative Adversarial Network Augmented Deep Learning Model. <i>Cancers</i> , 2023, 15, 1922.	1.7	1
1321	What Is Known about Breast Cancer in Young Women?. <i>Cancers</i> , 2023, 15, 1917.	1.7	18
1322	Using Oncotype DX breast recurrence scoreâ€™ assay to define the role of neoadjuvant endocrine therapy in early-stage hormone receptor-positive breast cancer. <i>Breast Cancer Research and Treatment</i> , 2023, 199, 91-98.	1.1	3
1323	Metaplastic carcinoma of the breast: matched cohort analysis of recurrence and survival. <i>Breast Cancer Research and Treatment</i> , 2023, 199, 355-361.	1.1	1
1324	Evaluating the Necessity for Routine Sentinel Lymph Node Biopsy in Postmenopausal Patients Being Treated for Clinically Node Negative Breast Cancer the Era of RxPONDER. <i>Clinical Breast Cancer</i> , 2023, 23, 500-507.	1.1	0

#	ARTICLE	IF	CITATIONS
1325	Facing inevitable PARPi resistance: Mechanisms and therapeutic strategies for breast cancer treatment. , 2023, 1, .		2
1326	Possible correlation of apical localization of MUC1 glycoprotein with luminal A-like status of breast cancer. Scientific Reports, 2023, 13, .	1.6	1
1327	A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology. Therapeutic Advances in Medical Oncology, 2023, 15, 175883592311563.	1.4	3
1328	BCR-Net: A deep learning framework to predict breast cancer recurrence from histopathology images. PLoS ONE, 2023, 18, e0283562.	1.1	3
1329	Design of a printed electrochemical strip towards miRNA-21 detection in urine samples: optimization of the experimental procedures for real sample application. Analytical and Bioanalytical Chemistry, 2023, 415, 4511-4520.	1.9	9
1330	Novel Computational Methods for Cancer Drug Design. Current Medicinal Chemistry, 2023, 30, .	1.2	1
1331	Validation of the prognosis of patients with ER ⁺ positive, HER2 ⁻ negative and node ⁻ negative invasive breast cancer classified as low risk by Curebest [®] 95GC Breast in a multi ⁻ institutional registry study. Oncology Letters, 2023, 25, .	0.8	1
1332	HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series. Breast Cancer Research and Treatment, 2023, 199, 349-354.	1.1	2
1333	Breast Cancer: Impact of New Treatments?. Cancers, 2023, 15, 2205.	1.7	4
1334	Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer. Journal of Breast Cancer, 2023, 26, 105.	0.8	2
1335	Exploiting convergent phenotypes to derive a pan-cancer cisplatin response gene expression signature. Npj Precision Oncology, 2023, 7, .	2.3	2
1340	Evaluation of multigene assays as predictors for response to neoadjuvant chemotherapy in early-stage breast cancer patients. Npj Breast Cancer, 2023, 9, .	2.3	0
1355	Cancers hormono-dépendants : sein et prostate. , 2023, , 183-192.		0
1395	Imagine beyond: recent breakthroughs and next challenges in mammary gland biology and breast cancer research. Journal of Mammary Gland Biology and Neoplasia, 2023, 28, .	1.0	2
1406	Diagnostic discovery. , 2023, , 59-65.		0
1410	Artificial Intelligence in Breast Pathology. , 2023, , 501-510.		0
1423	Circulating Tumor Cells (CTC) and Tumor-Derived Extracellular Vesicles (tdEV). Current Cancer Research, 2023, , 113-136.	0.2	0
1428	Suboptimal use of ovarian function suppression in very young women with early breast cancer: a real-world data study. Breast Cancer Research and Treatment, 0, , .	1.1	0

#	ARTICLE	IF	CITATIONS
1446	Dynamic treatment regimens and biomarker-driven strategies: Bridging the two worlds. , 2024, , 283-292.		0
1464	miRNAs as biomarkers breast cancer and their influence on tumor epigenetics. , 2024, , 173-205.		0
1468	Nodal pCR and overall survival following neoadjuvant chemotherapy for node positive ER+/Her2- breast cancer. Breast Cancer Research and Treatment, 0, , .	1.1	0
1477	Adjuvant Systemic Treatment in Early Breast Cancer. , 2023, , 275-286.		0
1488	Translating Molecular Subtypes into Clinical Practice: Precision Medicine in Gastric Cancer. , 0, , .		0
1496	Optimal adjuvant therapy in older (≥70 years of age) women with low-risk early-stage breast cancer. Npj Breast Cancer, 2023, 9, .	2.3	1
1510	A Precise Approach for Radiotherapy of Breast Cancer. Cancer Treatment and Research, 2023, , 175-198.	0.2	0
1514	A Closer Look at Weak Supervision's Limitations in WSI Recurrence Score Prediction. , 2023, , .		0
1515	Machine learning applications in cancer genomics. , 2024, , 41-72.		0
1518	How does time speak about cancer, its diagnosis, treatments, and challenges?. , 2024, , 55-81.		0
1522	Neoadjuvant endocrine treatment in hormone receptor-positive breast cancer: Does it result in more breast-conserving surgery?. Breast Cancer Research and Treatment, 0, , .	1.1	1
1526	Breast Cancer in Women of Asian Heritage: Disparity Trends in the Asian American Breast Cancer Population Literature. Current Breast Cancer Reports, 0, , .	0.5	0
1534	Searching for the "Holy Grail" of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA). Breast Cancer Research and Treatment, 0, , .	1.1	0
1550	Artificial intelligence in cancer research and precision medicine. , 2024, , 1-23.		0